



US007374758B2

(12) **United States Patent**
Papadopoulos et al.

(10) **Patent No.:** **US 7,374,758 B2**

(45) **Date of Patent:** ***May 20, 2008**

(54) **MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES AND METHODS OF USING THEREOF**

(75) Inventors: **Nicholas J. Papadopoulos**, Lagrangeville, NY (US); **Samuel Davis**, New York, NY (US); **George D. Yancopoulos**, Yorktown Heights, NY (US)

(73) Assignee: **Regeneron Pharmaceuticals, Inc.**, Tarrytown, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 489 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **11/016,503**

(22) Filed: **Dec. 17, 2004**

(65) **Prior Publication Data**

US 2005/0245447 A1 Nov. 3, 2005

Related U.S. Application Data

(62) Division of application No. 10/009,852, filed as application No. PCT/US00/14142 on May 23, 2000, now Pat. No. 7,070,959.

(60) Provisional application No. 60/138,133, filed on Jun. 8, 1999.

(51) **Int. Cl.**

A61K 38/18 (2006.01)

C07K 14/71 (2006.01)

C12N 15/62 (2006.01)

(52) **U.S. Cl.** **424/134.1**; 424/192.1; 514/2; 514/23; 530/350; 536/23.4

(58) **Field of Classification Search** None
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,712,380 A	1/1998	Kendall et al.	
6,011,003 A	1/2000	Charnock-Jones et al.	
2004/0265309 A1 *	12/2004	Kandel et al.	424/145.1
2005/0175610 A1 *	8/2005	Wiegand et al.	424/145.1
2005/0260203 A1 *	11/2005	Wiegand et al.	424/145.1
2005/0281822 A1 *	12/2005	Cedarbaum et al.	424/145.1
2005/0281831 A1 *	12/2005	Davis-Smyth et al.	424/178.1
2006/0210566 A1 *	9/2006	Holash et al.	424/145.1
2007/0037748 A1 *	2/2007	Stahl et al.	514/12

FOREIGN PATENT DOCUMENTS

WO	WO97/44453	11/1997
WO	WO98/13071	4/1998
WO	WO99/03996	1/1999

OTHER PUBLICATIONS

Wells, J.A. (1990). Additivity of mutational effects in proteins. *Biochemistry*. 29(37):8509-8517.*

Ngo et al. (1994). Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) *The Protein Folding Problem and Tertiary Structure Prediction*. Birkhauser:Boston, pp. 491-495.*

Herley et al. (1999). Characterization of the VEGF binding site on the Flt-1 receptor. *Biochemical and Biophysical Research Communications*. 262:731-738.*

Terman, B.I., et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase", *Oncogene* (1991) 6:1677-1683.

Terman, B.I., et al., "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor", *Biochem Biophys Res Comm* (1992) 187(3):1579-1586.

Tsutsumi, Y., et al., "PEGylation of interleukin-6 effectively increases its thrombopoietic potency", *Thrombosis and Haemostasis* (1997) 77(1):168-173.

Dunca, R. and Spreafico, F., "Polymer Conjugates", *Drug Delivery Systems* (1994) 27(4):290-306.

Hileman, R.E., et al., "Glycosaminoglycan-protein interactions: definitions of consensus sites in glycosaminoglycan binding proteins", *BioEssays* (1998) 20:156-167.

de Vries, Carlie, et al., "The *fms*-like tyrosine kinase, a receptor for vascular endothelial growth factor", *Science* (1992) 225:989-991.

Sharifi, J., et al., "Improving monoclonal antibody pharmacokinetics via chemical modification", *Quart J Nucl Med* (1998) 42:242-249.

Jensen-Pippo, K.E., et al., "Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol)", (1996) *Pharm Res* 13(1):102-107.

Tanaka, K., et al., "Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 Tyrosine kinase)", (1997) *Jpn J Cancer Res* 88:867-876.

Yang, J.C., et al., "The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma", (1995) *Cancer* 76(4): 687-694.

Davis-Smyth, T., et al., 1996, "The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade", *The EMBO Journal* 15(18):4919-4927.

* cited by examiner

Primary Examiner—Christine J Saoud

Assistant Examiner—Jon M Lockard

(74) *Attorney, Agent, or Firm*—Valeta Gregg, Esq.

(57) **ABSTRACT**

Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.

3 Claims, 55 Drawing Sheets

CELLTRION EXHIBIT - 1019

Celltrion, Inc. v. Regeneron Pharmaceuticals, Inc.

Fig.1.




Fig.2.




Fig.3.




Fig.4.




Fig.5.




Fig.6A.




Fig.6B.




Fig.7.




Fig.8.




Fig.9.




Fig.10A.

10 20 30 40 50 60
* * * * *
ATG GTC AGC TAC TGG GAC ACC GGG GTC CTG CTG TGC GCG CTG CTC AGC TGT CTG CTT CTC
TAC CAG TCG ATG ACC CTG TGG CCC CAG GAC GAC ACG GCG GAC GAG TCG ACA GAC GAA GAG
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser Cys Leu Leu Leu>

70 80 90 100 110 120
* * * * *
ACA GGA TCT AGT TCA GGT TCA AAA TTA AAA GAT CCT GAA CTG AGT TTA AAA GGC ACC CAG
TGT CCT AGA TCA AGT CCA AGT TTT AAT TTT CTA GGA CTT GAC TCA AAT TTT CCG TGG GTC
Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro Glu Leu Ser Leu Lys Gly Thr Gln>

130 140 150 160 170 180
* * * * *
CAC ATC ATG CAA GCA GGC CAG ACA CTG CAT CTC CAA TGC AGG GGG GAA GCA GCC CAT AAA
GTG TAG TAC GTT CGT CCG GTC TGT GAC GTA GAG GTT ACG TCC CCC CTT CGT CCG GTA TTT
His Ile Met Gln Ala Gly Gln Thr Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys>

190 200 210 220 230 240
* * * * *
TGG TCT TTG CCT GAA ATG GTG AGT AAG GAA AGC GAA AGG CTG AGC ATA ACT AAA TCT GCC
ACC AGA AAC GGA CTT TAC CAC TCA TTC CTT TCG CTT TCC GAC TCG TAT TGA TTT AGA CCG
Trp Ser Leu Pro Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala>

250 260 270 280 290 300
* * * * *
TGT GGA AGA AAT GGC AAA CAA TTC TGC AGT ACT TTA ACC TTG AAC ACA GCT CAA GCA AAC
ACA CCT TCT TTA CCG TTT GTT AAG ACG TCA TGA AAT TGG AAC TTG TGT CGA GTT CGT TTG
Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr Ala Gln Ala Asn>

310 320 330 340 350 360
* * * * *
CAC ACT GGC TTC TAC AGC TGC AAA TAT CTA GCT GTA CCT ACT TCA AAG AAG AAG GAA ACA
GTG TGA CCG AAG ATG TCG ACG TTT ATA GAT CGA CAT GGA TGA AGT TTC TTC TTC CTT TGT
His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val Pro Thr Ser Lys Lys Lys Glu Thr>

370 380 390 400 410 420
* * * * *
GAA TCT GCA ATC TAT ATA TTT ATT AGT GAT ACA GGT AGA CCT TTC GTA GAG ATG TAC AGT
CTT AGA CGT TAG ATA TAT AAA TAA TCA CTA TGT CCA TCT GGA AAG CAT CTC TAC ATG TCA
Glu Ser Ala Ile Tyr Ile Phe Ile Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser>

430 440 450 460 470 480
* * * * *
GAA ATC CCC GAA ATT ATA CAC ATG ACT GAA GGA AGG GAG CTC GTC ATT CCC TGC CCG GTT
CTT TAG GGG CTT TAA TAT GTG TAC TGA CTT CCT TCC CTC GAG CAG TAA GGG ACG GCC CAA
Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val>

490 500 510 520 530 540
* * * * *
ACG TCA CCT AAC ATC ACT GTT ACT TTA AAA AAG TTT CCA CTT GAC ACT TTG ATC CCT GAT
TGC AGT GGA TTG TAG TGA CAA TGA AAT TTT TTC AAA GGT GAA CTG TGA AAC TAG GGA CTA
Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp>

Fig.10B.

550 560 570 580 590 600
* * * * *
GGA AAA CGC ATA ATC TGG GAC AGT AGA AAG GGC TTC ATC ATA TCA AAT GCA ACG TAC AAA
CCT TTT GCG TAT TAG ACC CTG TCA TCT TTC CCG AAG TAG TAT AGT TTA CGT TGC ATG TTT
Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys>

610 620 630 640 650 660
* * * * *
GAA ATA GGG CTT CTG ACC TGT GAA GCA ACA GTC AAT GGG CAT TTG TAT AAG ACA AAC TAT
CTT TAT CCC GAA GAC TGG ACA CTT CGT TGT CAG TTA CCC GTA AAC ATA TTC TGT TTG ATA
Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr>

670 680 690 700 710 720
* * * * *
CTC ACA CAT CGA CAA ACC AAT ACA ATC ATA GAT GTC CAA ATA AGC ACA CCA CGC CCA GTC
GAG TGT GTA GCT GTT TGG TTA TGT TAG TAT CTA CAG GTT TAT TCG TGT GGT GCG GGT CAG
Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val>

730 740 750 760 770 780
* * * * *
AAA TTA CTT AGA GGC CAT ACT CTT GTC CTC AAT TGT ACT GCT ACC ACT CCC TTG AAC ACG
TTT AAT GAA TCT CCG GTA TGA GAA CAG GAG TTA ACA TGA CGA TGG TGA GGG AAC TTG TGC
Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr>

790 800 810 820 830 840
* * * * *
AGA GTT CAA ATG ACC TGG AGT TAC CCT GAT GAA AAA AAT AAG AGA GCT TCC GTA AGG CGA
TCT CAA GTT TAC TGG ACC TCA ATG GGA CTA CTT TTT TTA TTC TCT CGA AGG CAT TCC GCT
Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys Asn Lys Arg Ala Ser Val Arg Arg>

850 860 870 880 890 900
* * * * *
CGA ATT GAC CAA AGC AAT TCC CAT GCC AAC ATA TTC TAC AGT GTT CTT ACT ATT GAC AAA
GCT TAA CTG GTT TCG TTA AGG GTA CCG TTG TAT AAG ATG TCA CAA GAA TGA TAA CTG TTT
Arg Ile Asp Gln Ser Asn Ser His Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys>

910 920 930 940 950 960
* * * * *
ATG CAG AAC AAA GAC AAA GGA CTT TAT ACT TGT CGT GTA AGG AGT GGA CCA TCA TTC AAA
TAC GTC TTG TTT CTG TTT CCT GAA ATA TGA ACA GCA CAT TCC TCA CCT GGT AGT AAG TTT
Met Gln Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys>

970 980 990 1000 1010 1020
* * * * *
TCT GTT AAC ACC TCA GTG CAT ATA TAT GAT AAA GCA GGC CCG GGC GAG CCC AAA TCT TGT
AGA CAA TTG TGG AGT CAC GTA TAT ATA CTA TTT CGT CCG GGC CCG CTC GGG TTT AGA ACA
Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Gly Pro Gly Glu Pro Lys Ser Cys>

1030 1040 1050 1060 1070 1080
* * * * *
GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC
CTG TTT TGA GTG TGT ACG GGT GGC ACG GGT CGT GGA CTT GAG GAC CCC CCT GGC AGT CAG
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val>

Fig.10C.

1090	1100	1110	1120	1130	1140
* * *	* *	* *	* *	* *	* *
TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA	AAG GAG AAG GGG GGT TTT GGG TTC CTG TGG GAG TAC TAG AGG GCC TGG GGA CTC CAG TGT	Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr>			
1150	1160	1170	1180	1190	1200
* * *	* *	* *	* *	* *	* *
TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC	ACG CAC CAC CAC CTG CAC TGG GTG CTT CTG GGA CTC CAG TTC AAG TTG ACC ATG CAC CTG	Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp>			
1210	1220	1230	1240	1250	1260
* * *	* *	* *	* *	* *	* *
GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC	CCG CAC CTC CAC GTA TTA CCG TTC TGT TTC GGC GCC CTC CTC GTC ATG TTG TCG TGC ATG	Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr>			
1270	1280	1290	1300	1310	1320
* * *	* *	* *	* *	* *	* *
CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG	GCA CAC CAG TCG CAG GAG TGG CAG GAC GTG GTC CTG ACC GAC TTA CCG TTC CTC ATG TTC	Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys>			
1330	1340	1350	1360	1370	1380
* * *	* *	* *	* *	* *	* *
TGC AAG GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC AAA	ACG TTC CAG AGG TTG TTT CCG GAG GGT CCG GGG TAG CTC TTT TGG TAG AGG TTT CCG TTT	Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys>			
1390	1400	1410	1420	1430	1440
* * *	* *	* *	* *	* *	* *
GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG GAT GAG CTG ACC AAG	CCC GTC GGG GCT CTT GGT GTC CAC ATG TGG GAC GGG GGT AGG GCC CTA CTC GAC TGG TTC	Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys>			
1450	1460	1470	1480	1490	1500
* * *	* *	* *	* *	* *	* *
AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG	TTG GTC CAG TCG GAC TGG ACG GAC CAG TTT COG AAG ATA GGG TCG CTG TAG CCG CAC CTC	Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu>			
1510	1520	1530	1540	1550	1560
* * *	* *	* *	* *	* *	* *
TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC	ACC CTC TCG TTA CCC GTC GGC CTC TTG TTG ATG TTC TGG TGC GGA GGG CAC GAC CTG AGG	Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser>			
1570	1580	1590	1600	1610	1620
* * *	* *	* *	* *	* *	* *
GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG	CTG CCG AGG AAG AAG GAG ATG TCG TTC GAG TGG CAC CTG TTC TCG TCC ACC GTC GTC CCC	Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly>			

Fig.10D.

```
          1630          1640          1650          1660          1670          1680
      *      *      *      *      *      *      *      *      *      *
AAC GTC TTC TCA TGC TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC
TTG CAG AAG AGT ACG AGG CAC TAC GTA CTC CGA GAC GTG TTG GTG ATG TGC GTC TTC TCG
Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser>

          1690          1700
      *      *      *      *
CTC TCC CTG TCT CCG GGT AAA TGA
GAG AGG GAC AGA GGC CCA TTT ACT
Leu Ser Leu Ser Pro Gly Lys ***>
```

Fig.11.




Fig.12A.




Fig.12B.




Fig.13A.

```

      10      20      30      40      50      60
      *      *      *      *      *      *
ATG GTC AGC TAC TGG GAC ACC GGG GTC CTG CTG TGC GCG CTG CTC AGC TGT CTG CTT CTC
TAC CAG TCG ATG ACC CTG TGG CCC CAG GAC GAC ACG CGC GAC GAG TCG ACA GAC GAA GAG
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser Cys Leu Leu Leu>

      70      80      90      100     110     120
      *      *      *      *      *      *
ACA GGA TCT AGT TCA GGT TCA AAA TTA AAA GAT CCT GAA CTG AGT TTA AAA GGC ACC CAG
TGT CCT AGA TCA AGT CCA AGT TTT AAT TTT CTA GGA CTT GAC TCA AAT TTT CCG TGG GTC
Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro Glu Leu Ser Leu Lys Gly Thr Gln>

      130     140     150     160     170     180
      *      *      *      *      *      *
CAC ATC ATG CAA GCA GGC CAG ACA CTG CAT CTC CAA TGC AGG GGG GAA GCA GCC CAT AAA
GTG TAG TAC GTT CGT CCG GTC TGT GAC GTA GAG GTT ACG TCC CCC CTT CGT CCG GTA TTT
His Ile Met Gln Ala Gly Gln Thr Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys>

      190     200     210     220     230     240
      *      *      *      *      *      *
TGG TCT TTG CCT GAA ATG GTG AGT AAG GAA AGC GAA AGG CTG AGC ATA ACT AAA TCT GCC
ACC AGA AAC GGA CTT TAC CAC TCA TTC CTT TCG CTT TCC GAC TCG TAT TGA TTT AGA CCG
Trp Ser Leu Pro Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala>

      250     260     270     280     290     300
      *      *      *      *      *      *
TGT GGA AGA AAT GGC AAA CAA TTC TGC AGT ACT TTA ACC TTG AAC ACA GCT CAA GCA AAC
ACA CCT TCT TTA CCG TTT GTT AAG ACG TCA TGA AAT TGG AAC TTG TGT CGA GTT CGT TTG
Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr Ala Gln Ala Asn>

      310     320     330     340     350     360
      *      *      *      *      *      *
CAC ACT GGC TTC TAC AGC TGC AAA TAT CTA GCT GTA CCT ACT TCA AAG AAG AAG GAA ACA
GTG TGA CCG AAG ATG TCG ACG TTT ATA GAT CGA CAT GGA TGA AGT TTC TTC TTC CTT TGT
His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val Pro Thr Ser Lys Lys Lys Glu Thr>

      370     380     390     400     410     420
      *      *      *      *      *      *
GAA TCT GCA ATC TAT ATA TTT ATT AGT GAT ACA GGT AGA CCT TTC GTA GAG ATG TAC AGT
CTT AGA CGT TAG ATA TAT AAA TAA TCA CTA TGT CCA TCT GGA AAG CAT CTC TAC ATG TCA
Glu Ser Ala Ile Tyr Ile Phe Ile Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser>

      430     440     450     460     470     480
      *      *      *      *      *      *
GAA ATC CCC GAA ATT ATA CAC ATG ACT GAA GGA AGG GAG CTC GTC ATT CCC TGC CGG GTT
CTT TAG GGG CTT TAA TAT GTG TAC TGA CTT CCT TCC CTC GAG CAG TAA GGG ACG GCC CAA
Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val>

      490     500     510     520     530     540
      *      *      *      *      *      *
ACG TCA CCT AAC ATC ACT GTT ACT TTA AAA AAG TTT CCA CTT GAC ACT TTG ATC CCT GAT
TGC AGT GGA TTG TAG TGA CAA TGA AAT TTT TTC AAA GGT GAA CTG TGA AAC TAG GGA CTA
Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp>
```

Fig.13B.

550 560 570 580 590 600
* * * * *
GGA AAA CGC ATA ATC TGG GAC AGT AGA AAG GGC TTC ATC ATA TCA AAT GCA ACG TAC AAA
CCT TTT GCG TAT TAG ACC CTG TCA TCT TTC CCG AAG TAG TAT AGT TTA CGT TGC ATG TTT
Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys>

610 620 630 640 650 660
* * * * *
GAA ATA GGG CTT CTG ACC TGT GAA GCA ACA GTC AAT GGG CAT TTG TAT AAG ACA AAC TAT
CTT TAT CCC GAA GAC TGG ACA CTT CGT TGT CAG TTA CCC GTA AAC ATA TTC TGT TTG ATA
Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr>

670 680 690 700 710 720
* * * * *
CTC ACA CAT CGA CAA ACC AAT ACA ATC ATA GAT GTC CAA ATA AGC ACA CCA CGC CCA GTC
GAG TGT GTA GCT GTT TGG TTA TGT TAG TAT CTA CAG GTT TAT TCG TGT GGT GCG GGT CAG
Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val>

730 740 750 760 770 780
* * * * *
AAA TTA CTT AGA GGC CAT ACT CTT GTC CTC AAT TGT ACT GCT ACC ACT CCC TTG AAC ACG
TTT AAT GAA TCT CCG GTA TGA GAA CAG GAG TTA ACA TGA CGA TGG TGA GGG AAC TTG TGC
Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr>

790 800 810 820 830 840
* * * * *
AGA GTT CAA ATG ACC TGG AGT TAC CCT GAT GAA ATT GAC CAA AGC AAT TCC CAT GCC AAC
TCT CAA GTT TAC TGG ACC TCA ATG GGA CTA CTT TAA CTG GTT TCG TTA AGG GTA CCG TTG
Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Ile Asp Gln Ser Asn Ser His Ala Asn>

850 860 870 880 890 900
* * * * *
ATA TTC TAC AGT GTT CTT ACT ATT GAC AAA ATG CAG AAC AAA GAC AAA GGA CTT TAT ACT
TAT AAG ATG TCA CAA GAA TGA TAA CTG TTT TAC GTC TTG TTT CTG TTT CCT GAA ATA TGA
Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys Met Gln Asn Lys Asp Lys Gly Leu Tyr Thr>

910 920 930 940 950 960
* * * * *
TGT CGT GTA AGG AGT GGA CCA TCA TTC AAA TCT GTT AAC ACC TCA GTG CAT ATA TAT GAT
ACA GCA CAT TCC TCA CCT GGT AGT AAG TTT AGA CAA TTG TGG AGT CAC GTA TAT ATA CTA
Cys Arg Val Arg Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His Ile Tyr Asp>

970 980 990 1000 1010 1020
* * * * *
AAA GCA GGC CCG GGC GAG CCC AAA TCT TGT GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA
TTT CGT CCG GGC CCG CTC GGG TTT AGA ACA CTG TTT TGA GTG TGT ACG GGT GGC ACG GGT
Lys Ala Gly Pro Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro>

1030 1040 1050 1060 1070 1080
* * * * *
GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC
CGT GGA CTT GAG GAC CCC CCT GGC AGT CAG AAG GAG AAG GGG GGT TTT GGG TTC CTG TGG
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr>

Fig.13C.

1090	1100	1110	1120	1130	1140
* * *	* *	* *	* *	* *	* *
CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC					
GAG TAC TAG AGG GCC TGG GGA CTC CAG TGT ACG CAC CAC CAC CTG CAC TCG GTG CTT CTG					
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp>					
1150	1160	1170	1180	1190	1200
* * *	* *	* *	* *	* *	* *
CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG					
GGA CTC CAG TTC AAG TTG ACC ATG CAC CTG CCG CAC CTC CAC GTA TTA CGG TTC TGT TTC					
Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys>					
1210	1220	1230	1240	1250	1260
* * *	* *	* *	* *	* *	* *
CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG GTG AGC GTC CTC ACC GTC CTG CAC					
GGC GCC CTC CTC GTC ATG TTG TCG TGC ATG GCA CAC CAG TCG CAG GAG TGG CAG GAC GTG					
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His>					
1270	1280	1290	1300	1310	1320
* * *	* *	* *	* *	* *	* *
CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC CCA GCC					
GTC CTG ACC GAC TTA CCG TTC CTC ATG TTC ACG TTC CAG AGG TTG TTT CGG GAG GGT CGG					
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala>					
1330	1340	1350	1360	1370	1380
* * *	* *	* *	* *	* *	* *
CCC ATC GAG AAA ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC					
GGG TAG CTC TTT TGG TAG AGG TTT CCG TTT CCC GTC GGG GCT CTT GGT GTC CAC ATG TGG					
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr>					
1390	1400	1410	1420	1430	1440
* * *	* *	* *	* *	* *	* *
CTG CCC CCA TCC CGG GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA					
GAC GGG GGT AGG GCC CTA CTC GAC TGG TTC TTG GTC CAG TCG GAC TGG ACG GAC CAG TTT					
Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys>					
1450	1460	1470	1480	1490	1500
* * *	* *	* *	* *	* *	* *
GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC					
CCG AAG ATA GGG TCG CTG TAG CCG CAC CTC ACC CTC TCG TTA CCC GTC GGC CTC TTG TTG					
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn>					
1510	1520	1530	1540	1550	1560
* * *	* *	* *	* *	* *	* *
TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC					
ATG TTC TGG TGC GGA GGG CAC GAC CTG AGG CTG CCG AGG AAG AAG GAG ATG TCG TTC GAG					
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu>					
1570	1580	1590	1600	1610	1620
* * *	* *	* *	* *	* *	* *
ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG CAT GAG					
TGG CAC CTG TTC TCG TCC ACC GTC GTC CCC TTG CAG AAG AGT ACG AGG CAC TAC GTA CTC					
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu>					

Fig.13D.

	1630		1640		1650		1660		1670								
	*	*	*	*	*	*	*	*	*								
GCT	CTG	CAC	AAC	CAC	TAC	ACG	CAG	AAG	AGC	CTC	TCC	CTG	TCT	CCG	GGT	AAA	TGA
CGA	GAC	GTG	TTG	GTG	ATG	TGC	GTC	TTC	TCG	GAG	AGG	GAC	AGA	GGC	CCA	TTT	ACT
Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	***>

Fig. 14A.

	10	20	30	40	50	60													
*	*	*	*	*	*	*													
ATG	GTC	AGC	TAC	TGG	GAC	ACC	GGG	GTC	CTG	CTG	TGC	GCG	CTG	CTC	AGC	TGT	CTG	CTT	CTC
TAC	CAG	TCG	ATG	ACC	CTG	TGG	CCC	CAG	GAC	GAC	ACG	CGC	GAC	GAG	TCG	ACA	GAC	GAA	GAG
Met	Val	Ser	Tyr	Trp	Asp	Thr	Gly	Val	Leu	Leu	Cys	Ala	Leu	Leu	Ser	Cys	Leu	Leu	Leu>
	70	80	90	100	110	120													
*	*	*	*	*	*	*													
ACA	GGA	TCT	AGT	TCC	GGA	GGT	AGA	CCT	TTC	GTA	GAG	ATG	TAC	AGT	GAA	ATC	CCC	GAA	ATT
TGT	CCT	AGA	TCA	AGG	CCT	CCA	TCT	GGA	AAG	CAT	CTC	TAC	ATG	TCA	CTT	TAG	GGG	CTT	TAA
Thr	Gly	Ser	Ser	Ser	Gly	Gly	Arg	Pro	Phe	Val	Glu	Met	Tyr	Ser	Glu	Ile	Pro	Glu	Ile>
	130	140	150	160	170	180													
*	*	*	*	*	*	*													
ATA	CAC	ATG	ACT	GAA	GGA	AGG	GAG	CTC	GTC	ATT	CCC	TGC	CGG	GTT	ACG	TCA	CCT	AAC	ATC
TAT	GTG	TAC	TGA	CTT	CCT	TCC	CTC	GAG	CAG	TAA	GGG	ACG	GCC	CAA	TGC	AGT	GGA	TTG	TAG
Ile	His	Met	Thr	Glu	Gly	Arg	Glu	Leu	Val	Ile	Pro	Cys	Arg	Val	Thr	Ser	Pro	Asn	Ile>
	190	200	210	220	230	240													
*	*	*	*	*	*	*													
ACT	GTT	ACT	TTA	AAA	AAG	TTT	CCA	CTT	GAC	ACT	TTG	ATC	CCT	GAT	GGA	AAA	CGC	ATA	ATC
TGA	CAA	TGA	AAT	TTT	TTC	AAA	GGT	GAA	CTG	TGA	AAC	TAG	GGA	CTA	CCT	TTT	GCG	TAT	TAG
Thr	Val	Thr	Leu	Lys	Lys	Phe	Pro	Leu	Asp	Thr	Leu	Ile	Pro	Asp	Gly	Lys	Arg	Ile	Ile>
	250	260	270	280	290	300													
*	*	*	*	*	*	*													
TGG	GAC	AGT	AGA	AAG	GGC	TTC	ATC	ATA	TCA	AAT	GCA	ACG	TAC	AAA	GAA	ATA	GGG	CTT	CTG
ACC	CTG	TCA	TCT	TTC	CCG	AAG	TAG	TAT	AGT	TTA	CGT	TGC	ATG	TTT	CTT	TAT	CCC	GAA	GAC
Trp	Asp	Ser	Arg	Lys	Gly	Phe	Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys	Glu	Ile	Gly	Leu	Leu>
	310	320	330	340	350	360													
*	*	*	*	*	*	*													
ACC	TGT	GAA	GCA	ACA	GTC	AAT	GGG	CAT	TTG	TAT	AAG	ACA	AAC	TAT	CTC	ACA	CAT	CGA	CAA
TGG	ACA	CTT	CGT	TGT	CAG	TTA	CCC	GTA	AAC	ATA	TTC	TGT	TTG	ATA	GAG	TGT	GTA	GCT	GTT
Thr	Cys	Glu	Ala	Thr	Val	Asn	Gly	His	Leu	Tyr	Lys	Thr	Asn	Tyr	Leu	Thr	His	Arg	Gln>
	370	380	390	400	410	420													
*	*	*	*	*	*	*													
ACC	AAT	ACA	ATC	ATA	GAT	GTC	CAA	ATA	AGC	ACA	CCA	CGC	OCA	GTC	AAA	TTA	CTT	AGA	GGC
TGG	TTA	TGT	TAG	TAT	CTA	CAG	GTT	TAT	TCG	TGT	GGT	GCG	GGT	CAG	TTT	AAT	GAA	TCT	CCG
Thr	Asn	Thr	Ile	Ile	Asp	Val	Gln	Ile	Ser	Thr	Pro	Arg	Pro	Val	Lys	Leu	Leu	Arg	Gly>
	430	440	450	460	470	480													
*	*	*	*	*	*	*													
CAT	ACT	CTT	GTC	CTC	AAT	TGT	ACT	GCT	ACC	ACT	CCC	TTG	AAC	ACG	AGA	GTT	CAA	ATG	ACC
GTA	TGA	GAA	CAG	GAG	TTA	ACA	TGA	CGA	TGG	TGA	GGG	AAC	TTG	TGC	TCT	CAA	GTT	TAC	TGG
His	Thr	Leu	Val	Leu	Asn	Cys	Thr	Ala	Thr	Thr	Pro	Leu	Asn	Thr	Arg	Val	Gln	Met	Thr>
	490	500	510	520	530	540													
*	*	*	*	*	*	*													
TGG	AGT	TAC	CCT	GAT	GAA	ATT	GAC	CAA	AGC	AAT	TCC	CAT	GCC	AAC	ATA	TTC	TAC	AGT	GTT
ACC	TCA	ATG	GGA	CTA	CTT	TAA	CTG	GTT	TCG	TTA	AGG	GTA	CGG	TTG	TAT	AAG	ATG	TCA	CAA
Trp	Ser	Tyr	Pro	Asp	Glu	Ile	Asp	Gln	Ser	Asn	Ser	His	Ala	Asn	Ile	Phe	Tyr	Ser	Val>

Fig. 14B.

550 560 570 580 590 600
* * * * *
CTT ACT ATT GAC AAA ATG CAG AAC AAA GAC AAA GGA CTT TAT ACT TGT CGT GTA AGG AGT
GAA TGA TAA CTG TTT TAC GTC TTG TTT CTG TTT CCT GAA ATA TGA ACA GCA CAT TCC TCA
Leu Thr Ile Asp Lys Met Gln Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser>

610 620 630 640 650 660
* * * * *
GGA CCA TCA TTC AAA TCT GTT AAC ACC TCA GTG CAT ATA TAT GAT AAA GCA GGC CCG GGC
CCT GGT AGT AAG TTT AGA CAA TTG TGG AGT CAC GTA TAT ATA CTA TTT CGT CCG GGC CCG
Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Gly Pro Gly>

670 680 690 700 710 720
* * * * *
GAG CCC AAA TCT TGT GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG
CTC GGG TTT AGA ACA CTG TTT TGA GTG TGT ACG GGT GGC ACG GGT CGT GGA CTT GAG GAC
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu>

730 740 750 760 770 780
* * * * *
GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG ATC TCC CGG
CCC CCT GGC AGT CAG AAG GAG AAG GGG GGT TTT GGG TTC CTG TGG GAG TAC TAG AGG GCC
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg>

790 800 810 820 830 840
* * * * *
ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC
TGG GGA CTC CAG TGT ACG CAC CAC CAC CTG CAC TCG GTG CTT CTG GGA CTC CAG TTC AAG
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe>

850 860 870 880 890 900
* * * * *
AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG CCG GAG GAG CAG
TTG ACC ATG CAC CTG CCG CAC CTC CAC GTA TTA CCG TTC TGT TTC GGC GCC CTC CTC GTC
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln>

910 920 930 940 950 960
* * * * *
TAC AAC AGC ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT
ATG TTG TCG TGC ATG GCA CAC CAG TCG CAG GAG TGG CAG GAC GTG GTC CTG ACC GAC TTA
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn>

970 980 990 1000 1010 1020
* * * * *
GGC AAG GAG TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC
CCG TTC CTC ATG TTC ACG TTC CAG AGG TTG TTT CCG GAG GGT CCG GGG TAG CTC TTT TGG
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr>

1030 1040 1050 1060 1070 1080
* * * * *
ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG
TAG AGG TTT CCG TTT CCC GTC GGG GCT CTT GGT GTC CAC ATG TGG GAC GGG GGT AGG GCC
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg>

Fig.14C.

```
      1090      1100      1110      1120      1130      1140
      *        *        *        *        *        *
GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC
CTA CTC GAC TGG TTC TTG GTC CAG TCG GAC TGG ACG GAC CAG TTT CCG AAG ATA GGG TCG
Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser>

      1150      1160      1170      1180      1190      1200
      *        *        *        *        *        *
GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT
CTG TAG CCG CAC CTC ACC CTC TCG TTA CCC GTC GGC CTC TTG TTG ATG TTC TGG TGC GGA
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro>

      1210      1220      1230      1240      1250      1260
      *        *        *        *        *        *
CCC GTG CTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC
GGG CAC GAC CTG AGG CTG CCG AGG AAG AAG GAG ATG TCG TTC GAG TGG CAC CTG TTC TCG
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser>

      1270      1280      1290      1300      1310      1320
      *        *        *        *        *        *
AGG TGG CAG CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC
TCC ACC GTC GTC CCC TTG CAG AAG AGT ACG AGG CAC TAC GTA CTC CGA GAC GTG TTG GTG
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His>

      1330      1340      1350
      *        *        *        *        *
TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT AAA TGA
ATG TGC GTC TTC TCG GAG AGG GAC AGA GGC CCA TTT ACT
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys ***>
```

Fig. 15A.

```
      10      20      30      40      50      60
*   *   *   *   *   *   *   *   *   *   *
ATG GTC AGC TAC TGG GAC ACC GGG GTC CTG CTG TGC GCG CTG CTC AGC TGT CTG CTT CTC
TAC CAG TCG ATG ACC CTG TGG CCC CAG GAC GAC ACG CGC GAC GAG TCG ACA GAC GAA GAG
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser Cys Leu Leu Leu>

      70      80      90      100     110     120
*   *   *   *   *   *   *   *   *   *   *
ACA GGA TCT AGT TCC GGA GGT AGA CCT TTC GTA GAG ATG TAC AGT GAA ATC CCC GAA ATT
TGT CCT AGA TCA AGG CCT CCA TCT GGA AAG CAT CTC TAC ATG TCA CTT TAG GGG CTT TAA
Thr Gly Ser Ser Ser Gly Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile>

     130     140     150     160     170     180
*   *   *   *   *   *   *   *   *   *   *
ATA CAC ATG ACT GAA GGA AGG GAG CTC GTC ATT CCC TGC CGG GTT ACG TCA CCT AAC ATC
TAT GTG TAC TGA CTT CCT TCC CTC GAG CAG TAA GGG ACG GCC CAA TGC AGT GGA TTG TAG
Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile>

     190     200     210     220     230     240
*   *   *   *   *   *   *   *   *   *   *
ACT GTT ACT TTA AAA AAG TTT CCA CTT GAC ACT TTG ATC CCT GAT GGA AAA CGC ATA ATC
TGA CAA TGA AAT TTT TTC AAA GGT GAA CTG TGA AAC TAG GGA CTA CCT TTT GCG TAT TAG
Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile>

     250     260     270     280     290     300
*   *   *   *   *   *   *   *   *   *   *
TGG GAC AGT AGA AAG GGC TTC ATC ATA TCA AAT GCA ACG TAC AAA GAA ATA GGG CTT CTG
ACC CTG TCA TCT TTC CCG AAG TAG TAT AGT TTA CGT TGC ATG TTT CTT TAT CCC GAA GAC
Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu>

     310     320     330     340     350     360
*   *   *   *   *   *   *   *   *   *   *
ACC TGT GAA GCA ACA GTC AAT GGG CAT TTG TAT AAG ACA AAC TAT CTC ACA CAT CGA CAA
TGG ACA CTT CGT TGT CAG TTA CCC GTA AAC ATA TTC TGT TTG ATA GAG TGT GTA GCT GTT
Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln>

     370     380     390     400     410     420
*   *   *   *   *   *   *   *   *   *   *
ACC AAT ACA ATC ATA GAT GTC CAA ATA AGC ACA CCA CGC CCA GTC AAA TTA CTT AGA GGC
TGG TTA TGT TAG TAT CTA CAG GTT TAT TCG TGT GGT GCG GGT CAG TTT AAT GAA TCT CCG
Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val Lys Leu Leu Arg Gly>

     430     440     450     460     470     480
*   *   *   *   *   *   *   *   *   *   *
CAT ACT CTT GTC CTC AAT TGT ACT GCT ACC ACT CCC TTG AAC ACG AGA GTT CAA ATG ACC
GTA TGA GAA CAG GAG TTA ACA TGA CGA TGG TGA GGG AAC TTG TGC TCT CAA GTT TAC TGG
His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr Arg Val Gln Met Thr>

     490     500     510     520     530     540
*   *   *   *   *   *   *   *   *   *   *
TGG AGT TAC CCT GAT GAA AAA AAT AAG AGA GCT TCC GTA AGG CGA CGA ATT GAC CAA AGC
ACC TCA ATG GGA CTA CTT TTT TTA TTC TCT CGA AGG CAT TCC GCT GCT TAA CTG GTT TCG
Trp Ser Tyr Pro Asp Glu Lys Asn Lys Arg Ala Ser Val Arg Arg Arg Ile Asp Gln Ser>
```

Fig.15B.

550 560 570 580 590 600
* * * * *
AAT TCC CAT GCC AAC ATA TTC TAC AGT GTT CTT ACT ATT GAC AAA ATG CAG AAC AAA GAC
TTA AGG GTA CGG TTG TAT AAG ATG TCA CAA GAA TGA TAA CTG TTT TAC GTC TTG TTT CTG
Asn Ser His Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys Met Gln Asn Lys Asp>

610 620 630 640 650 660
* * * * *
AAA GGA CTT TAT ACT TGT CGT GTA AGG AGT GGA CCA TCA TTC AAA TCT GTT AAC ACC TCA
TTT CCT GAA ATA TGA ACA GCA CAT TCC TCA CCT GGT AGT AAG TTT AGA CAA TTG TGG AGT
Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser>

670 680 690 700 710 720
* * * * *
GTG CAT ATA TAT GAT AAA GCA GGC CCG GGC GAG CCC AAA TCT TGT GAC AAA ACT CAC ACA
CAC GTA TAT ATA CTA TTT CGT CCG GGC CCG CTC GGG TTT AGA ACA CTG TTT TGA GTG TGT
Val His Ile Tyr Asp Lys Ala Gly Pro Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr>

730 740 750 760 770 780
* * * * *
TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA
ACG GGT GGC ACG GGT CGT GGA CTT GAG GAC CCC CCT GGC AGT CAG AAG GAG AAG GGG GGT
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro>

790 800 810 820 830 840
* * * * *
AAA CCC AAG GAC ACC CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC
TTT GGG TTC CTG TGG GAG TAC TAG AGG GCC TGG GGA CTC CAG TGT ACG CAC CAC CAC CTG
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp>

850 860 870 880 890 900
* * * * *
GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT
CAC TGG GTG CTT CTG GGA CTC CAG TTC AAG TTG ACC ATG CAC CTG CCG CAC CTC CAC GTA
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His>

910 920 930 940 950 960
* * * * *
AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG GTC AGC GTC
TTA CGG TTC TGT TTC GGC GCC CTC CTC GTC ATG TTG TCG TGC ATG GCA CAC CAG TCG CAG
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val>

970 980 990 1000 1010 1020
* * * * *
CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC AAC
GAG TGG CAG GAC GTG GTC CTG ACC GAC TTA CCG TTC CTC ATG TTC ACG TTC CAG AGG TTG
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn>

1030 1040 1050 1060 1070 1080
* * * * *
AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA
TTT CGG GAG GGT CGG GGG TAG CTC TTT TGG TAG AGG TTT CGG TTT CCC GTC GGG GCT CTT
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu>

Fig. 15C.

```

      1090      1100      1110      1120      1130      1140
      *        *        *        *        *        *
CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG
GGT GTC CAC ATG TGG GAC GGG GGT AGG GCC CTA CTC GAC TGG TTC TTG GTC CAG TCG GAC
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu>

      1150      1160      1170      1180      1190      1200
      *        *        *        *        *        *
ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG
TGG ACG GAC CAG TTT CCG AAG ATA GGG TCG CTG TAG CGG CAC CTC ACC CTC TCG TTA CCC
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly>

      1210      1220      1230      1240      1250      1260
      *        *        *        *        *        *
CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC GGC TCC TTC TTC
GTC GGC CTC TTG TTG ATG TTC TGG TGC GGA GGG CAC GAC CTG AGG CTG CCG AGG AAG AAG
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe>

      1270      1280      1290      1300      1310      1320
      *        *        *        *        *        *
CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC TCA TGC
GAG ATG TCG TTC GAG TGG CAC CTG TTC TCG TCC ACC GTC GTC CCC TTG CAG AAG AGT ACG
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys>

      1330      1340      1350      1360      1370      1380
      *        *        *        *        *        *
TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG
AGG CAC TAC GTA CTC CGA GAC GTG TTG GTG ATG TGC GTC TTC TCG GAG AGG GAC AGA GGC
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro>

      *
GGT AAA TGA
CCA TTT ACT
Gly Lys ***>
```

Fig.16A.

```

      10      20      30      40      50      60
      *      *      *      *      *      *
ATG GTC AGC TAC TGG GAC ACC GGG GTC CTG CTG TGC GCG CTG CTC AGC TGT CTG CTT CTC
TAC CAG TCG ATG ACC CTG TGG CCC CAG GAC GAC ACG CGC GAC GAG TCG ACA GAC GAA GAG
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser Cys Leu Leu Leu>

      70      80      90      100     110     120
      *      *      *      *      *      *
ACA GGA TCT AGT TCA GGT TCA AAA TTA AAA GAT CCT GAA CTG AGT TTA AAA GGC ACC CAG
TGT CCT AGA TCA AGT CCA AGT TTT AAT TTT CTA GGA CTT GAC TCA AAT TTT CCG TGG GTC
Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro Glu Leu Ser Leu Lys Gly Thr Gln>

      130     140     150     160     170     180
      *      *      *      *      *      *
CAC ATC ATG CAA GCA GGC CAG ACA CTG CAT CTC CAA TGC AGG GGG GAA GCA GCC CAT AAA
GTG TAG TAC GTT CGT CCG GTC TGT GAC GTA GAG GTT ACG TCC CCC CTT CGT CCG GTA TTT
His Ile Met Gln Ala Gly Gln Thr Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys>

      190     200     210     220     230     240
      *      *      *      *      *      *
TGG TCT TTG CCT GAA ATG GTG AGT AAG GAA AGC GAA AGG CTG AGC ATA ACT AAA TCT GCC
ACC AGA AAC GGA CTT TAC CAC TCA TTC CTT TCG CTT TCC GAC TCG TAT TGA TTT AGA CGG
Trp Ser Leu Pro Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala>

      250     260     270     280     290     300
      *      *      *      *      *      *
TGT GGA AGA AAT GGC AAA CAA TTC TGC AGT ACT TTA ACC TTG AAC ACA GCT CAA GCA AAC
ACA CCT TCT TTA CCG TTT GTT AAG ACG TCA TGA AAT TGG AAC TTG TGT CGA GTT CGT TTG
Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr Ala Gln Ala Asn>

      310     320     330     340     350     360
      *      *      *      *      *      *
CAC ACT GGC TTC TAC AGC TGC AAA TAT CTA GCT GTA CCT ACT TCA AAG AAG AAG GAA ACA
GTG TGA CCG AAG ATG TCG ACG TTT ATA GAT CGA CAT GGA TGA AGT TTC TTC TTC CTT TGT
His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val Pro Thr Ser Lys Lys Lys Glu Thr>

      370     380     390     400     410     420
      *      *      *      *      *      *
GAA TCT GCA ATC TAT ATA TTT ATT AGT GAT ACA GGT AGA CCT TTC GTA GAG ATG TAC AGT
CTT AGA CGT TAG ATA TAT AAA TAA TCA CTA TGT CCA TCT GGA AAG CAT CTC TAC ATG TCA
Glu Ser Ala Ile Tyr Ile Phe Ile Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser>

      430     440     450     460     470     480
      *      *      *      *      *      *
GAA ATC CCC GAA ATT ATA CAC ATG ACT GAA GGA AGG GAG CTC GTC ATT CCC TGC CGG GTT
CTT TAG GGG CTT TAA TAT GTG TAC TGA CTT CCT TCC CTC GAG CAG TAA GGG ACG GCC CAA
Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val>

      490     500     510     520     530     540
      *      *      *      *      *      *
ACG TCA CCT AAC ATC ACT GTT ACT TTA AAA AAG TTT CCA CTT GAC ACT TTG ATC CCT GAT
TGC AGT GGA TTG TAG TGA CAA TGA AAT TTT TTC AAA GGT GAA CTG TGA AAC TAG GGA CTA
Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp>
```

Fig.16B.

550 560 570 580 590 600
* * * * *
GGA AAA CGC ATA ATC TGG GAC AGT AGA AAG GGC TTC ATC ATA TCA AAT GCA ACG TAC AAA
CCT TTT GCG TAT TAG ACC CTG TCA TCT TTC CCG AAG TAG TAT AGT TTA CGT TGC ATG TTT
Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys>

610 620 630 640 650 660
* * * * *
GAA ATA GGG CTT CTG ACC TGT GAA GCA ACA GTC AAT GGG CAT TTG TAT AAG ACA AAC TAT
CTT TAT CCC GAA GAC TGG ACA CTT CGT TGT CAG TTA CCC GTA AAC ATA TTC TGT TTG ATA
Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr>

670 680 690 700 710 720
* * * * *
CTC ACA CAT CGA CAA ACC AAT ACA ATC ATA GAT GTC CAA ATA AGC ACA CCA CGC CCA GTC
GAG TGT GTA GCT GTT TGG TTA TGT TAG TAT CTA CAG GTT TAT TCG TGT GGT GCG GGT CAG
Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val>

730 740 750 760 770 780
* * * * *
AAA TTA CTT AGA GGC CAT ACT CTT GTC CTC AAT TGT ACT GCT ACC ACT CCC TTG AAC ACG
TTT AAT GAA TCT CCG GTA TGA GAA CAG GAG TTA ACA TGA CGA TGG TGA GGG AAC TTG TGC
Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr>

790 800 810 820 830 840
* * * * *
AGA GTT CAA ATG ACC TGG AGT TAC CCT GAT GAA AAA AAT AAG AAC GCT TCC GTA AGG CGA
TCT CAA GTT TAC TGG ACC TCA ATG GGA CTA CTT TTT TTA TTC TTG CGA AGG CAT TCC GCT
Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys Asn Lys Asn Ala Ser Val Arg Arg>

850 860 870 880 890 900
* * * * *
CGA ATT GAC CAA AGC AAT TCC CAT GCC AAC ATA TTC TAC AGT GTT CTT ACT ATT GAC AAA
GCT TAA CTG GTT TCG TTA AGG GTA CGG TTG TAT AAG ATG TCA CAA GAA TGA TAA CTG TTT
Arg Ile Asp Gln Ser Asn Ser His Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys>

910 920 930 940 950 960
* * * * *
ATG CAG AAC AAA GAC AAA GGA CTT TAT ACT TGT CGT GTA AGG AGT GGA CCA TCA TTC AAA
TAC GTC TTG TTT CTG TTT CCT GAA ATA TGA ACA GCA CAT TCC TCA CCT GGT AGT AAG TTT
Met Gln Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys>

970 980 990 1000 1010 1020
* * * * *
TCT GTT AAC ACC TCA GTG CAT ATA TAT GAT AAA GCA GGC CCG GGC GAG CCC AAA TCT TGT
AGA CAA TTG TGG AGT CAC GTA TAT ATA CTA TTT CGT CCG GGC CCG CTC GGG TTT AGA ACA
Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Gly Pro Gly Glu Pro Lys Ser Cys>

1030 1040 1050 1060 1070 1080
* * * * *
GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC
CTG TTT TGA GTG TGT ACG GGT GGC ACG GGT CGT GGA CTT GAG GAC CCC CCT GGC AGT CAG
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val>

Fig.16C.

```

      1090      1100      1110      1120      1130      1140
      *        *        *        *        *        *
TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG ATC TCG CGG ACC CCT GAG GTC ACA
AAG GAG AAG GGG GGT TTT GGG TTC CTG TGG GAG TAC TAG AGG GCC TGG GGA CTC CAG TGT
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr>

      1150      1160      1170      1180      1190      1200
      *        *        *        *        *        *
TGC GTG GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC
ACG CAC CAC CAC CTG CAC TCG GTG CTT CTG GGA CTC CAG TTC AAG TTG ACC ATG CAC CTG
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp>

      1210      1220      1230      1240      1250      1260
      *        *        *        *        *        *
GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC
CCG CAC CTC CAC GTA TTA CGG TTC TGT TTC GGC GCC CTC CTC GTC ATG TTG TCG TGC ATG
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr>

      1270      1280      1290      1300      1310      1320
      *        *        *        *        *        *
CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG
GCA CAC CAG TCG CAG GAG TGG CAG GAC GTG GTC CTG ACC GAC TTA CCG TTC CTC ATG TTC
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys>

      1330      1340      1350      1360      1370      1380
      *        *        *        *        *        *
TGC AAG GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC AAA
ACG TTC CAG AGG TTG TTT CGG GAG GGT CGG GGG TAG CTC TTT TGG TAG AGG TTT CGG TTT
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys>

      1390      1400      1410      1420      1430      1440
      *        *        *        *        *        *
GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG GAT GAG CTG ACC AAG
CCC GTC GGG GCT CTT GGT GTC CAC ATG TGG GAC GGG GGT AGG GCC CTA CTC GAC TGG TTC
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys>

      1450      1460      1470      1480      1490      1500
      *        *        *        *        *        *
AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG
TTG GTC CAG TCG GAC TGG ACG GAC CAG TTT CCG AAG ATA GGG TCG CTG TAG CGG CAC CTC
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu>

      1510      1520      1530      1540      1550      1560
      *        *        *        *        *        *
TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC
ACC CTC TCG TTA CCC GTC GGC CTC TTG TTG ATG TTC TGG TGC GGA GGG CAC GAC CTG AGG
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser>

      1570      1580      1590      1600      1610      1620
      *        *        *        *        *        *
GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG
CTG CCG AGG AAG AAG GAG ATG TCG TTC GAG TGG CAC CTG TTC TCG TCC ACC GTC GTC CCC
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly>

```

Fig.16D.

```
          1630          1640          1650          1660          1670          1680
          *            *            *            *            *            *
AAC GTC TTC TCA TGC TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC
TTG CAG AAG AGT ACG AGG CAC TAC GTA CTC CGA GAC GTG TTG GTG ATG TGC GTC TTC TCG
Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser>

          1690          1700
          *            *            *            *
CTC TCC CTG TCT CCG GGT AAA TGA
GAG AGG GAC AGA GGC CCA TTT ACT
Leu Ser Leu Ser Pro Gly Lys ***>
```

Fig. 17.




Fig.18.




Fig.19.




Fig.20.




Fig.21A.

>EcoRI_site
10 20 30 40 50 60 70 80
AAGCTTGGGCTGCAGGTCGATCGACTCTAGAGGATCGATCCCCGGGCGAGCTCGAATTGCAACCAACCATGGTCAGCTAC
TTCGAACCGACGTCAGCTAGCTGAGATCTCCTAGCTAGGGGCCGCTCGAGCTTAAGCGTTGGTGGTACCAGTCGATG
M V S Y>
1 4

>
>BspEI_bridge
90 100 110 120 130 140 150 160
TGGGACACCGGGTCTGCTGTGCGCGCTGCTCAGCTGTCTGCTTCTCACAGGATCTAGTTCCGGAGGTAGACCTTTCGT
ACCCGTGTGGCCCCAGGACGACACGCGCGACGAGTTCGACAGACGAAGAGTGTCTAGATCAAGGCCCTCCATCTCGAAAAGCA
W D T G V L L C A L L S C L L L T G S S>

FLTL1 SS
S G>

G R P F V>
31

170 180 190 200 210 220 230 240
AGAGATGTACAGTGAAATCCCCGAAATTATACACATGACTGAAGGAAGGGAGCTCGTCAATCCCTGCCGGGTACGTCAC
TCTCTACATGTCACTTTAGGGGCTTTAATATGTGTACTGACTTCCTTCCCTCGAGCAGTAAGGGACGGCCCAATGCAGTG
E M Y S E I P E I I H M T E G R E L V I P C R V T S>
57

HFLT1 D2
250 260 270 280 290 300 310 320
CTAACATCACTGTTACTTTAAAAAAGTTTCCACTTGACACTTTGATCCCTGATGGAAAACGCATAATCTGGGACAGTAGA
GATTGTAGTGACAATGAAATTTTTTCAAAGGTGAAGTGTGAAACTAGGGACTACCTTTTGCGTATTAGACCCCTGTCATCT
P N I T V T L K K F P L D T L I P D G K R I I W D S R>
84

HFLT1 D2
330 340 350 360 370 380 390 400
AAGGGCTTCATCATATCAAAATGCAACGTACAAAGAAATAGGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTA
TTCCCGAAGTAGTATAGTTTACGTTGCATGTTTCTTTATCCCGAAGACTGGACACTTGGTTGTCAGTTACCCGTAAACAT
K G F I I S N A T Y K E I G L L T C E A T V N G H L Y>
111

HFLT1 D2
410 420 430 440 450 460 470 480
TAAGACAAACTATCTCACACATCGACAAACCAATACAATCATAGATGTGGTTCTGAGTCCGTCTCATGGAATTGAACTAT
ATTCTGTTTGATAGAGTGTGTAGCTGTTTGGTTATGTTAGTATCTACACCAAGACTCAGGCAGAGTACCCTTAACCTGATA
K T N Y L T H R Q T N T I I D>

HFLT1 D2
V V L S P S H G I E L>
137

HFLK1 D3

Fig.21B.

490 500 510 520 530 540 550 560
CTGTGGAGAAAAGCTTGTCTTAAATTGTACAGCAAGAACTGAACATAATGTGGGGATTGACTTCAACTGGGAATACCCCT
GACAACCTCTTTTCGAACAGAAATTTAACATGTCGTTCTTGACTTGATTACACCCCTAACTGAAGTTGACCCCTATGGGA
S V G E K L V L N C T A R T E L N V G I D F N W E Y P>
164
HFLK1 D3>

570 580 590 600 610 620 630 640
TCTTCGAAGCATCAGCATAAGAACTTGTAAACCGAGACCTAAAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTGTAG
AGAAGCTTCGTAGTCGTATTCTTTGAACATTTGGCTCTGGATTTTTGGGTCAGACCCCTCACTCTACTTCTTTAAAAACTC
S S K H Q H K K L V N R D L K T Q S G S E M K K F L S>
191
HFLK1 D3>

650 660 670 680 690 700 710 720
CACCTTAACATATAGATGGTGTAAACCGGAGTGACCAAGGATTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAGA
GTGGAATTGATATCTACCACATGGGGCTCACTGGTTCTTAACATGTGGACACGTCGTAGGTCACCCGACTACTGGTTCT
T L T I D G V T R S D Q G L Y T C A A S S G L M T K>
217
HFLK1 D3>

>Srf_Bridge_
730 740 750 760 770 780 790 800
AGAACAGCACATTTGTTCAGGGTCCATGAAAAGGGCCCGGGCGACAAAACCTCACACATGCCACCGTGCCGAGCACCTGAA
TCTTGTGCGTTAAACAGTCCAGGTACTTTTCCCGGGCCCGCTGTTTGTAGTGTGTACGGGTGGCACGGGTCTGGGACTT
K N S T F V R V H E K>
HFLK1 D3>
G P G>
D K T H T C P P C P A P E>
244
FCAC1 (A)>

810 820 830 840 850 860 870 880
CTCCTGGGGGACCGTCAGTCTTCTCTTCCCCCAAAACCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTCAC
GAGGACCCCTTGGCAGTCAAGAGGAGAAGGGGGTTTGGGTTCTGTGGGAGTACTAGAGGGCTGGGGACTCCAGTG
L L G G P S V F L F P P K P K D T L M I S R T P E V T>
271
FCAC1 (A)>

890 900 910 920 930 940 950 960
ATGCGTGGTGGTGGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATG
TACGCACCAACCACTGCCTCGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATGCACCTGCCGCACCTCCAGTATTAC
C V V V D V S H E D P E V K F N W Y V D G V E V H N>
297
FCAC1 (A)>

970 980 990 1000 1010 1020 1030 1040
CCAAGACAAAGCCGGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTTCAGCGTCCCTACCGTCCCTGCACCAAGGACTGG
GGTTCGTGTTTCGGCGCCCTCTCGTTCATGTTGTCGTGTCATGGCACACCAAGTCGAGGAGTGGCAGGACGTGGTCTGACC
A K T K P R E E Q Y N S T Y R V V S V L T V L H Q D W>
324
FCAC1 (A)>

Fig.21C.

```

1050      1060      1070      1080      1090      1100      1110      1120
CTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAA
GACTTACCGTTTCCTCATGTTTCACGTTCCAGAGGTTGTTTCGGGAGGGTCGGGGGTAGCTCTTTTGGTAGAGGTTTCGGTT
L N G K E Y K C K V S N K A L P A P I E K T I S K A K>
                                                    351
_____FCAC1 (A)_____>

                                     >A>C_A_allotype
                                     |
                                     >G>T_A_allotype
                                     |   |
1130      1140      1150      1160      1170      1180      1190      1200
AGGGCAGCCCCGAGAACCACAGGTGTACACCCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCT
TCCCGTCGGGGCTCTTGGTGTCCACATGTGGGACGGGGGTAGGGCCCTACTCGACTGGTTCCTGGTCCAGTCGGACTGGA
G Q P R E P Q V Y T L P P S R D E L T K N Q V S L T>
                                                    377
_____FCAC1 (A)_____>

1210      1220      1230      1240      1250      1260      1270      1280
GCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACCTACAAGACC
CGGACCAGTTTCCGAAGATAGGGTCGCTGTAGCGGCACCTCACCTCTCGTTACCCGTCGGCCTCTTGTGTGATGTTCTGG
C L V K G F Y P S D I A V E W E S N G Q P E N N Y K T>
                                                    404
_____FCAC1 (A)_____>

                                     >T>C
                                     |
1290      1300      1310      1320      1330      1340      1350      1360
ACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGG
TGCGGAGGGCACGACCTGAGGCTGCCGAGGAAGAAGGAGATATCGTTTCGAGTGGCACCTGTTCTCGTCCACCGTCGTCCC
T P P V L D S D G S F F L Y S K L T V D K S R W Q Q G>
                                                    431
_____FCAC1 (A)_____>

1370      1380      1390      1400      1410      1420      1430      1440
GAACGCTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACCTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTA
CTTGCAAGAGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGTATGTGCGTCTTCTCGGAGAGGGACAGAGGCCCAT
N V F S C S V M H E A L H N H Y T Q K S L S L S P G>
                                                    457
_____FCAC1 (A)_____>

>NotI_site
|
|1450
AATGAGCGGCCGC
TTACTCGCCGGCG
K *>
458
_____>
```

Fig.22A.

>EcoRI_site
|
10 20 30 40 50 60 70 80
AAGCTTGGGCTGCAGGTGATCGACTCTAGAGGATCGATCCCCGGGCGAGCTCGAATTTCGCAACCACCATGGTCAGCTAC
TTCGAACCCGACGTCCAGCTAGCTGAGATCTCCTAGCTAGGGGCCCGCTCGAGCTTAAGCGTTGGTGGTACCAGTCGATG
M V S Y>
1 4
_____>

>BspEI_bridge
|
90 100 110 120 130 140 150 160
TGGGACACCGGGTCTGCTGTGCGCGCTGCTCAGCTGTCTGCTTCTCACAGGATCTAGTTCCGGAGGTAGACCTTTGCT
ACCTGTGGCCCCAGGACGACACGCGCGACGAGTCGACAGACGAAGAGTGTCTAGATCAAGGCCTCCATCTGGAAAGCA
W D T G V L L C A L L S C L L T G S S>
_____FLT1 SIGNAL SEQUENCE_____>
S G>
_____>
G R P F V>
31
_____>

170 180 190 200 210 220 230 240
AGAGATGTACAGTGAAATCCCCGAAATTATACACATGACTGAAGGAAGGGAGCTCGTCAATCCCTGCCGGGTACGTAC
TCTCTACATGTCACTTTAGGGGCTTTAATATGTGTACTGACTTCCTTCCCTCGAGCAGTAAGGGACGGCCCAATGCAGTG
E M Y S E I P E I I H M T E G R E L V I P C R V T S>
57
_____FLT1 IG DOMAIN 2_____>

250 260 270 280 290 300 310 320
CTAACATCACTGTTACTTTAAAAAAGTTTCCACTTGACACTTTTGATCCCTGTATGGAAAACGCATAATCTGGGACAGTAGA
GATGTAGTGACAAATGAAATTTTTCAAAGGTGAACGTGAAACTAGGGACTACCTTTTGGGTATTAGACCCCTGTCATCT
P N I T V T L K K F P L D T L I P D G K R I I W D S R>
84
_____FLT1 IG DOMAIN 2_____>

330 340 350 360 370 380 390 400
AAGGGCTTCATCATATCAAATGCAACGTACAAAGAAATAGGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTA
TTCCCGAAGTAGTATAGTTTACGTTGCATGTTTCTTTATCCCGAAGACTGGACACTTCGTTGTCAGTTACCCGTAAACAT
K G F I I S N A T Y K E I G L L T C E A T V N G H L Y>
111
_____FLT1 IG DOMAIN 2_____>

410 420 430 440 450 460 470 480
TAAGACAAACTATCTCACACATCGACAAACCAATACAATCATAGATATCCAGCTGTTGCCAGGAAGTCGCTGGAGCTGC
ATCTGTTTGATAGAGTGTGTAGCTGTTTGGTTATGTTAGTATCTATAGGTCGACAAACGGGTCCTTCAGCGACCTCGACG
K T N Y L T H R Q T N T I I D>
_____FLT1 IG DOMAIN 2_____>
I Q L L P R K S L E L>
137
_____VEGFR3 (FLT4) IG DOMAIN 3_____>

Fig.22B.

490 500 510 520 530 540 550 560
TGGTAGGGGAGAAGCTGGTCCCTCAACTGCACCGTGTGGGCTGAGTTTAACTCAGGTGTCACCTTTGACTGGGACTACCCA
ACCATCCCCCTCTTCGACCAGGAGTTGACGTGGCACACCCGACTCAAATTGAGTCCACAGTGGAAACTGACCCGTGATGGGT
L V G E K L V L N C T V W A E F N S G V T F D W D Y P>
164
____VEGFR3 (FLT4) IG DOMAIN 3____>

570 580 590 600 610 620 630 640
GGGAAGCAGGCAGAGCGGGTAAAGTGGGTGCCCCGAGCGACGCTCCCAACAGACCCACACAGAACTCTCCAGCATCCTGAC
CCCTTCGTCCGTCTCGCCCCATTCACCCACGGGCTCGCTGCGAGGGTTGTCTGGGTGTGTCTTGAGAGGTGCGTAGGACTG
G K Q A E R G K W V P E R R S Q Q T H T E L S S I L T>
191
____VEGFR3 (FLT4) IG DOMAIN 3____>

650 660 670 680 690 700 710 720
CATCCACAACGTCAGCCAGCACGACCTGGGCTCGTATGTGTGCAAGGCCAACACGGCATCCAGCGATTTCTGGGAGAGCA
GTAGGTGTGTGAGTCCGTGCTGCTGGACCCGAGCATACACACGTTCCGGTTGTGTCCTAGGTGCGTAAAGCCCTCTCGT
I H N V S Q H D L G S Y V C K A N N G I Q R F R E S>
217
____VEGFR3 (FLT4) IG DOMAIN 3____>

730 740 750 760 770 780 790 800
COGAGGTCATTGTGCATGAAAATGGCCCGGGCGACAAAACCTCACACATGCCACCGTGCCGAGCACCTGAACCTCCTGGGG
GGCTCCAGTAACACGTACTTTTACCGGGCCCGCTGTTTGTAGTGTGTACGGGTGGCACGGGTGCTGGACTTGAGGACCC
T E V I V H E N>
____VEGFR3 (FLT4) IG____>
G P G>
____>
D K T H T C P P C P A P E L L G>
244
____FCAC1 - A ALLOTYP E____>

810 820 830 840 850 860 870 880
GGACCGTCAGTCTTCCTCTTCCCCCAAAACCCAAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGT
CCTGGCAGTCAGAAGGAGAAGGGGGGTTTGGGTTCCTGTGGGAGTACTAGAGGGCCTGGGACTCCAGTGTACGCCACA
G P S V F L F P P K P K D T L M I S R T P E V T C V V>
271
____FCAC1 - A ALLOTYP E____>

890 900 910 920 930 940 950 960
GGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAA
CCACCTGCACTCGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATGCACCTGCCGCACCTCCACGTATTACGGTTCTGTT
V D V S H E D P E V K F N W Y V D G V E V H N A K T>
297
____FCAC1 - A ALLOTYP E____>

970 980 990 1000 1010 1020 1030 1040
AGCCCGGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTACGCTCCTCACCGTCTGACCAGGACTGGCTGAATGGC
TCGGCGCCCTCCTCGTCATGTTGTGTCGTCATGGCACACCAAGTTCGAGGAGTGGCAGGACGTGGTCTTGACCGACTTACCG
K P R E E Q Y N S T Y R V V S V L T V L H Q D W L N G>
324
____FCAC1 - A ALLOTYP E____>

Fig.22C.

```

      1050      1060      1070      1080      1090      1100      1110      1120
AAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCC
TTCTCATGTTTCACGTTCAGAGGTTGTTTCGGGAGGGTCGGGGGTAGCTCTTTTGGTAGAGGTTTCGGTTTCCCGTCGG
K E Y K C K V S N K A L P A P I E K T I S K A K G Q P>
                                                                 351
_____FCAC1 - A ALLOTYP_____>

                                >A>C_A_allotype
                                |
                                >G>T_A_allotype
                                |
                                |
      1130      1140      1150      1160      1170      1180      1190      1200
CCGAGAACCACAGGTGTACACCCCTGCCCOCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGGCTGTC
GGCTCTTGGTGTCCACATGTGGGACGGGGGTAGGGGCCCTACTCGACTGGTTCTTGGTCCAGTCGGACTGGACGGACCACT
R E P Q V Y T L P P S R D E L T K N Q V S L T C L V>
                                                                 377
_____FCAC1 - A ALLOTYP_____>


      1210      1220      1230      1240      1250      1260      1270      1280
AAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACCTACAAGACCACGCTCCC
TTCCGAAGATAGGGTCGCTGTAGCGGCACCTCACCCCTCTCGTTACCCGTCGGCCTCTTGTGTGATGTTCTGGTGGCGAGGG
K G F Y P S D I A V E W E S N G Q P E N N Y K T T P P>
                                                                 404
_____FCAC1 - A ALLOTYP_____>

                                >T>C
                                |
      1290      1300      1310      1320      1330      1340      1350      1360
GTGCTGGACTCCGACGGCTCCTTCTTCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTT
CACGACCTGAGGCTGCCGAGGAAGAAGGAGATATCGTTTCGAGTGGCACCTGTCTCGTCCACCGTCGTCCCTTGCAGAA
V L D S D G S F F L Y S K L T V D K S R W Q Q G N V F>
                                                                 431
_____FCAC1 - A ALLOTYP_____>

                                >NotI_site
                                |
      1370      1380      1390      1400      1410      1420      1430      1440
CTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCCTCTCCCTGTCTCCGGGTAAATGAGCGG
GAGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGAATGTCGTCTTCTCGGAGAGGGACAGAGGCCCAATTACTCGCC
S C S V M H E A L H N H Y T Q K S L S L S P G K *>
                                                                 455
_____FCAC1 - A ALLOTYP_____>

CCGC
GGCG
```

Fig.23.



- Flt1D2Flk1D3.FcdeltaC1(a)
- △ Flt1D2VEGFR3D3.FcdeltaC1(a)
- ▽ TIE2-Fc
- Flt1(1-3)-Fc

Fig.24A.

```

      10      20      30      40      50      60
      *      *      *      *      *      *
ATG GTC AGC TAC TGG GAC ACC GGG GTC CTG CTG TGC GCG CTG CTC AGC TGT CTG CTT CTC
TAC CAG TCG ATG ACC CTG TGG CCC CAG GAC GAC ACG CGC GAC GAG TCG ACA GAC GAA GAG
M V S Y W D T G V L L C A L L S C L L L>
1_____5_____hFLT1 SIGNAL SEQUENCE_____15_____20>

      70      80      90      100      110      120
      *      *      *      *      *      *
ACA GGA TCT AGT TOC GGA AGT GAT ACC GGT AGA CCT TTC GTA GAG ATG TAC AGT GAA ATC
TGT CCT AGA TCA AGG OCT TCA CTA TGG CCA TCT GGA AAG CAT CTC TAC ATG TCA CTT TAG
T G S S S G>
21_hFLT1 SIGNAL SEQ_26>

      S D T G R P F V E M Y S E I>
      27_____30_____hFLT1 IG DOMAIN 2_____40>

      130      140      150      160      170      180
      *      *      *      *      *      *
CCC GAA ATT ATA CAC ATG ACT GAA GGA AGG GAG CTC GTC ATT CCC TGC CGG GTT ACG TCA
GGG CTT TAA TAT GTG TAC TGA CTT OCT TOC CTC GAG CAG TAA GGG ACG GCC CAA TGC AGT
P E I I H M T E G R E L V I P C R V T S>
41_____45_____hFLT1 IG DOMAIN 2_____55_____60>

      190      200      210      220      230      240
      *      *      *      *      *      *
CCT AAC ATC ACT GTT ACT TTA AAA AAG TTT CCA CTT GAC ACT TTG ATC CCT GAT GGA AAA
GGA TTG TAG TGA CAA TGA AAT TTT TTC AAA GGT GAA CTG TGA AAC TAG GGA CTA CCT TTT
P N I T V T L K K F P L D T L I P D G K>
61_____65_____hFLT1 IG DOMAIN 2_____75_____80>

      250      260      270      280      290      300
      *      *      *      *      *      *
CGC ATA ATC TGG GAC AGT AGA AAG GGC TTC ATC ATA TCA AAT GCA ACG TAC AAA GAA ATA
GCG TAT TAG ACC CTG TCA TCT TTC CCG AAG TAG TAT AGT TTA CGT TGC ATG TTT CTT TAT
R I I W D S R K G F I I S N A T Y K E I>
81_____85_____hFLT1 IG DOMAIN 2_____95_____100>

      310      320      330      340      350      360
      *      *      *      *      *      *
GGG CTT CTG ACC TGT GAA GCA ACA GTC AAT GGG CAT TTG TAT AAG ACA AAC TAT CTC ACA
CCC GAA GAC TGG ACA CTT CGT TGT CAG TTA CCC GTA AAC ATA TTC TGT TTG ATA GAG TGT
G L L T C E A T V N G H L Y K T N Y L T>
101_____105_____hFLT1 IG DOMAIN 2_____115_____120>

      370      380      390      400      410      420
      *      *      *      *      *      *
CAT OGA CAA ACC AAT ACA ATC ATA GAT GTG GTT CTG AGT CCG TCT CAT GGA ATT GAA CTA
GTA GCT GTT TGG TTA TGT TAG TAT CTA CAC CAA GAC TCA GGC AGA GTA OCT TAA CTT GAT
H R Q T N T I I D>
121_____hFLT1 IG DOMAIN 2_____129>

      V V L S P S H G I E L>
      130_____hFLK1 IG DOMAIN 3_____140>

```

```

      430      440      450      460      470      480
      *        *        *        *        *        *
TCT GTT GGA GAA AAG CTT GTC TTA AAT TGT ACA GCA AGA ACT GAA CTA AAT GTG GGG ATT
AGA CAA CCT CTT TTC GAA CAG AAT TTA ACA TGT CGT TCT TGA CTT GAT TTA CAC CCC TAA
S V G E K L V L N C T A R T E L N V G I>
141_____145_____hFLK1 IG DOMAIN 3_____155_____160>

      490      500      510      520      530      540
      *        *        *        *        *        *
GAC TTC AAC TGG GAA TAC CCT TCT TCG AAG CAT CAG CAT AAG AAA CTT GTA AAC CGA GAC
CTG AAG TTG ACC CTT ATG GGA AGA AGC TTC GTA GTC GTA TTC TTT GAA CAT TTG GCT CTG
D F N W E Y P S S K H Q H K K L V N R D>
161_____165_____hFLK1 IG DOMAIN 3_____175_____180>

      550      560      570      580      590      600
      *        *        *        *        *        *
CTA AAA ACC CAG TCT GGG AGT GAG ATG AAG AAA TTT TTG AGC ACC TTA ACT ATA GAT GGT
GAT TTT TGG GTC AGA CCC TCA CTC TAC TTC TTT AAA AAC TCG TGG AAT TGA TAT CTA CCA
L K T Q S G S E M K K F L S T L T I D G>
181_____185_____hFLK1 IG DOMAIN 3_____195_____200>

      610      620      630      640      650      660
      *        *        *        *        *        *
GTA ACC CGG AGT GAC CAA GGA TTG TAC ACC TGT GCA GCA TCC AGT GGG CTG ATG ACC AAG
CAT TGG GCC TCA CTG GTT CCT AAC ATG TGG ACA CGT CGT AGG TCA CCC GAC TAC TGG TTC
V T R S D Q G L Y T C A A S S G L M T K>
201_____205_____hFLK1 IG DOMAIN 3_____215_____220>

      670      680      690      700      710      720
      *        *        *        *        *        *
AAG AAC AGC ACA TTT GTC AGG GTC CAT GAA AAG GAC AAA ACT CAC ACA TGC CCA CCG TGC
TTC TTG TCG TGT AAA CAG TCC CAG GTA CTT TTC CTG TTT TGA GTG TGT ACG GGT GGC ACG
K N S T F V R V H E K>
221_____hFLK1 IG DOMAIN 3_____231>

      D K T H T C P P C>
      232_____hFCAC1 A_____240>

      730      740      750      760      770      780
      *        *        *        *        *        *
CCA GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC
GGT CGT GGA CTT GAG GAC CCC CCT GGC AGT CAG AAG GAG AAG GGG GGT TTT GGG TTC CTG
P A P E L L G G P S V F L F P P K P K D>
241_____245_____hFCAC1 A_____255_____260>

      790      800      810      820      830      840
      *        *        *        *        *        *
ACC CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA
TGG GAG TAC TAG AGG GCC TGG GGA CTC CAG TGT ACG CAC CAC CAC CTG CAC TCG GTG CTT
T L M I S R T P E V T C V V V D V S H E>
261_____265_____hFCAC1 A_____275_____280>

      850      860      870      880      890      900
      *        *        *        *        *        *
GAC OCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GAG GGC GTG GAG GTG CAT AAT GCC AAG ACA
CTG GGA CTC CAG TTC AAG TTG ACC ATG CAC CTG CCG CAC CTC CAC CTA TTA CCG TTC TGT
D P E V K F N W Y V D G V E V H N A K T>
281_____285_____hFCAC1 A_____295_____300>

```

Fig.24C.

910 920 930 940 950 960
* * * * *
AAG CCG CCG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG
TTC GGC GCC CTC CTC GTC ATG TTG TCG TGC ATG GCA CAC CAG TCG CAG GAG TGG CAG GAC
K P R E E Q Y N S T Y R V V S V L T V L>
301_____305_____hFCAC1 A _____315_____320>

970 980 990 1000 1010 1020
* * * * *
CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC CCA
GTG GTC CTG ACC GAC TTA CCG TTC CTC ATG TTC ACG TTC CAG AGG TTG TTT CCG GAG GGT
H Q D W L N G K E Y K C K V S N K A L P>
321_____325_____hFCAC1 A _____335_____340>

1030 1040 1050 1060 1070 1080
* * * * *
GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC
CGG GGG TAG CTC TTT TGG TAG AGG TTT CCG TTT CCC GTC GGG GCT CTT GGT GTC CAC ATG
A P I E K T I S K A K G Q P R E P Q V Y>
341_____345_____hFCAC1 A _____355_____360>

1090 1100 1110 1120 1130 1140
* * * * *
ACC CTG CCC CCA TCC CCG GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC
TGG GAC GGG GGT AGG GCC CTA CTC GAC TGG TTC TTG GTC CAG TCG GAC TGG ACG GAC CAG
T L P P S R D E L T K N Q V S L T C L V>
361_____365_____hFCAC1 A _____375_____380>

1150 1160 1170 1180 1190 1200
* * * * *
AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC
TTT CCG AAG ATA GGG TCG CTG TAG CCG CAC CTC ACC CTC TCG TTA CCC GTC GGC CTC TTG
K G F Y P S D I A V E W E S N G Q P E N>
381_____385_____hFCAC1 A _____395_____400>

1210 1220 1230 1240 1250 1260
* * * * *
AAC TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG
TTG ATG TTC TGG TGC GGA GGG CAC GAC CTG AGG CTG CCG AGG AAG AAG GAG ATG TCG TTC
N Y K T T P P V L D S D G S F F L Y S K>
401_____405_____hFCAC1 A _____415_____420>

1270 1280 1290 1300 1310 1320
* * * * *
CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG CAT
GAG TGG CAC CTG TTC TCG TCC ACC GTC GTC CCC TTG CAG AAG AGT ACG AGG CAC TAC GTA
L T V D K S R W Q Q G N V F S C S V M H>
421_____425_____hFCAC1 A _____435_____440>

1330 1340 1350 1360 1370
* * * * *
GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT AAA TGA
CTC CGA GAC GTG TTG GTG ATG TGC GTC TTC TCG GAG AGG GAC AGA GGC CCA TTT ACT
E A L H N H Y T Q K S L S L S P G K *>
441_____445_____hFCAC1 A _____455_____458>

Fig.25A.




Fig.25B.




Fig.25C.




Fig.26A.




Fig.26B.




Fig.27.




Fig.28.

Binding Stoichiometry of hVEGF165 to Flt1D2Flk1D3.FcΔC1(a) & VEGFR1R2-FcΔC1(a)		
hVEGF165 (nM)	VEGF/Flt1D2Flk1D3.FcΔC1(a)	VEGF/VEGFR1R2-FcΔC1(a)
1	0.93	0.98
10	0.97	0.94
50	1	0.99
Average ± StDev	0.96 ± 0.03	0.97 ± 0.02

Fig.29.




Fig.30.




Fig.31.




Fig.32.




Fig.33.




Fig.34.




Fig.35.




Fig.36.

GRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDG 50
KRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIID 100
VVLSPSHGIELSVGEKLVLNCTARTELVGIDFNWEYPSSKHQHKKLVNR 150
DLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVH 200
EKGPGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD 250
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN 300
GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSL 350
TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS 400
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Fig.37.





Fig.38.






Fig.39.




Fig.40.

Fig.41.




Fig.42A.





Fig.42B.



MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES AND METHODS OF USING THEREOF

This application is a divisional of U.S. patent application Ser. No. 10/009,852, filed Dec. 6, 2001, now U.S. Pat. No. 7,070,959, which is a national stage application of International Application No. PCT/US00/14142, filed May 23, 2000, which claims priority of U.S. Provisional Application Ser. No. 60/138,133, filed Jun. 8, 1999. The disclosures of these applications are herein specifically incorporated by reference in their entirety.

INTRODUCTION

The field of this invention is modified polypeptides with improved pharmacokinetics. Specifically, the field of this invention relates to Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile. The field of this invention also relates to methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.

BACKGROUND

The ability of polypeptide ligands to bind to cells and thereby elicit a phenotypic response such as cell growth, survival, cell product secretion, or differentiation is often mediated through transmembrane receptors on the cells. The extracellular domain of such receptors (i.e. that portion of the receptor that is displayed on the surface of the cell) is generally the most distinctive portion of the molecule, as it provides the protein with its ligand binding characteristic. Binding of a ligand to the extracellular domain generally results in signal transduction which transmits a biological signal to intracellular targets. Often, this signal transduction acts via a catalytic intracellular domain. The particular array of sequence motifs of this catalytic intracellular domain determines its access to potential kinase substrates (Mohammadi, et al., 1990, *Mol. Cell. Biol.* 11:5068-5078; Fantl, et al., 1992, *Cell* 69:413-413). Examples of receptors that transduce signals via catalytic intracellular domains include the receptor tyrosine kinases (RTKs) such as the Trk family of receptors which are generally limited to cells of the nervous system, the cytokine family of receptors including the tripartite CNTF receptor complex (Stahl & Yancopoulos, 1994, *J. Neurobio.* 25:1454-1466) which is also generally limited to the cells of the nervous system, G-protein coupled receptors such as the β_2 -adrenergic receptor found on, for instance, cardiac muscle cells, and the multimeric IgE high affinity receptor Fc ϵ RI which is localized, for the most part, on mast cells and basophils (Sutton & Gould, 1993, *Nature* 366:421-428).

All receptors identified so far appear to undergo dimerization, multimerization, or some related conformational change following ligand binding (Schlessinger, J., 1988, *Trend Biochem. Sci.* 13:443-447; Ullrich & Schlessinger, 1990, *Cell* 61:203-212; Schlessinger & Ullrich, 1992, *Neuron* 9:383-391) and molecular interactions between dimerizing intracellular domains lead to activation of catalytic function. In some instances, such as platelet-derived growth factor (PDGF), the ligand is a dimer that binds two receptor molecules (Hart, et al., 1988, *Science*, 240:1529-1531; Heldin, 1989, *J. Biol. Chem.* 264:8905-8912) while, for

example, in the case of epidermal growth factor (EGF), the ligand is a monomer (Weber, et al., 1984, *J. Biol. Chem.* 259:14631-14636). In the case of the Fc ϵ RI receptor, the ligand, IgE, exists bound to Fc ϵ RI in a monomeric fashion and only becomes activated when antigen binds to the IgE/Fc ϵ RI complex and cross-links adjacent IgE molecules (Sutton & Gould, 1993, *Nature* 366:421-428).

Often, the tissue distribution of a particular receptor within higher organisms provides insight into the biological function of the receptor. The RTKs for some growth and differentiation factors, such as fibroblast growth factor (FGF), are widely expressed and therefore appear to play some general role in tissue growth and maintenance. Members of the Trk RTK family (Glass & Yancopoulos, 1993, *Trends in Cell Biol.* 3:262-268) of receptors are more generally limited to cells of the nervous system, and the Nerve Growth Factor family consisting of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5), which bind the Trk RTK family receptors, promote the differentiation of diverse groups of neurons in the brain and periphery (Lindsay, R. M., 1993, in *Neurotrophic Factors*, S. E. Loughlin & J. H. Fallon, eds., pp. 257-284, San Diego, Calif., Academic Press). Fc ϵ RI is localized to a very limited number of types of cells such as mast cells and basophils. Mast cells derive from bone marrow pluripotent hematopoietic stem cell lineage, but complete their maturation in the tissue following migration from the blood stream (See Janeway & Travers, 1996, in *Immunobiology*, 2d. Edition, M. Robertson & E. Lawrence, eds., pp. 1:3-1:4, Current Biology Ltd., London, UK, Publisher) and are involved in the allergic response.

Many studies have demonstrated that the extracellular domain of a receptor provides the specific ligand binding characteristic. Furthermore, the cellular environment in which a receptor is expressed may influence the biological response exhibited upon binding of a ligand to the receptor. For example, when a neuronal cell expressing a Trk receptor is exposed to a neurotrophin which binds to that receptor, neuronal survival and differentiation results. When the same receptor is expressed by a fibroblast, exposure to the neurotrophin results in proliferation of the fibroblast (Glass, et al., 1991, *Cell* 66:405-413).

A class of cell-derived dimeric mitogens with selectivity for vascular endothelial cells has been identified and designated vascular endothelial cell growth factor (VEGF). VEGF has been purified from conditioned growth media of rat glioma cells [Conn et al., (1990), *Proc. Natl. Acad. Sci. U.S.A.*, 87, pp. 2628-2632]; and conditioned growth media of bovine pituitary follicle stellate cells [Ferrara and Henzel, (1989), *Biochem. Biophys. Res. Comm.*, 161, pp. 851-858; Gospodarowicz et al., (1989), *Proc. Natl. Acad. Sci. U.S.A.*, 86, pp. 7311-7315] and conditioned growth medium from human U937 cells [Connolly, D. T. et al. (1989), *Science*, 246, pp. 1309-1312]. VEGF is a dimer with an apparent molecular mass of about 46 kDa with each subunit having an apparent molecular mass of about 23 kDa. VEGF has some structural similarities to platelet derived growth factor (PDGF), which is a mitogen for connective tissue cells but not mitogenic for vascular endothelial cells from large vessels.

The membrane-bound tyrosine kinase receptor, known as Flt, was shown to be a VEGF receptor [DeVries, C. et al., (1992), *Science*, 255, pp. 989-991]. The Flt receptor specifically binds VEGF which induces mitogenesis. Another form of the VEGF receptor, designated KDR, is also known to bind VEGF and induce mitogenesis. The partial cDNA

sequence and nearly full length protein sequence of KDR is known as well [Terman, B. I. et al., (1991) *Oncogene* 6, pp. 1677-1683; Terman, B. I. et al., (1992) *Biochem. Biophys. Res. Comm.* 187, pp. 1579-1586].

Persistent angiogenesis may cause or exacerbate certain diseases such as psoriasis, rheumatoid arthritis, hemangiomas, angiofibromas, diabetic retinopathy and neovascular glaucoma. An inhibitor of VEGF activity would be useful as a treatment for such diseases and other VEGF-induced pathological angiogenesis and vascular permeability conditions, such as tumor vascularization. The present invention relates to a VEGF inhibitor that is based on the VEGF receptor Flt1.

Plasma leakage, a key component of inflammation, occurs in a distinct subset of microvessels. In particular, in most organs plasma leakage occurs specifically in the venules. Unlike arterioles and capillaries, venules become leaky in response to numerous inflammatory mediators including histamine, bradykinin, and serotonin. One characteristic of inflammation is the plasma leakage that results from intercellular gaps that form in the endothelium of venules. Most experimental models of inflammation indicate that these intercellular gaps occur between the endothelial cells of postcapillary and collecting venules (Baluk, P., et al., *Am. J. Pathol.* 1998 152:1463-76). It has been shown that certain lectins may be used to reveal features of focal sites of plasma leakage, endothelial gaps, and finger-like processes at endothelial cell borders in inflamed venules (Thurston, G., et al., *Am. J.*

Physiol. 1996, 271: H2547-62). In particular, plant lectins have been used to visualize morphological changes at endothelial cell borders in inflamed venules of, for example, the rat trachea. Lectins, such as concanavalin A and ricin, that bind focally to inflamed venules reveal regions of the subendothelial vessel wall exposed by gaps that correspond to sites of plasma leakage (Thurston, G., et al., *Am J Physiol*, 1996, 271: H2547-62).

The properties of the microvessels are dynamic. Chronic inflammatory diseases, for example, are associated with microvascular remodeling, including angiogenesis and microvessel enlargement. Microvessels can also remodel by acquiring abnormal phenotypic properties. In a murine model of chronic airway inflammation, airway capillaries acquire properties of venules, including widened vessel diameter, increased immunoreactivity for von Willebrand factor, and increased immunoreactivity for P-selectin. In addition, these remodeled vessels leak in response to inflammatory mediators, whereas vessels in the same position in the airways of normal mice do not.

Certain substances have been shown to decrease or inhibit vascular permeability and/or plasma leakage. For example, mystixins are synthetic polypeptides that have been reported to inhibit plasma leakage without blocking endothelial gap formation (Baluk, P., et al., *J. Pharmacol. Exp. Ther.*, 1998, 284: 693-9). Also, the beta 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation (Baluk, P. and McDonald, D. M., *Am. J. Physiol.*, 1994, 266:L461-8).

The angiopoietins and members of the vascular endothelial growth factor (VEGF) family are the only growth factors thought to be largely specific for vascular endothelial cells. Targeted gene inactivation studies in mice have shown that VEGF is necessary for the early stages of vascular development and that Ang-1 is required for later stages of vascular remodeling.

U.S. Pat. No. 6,011,003, issued Jan. 4, 2000, in the name of Metris Therapeutics Limited, discloses an altered, soluble

form of FLT polypeptide being capable of binding to VEGF and thereby exerting an inhibitory effect thereon, the polypeptide comprising five or fewer complete immunoglobulin domains.

U.S. Pat. No. 5,712,380, issued Jan. 27, 1998 and assigned to Merck & Co., discloses vascular endothelial cell growth factor (VEGF) inhibitors that are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF.

Also assigned to Merck & Co. is PCT Publication No. WO 98/13071, published Apr. 2, 1998, which discloses gene therapy methodology for inhibition of primary tumor growth and metastasis by gene transfer of a nucleotide sequence encoding a soluble receptor protein which binds to VEGF.

PCT Publication No. WO 97/44453, published Nov. 27, 1997, in the name of Genentech, Inc., discloses novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors Flt1 and KDR, including the murine homologue to the human KDR receptor FLK1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof.

PCT Publication No. WO 97/13787, published Apr. 17, 1997, in the name of Toa Gosei Co., LTD., discloses a low molecular weight VEGF inhibitor usable in the treatment of diseases accompanied by neovascularization such as solid tumors. A polypeptide containing the first immunoglobulin-like domain and the second immunoglobulin-like domain in the extracellular region of a VEGF receptor FLT but not containing the sixth immunoglobulin-like domain and the seventh immunoglobulin-like domain thereof shows a VEGF inhibitory activity.

Sharifi, J. et al., 1998, *The Quarterly Jour. of Nucl. Med.* 42:242-249, disclose that because monoclonal antibodies (MAbs) are basic, positively charged proteins, and mammalian cells are negatively charged, the electrostatic interactions between the two can create higher levels of background binding resulting in low tumor to normal organ ratios. To overcome this effect, the investigators attempted to improve MAb clearance by using various methods such as secondary agents as well as chemical and charge modifications of the MAb itself.

Jensen-Pippo, et al., 1996, *Pharmaceutical Research* 13:102-107, disclose that pegylation of a therapeutic protein, recombinant human granulocyte colony stimulating factor (PEG-G-CSF), results in an increase in stability and in retention of in vivo bioactivity when administered by the intraduodenal route.

Tsutsumi, et al., 1997, *Thromb Haemost.* 77:168-73, disclose experiments wherein the in vivo thrombopoietic activity of polyethylene glycol-modified interleukin-6 (MPEG-IL-6), in which 54% of the 14 lysine amino groups of IL-6 were coupled with PEG, was compared to that of native IL-6.

Yang, et al., 1995, *Cancer* 76:687-94, disclose that conjugation of polyethylene glycol to recombinant human interleukin-2 (IL-2) results in a compound, polyethylene glycol-modified IL-2 (PEG-IL-2) that retains the in vitro and in vivo activity of IL-2, but exhibits a markedly prolonged circulating half-life.

R. Duncan and F. Spreafico, *Clin. Pharmacokinet.* 27: 290-306, 296 (1994) review efforts to improve the plasma half-life of asparaginase by conjugating polyethylene glycol.

PCT International Publication No. WO 99/03996 published Jan. 28, 1999 in the name of Regeneron Pharmaceu-

ticals, Inc. and The Regents of The University of California describes modified human noggin polypeptides having deletions of regions of basic amino acids. The modified human noggin polypeptides are described as retaining biological activity while having reduced affinity for heparin and superior pharmacokinetics in animal sera as compared to the unmodified human noggin.

SUMMARY OF THE INVENTION

The present invention is directed to VEGF antagonists with improved pharmacokinetic properties. A preferred embodiment is an isolated nucleic acid molecule encoding a fusion polypeptide capable of binding a VEGF polypeptide comprising (a) a nucleotide sequence encoding a VEGF receptor component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the VEGF receptor component is the only VEGF receptor component of the fusion polypeptide and wherein the nucleotide sequence of (a) consists essentially of a nucleotide sequence encoding the amino acid sequence of Ig domain 2 of the extracellular domain of a first VEGF receptor and a nucleotide sequence encoding the amino acid sequence of Ig domain 3 of the extracellular domain of a second VEGF receptor.

In a further embodiment, the isolated nucleic acid of the first VEGF receptor is Flt1.

In a further embodiment, the isolated nucleic acid of the second VEGF receptor is Flt1.

In yet another embodiment, the isolated nucleic acid of the second VEGF receptor is Flt4.

In another preferred embodiment, the nucleotide sequence encoding Ig domain 2 of the extracellular domain of the first VEGF receptor is upstream of the nucleotide sequence encoding Ig domain 3 of the extracellular domain of the second VEGF receptor.

In still another preferred embodiment, the nucleotide sequence encoding Ig domain 2 of the extracellular domain of the first VEGF receptor is downstream of the nucleotide sequence encoding Ig domain 3 of the extracellular domain of the second VEGF receptor.

In a preferred embodiment of the invention, the multimerizing component comprises an immunoglobulin domain.

In another embodiment, the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.

Preferred embodiments include an isolated nucleic acid molecule comprising a nucleotide sequence encoding a modified Flt1 receptor fusion polypeptide, wherein the coding region of the nucleic acid molecule consists of a nucleotide sequence selected from the group consisting of

- (a) the nucleotide sequence set forth in FIG. 13A-13D (SEQ ID NO:3);
- (b) the nucleotide sequence set forth in FIG. 14A-14C (SEQ ID NO:5);
- (c) the nucleotide sequence set forth in FIG. 15A-15C (SEQ ID NO:7);
- (d) the nucleotide sequence set forth in FIG. 16A-16D (SEQ ID NO:9);
- (e) the nucleotide sequence set forth in FIG. 21A-21C (SEQ ID NO:11);
- (f) the nucleotide sequence set forth in FIG. 22A-22C (SEQ ID NO:13);
- (g) the nucleotide sequence set forth in FIG. 24A-24C (SEQ ID NO:15); and
- (h) a nucleotide sequence which, as a result of the degeneracy of the genetic code, differs from the nucleotide

sequence of (a), (b), (c), (d), (e), (f), or (g) and which encodes a fusion polypeptide molecule having the biological activity of the modified Flt1 receptor fusion polypeptide.

In a further embodiment of the invention, a fusion polypeptide is encoded by the isolated nucleic acid molecules described above.

A preferred embodiment is a composition capable of binding a VEGF molecule to form a nonfunctional complex comprising a multimer of the fusion polypeptide.

Also preferred is a composition wherein the multimer is a dimer.

In yet another embodiment, the composition is in a carrier.

Another embodiment is a vector which comprises the nucleic acid molecules described above, including an expression vector comprising a the nucleic acid molecules described wherein the nucleic acid molecule is operatively linked to an expression control sequence.

Other included embodiments are a host-vector system for the production of a fusion polypeptide which comprises the expression vector, in a suitable host cell; the host-vector system wherein the suitable host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell; the host-vector system wherein the suitable host cell is *E. Coli*; the host-vector system wherein the suitable host cell is a COS cell; the host-vector system wherein the suitable host cell is a CHO cell.

Another embodiment of the invention is a method of producing a fusion polypeptide which comprises growing cells of the host-vector system under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.

Additional embodiments include a fusion polypeptide encoded by the nucleic acid sequence set forth in FIG. 10A-10D (SEQ ID NO:1) or FIG. 24A-24C (SEQ ID NO:15), which has been modified by acetylation or pegylation wherein the acetylation is accomplished with at least about a 100 fold molar excess of acetylation reagent or wherein acetylation is accomplished with a molar excess of acetylation reagent ranging from at least about a 10 fold molar excess to about a 100 fold molar excess or wherein the pegylation is 10K or 20K PEG.

A preferred embodiment includes a method of decreasing or inhibiting plasma leakage in a mammal comprising administering to the mammal the fusion polypeptide described above, including embodiments wherein the mammal is a human, the fusion polypeptide is acetylated or the fusion polypeptide is pegylated.

A further embodiments is a fusion polypeptide which specifically binds the VEGF receptor ligand VEGF.

A preferred embodiment of the invention is a method of blocking blood vessel growth in a human comprising administering an effective amount of the fusion polypeptide described above.

Also preferred is a method of inhibiting VEGF receptor ligand activity in a mammal comprising administering to the mammal an effective amount of the fusion polypeptide described above.

Preferred embodiments of these methods are wherein the mammal is a human.

Further embodiments of the methods of the invention include attenuation or prevention of tumor growth in a human; attenuation or prevention of edema in a human, especially wherein the edema is brain edema; attenuation or prevention of ascites formation in a human, especially wherein the ascites is ovarian cancer-associated ascites.

Preferred embodiments of the invention include a fusion polypeptide capable of binding a VEGF polypeptide comprising (a) a VEGF receptor component operatively linked to (b) a multimerizing component, wherein the VEGF receptor component is the only VEGF receptor component in the fusion polypeptide and consists essentially of the amino acid sequence of Ig domain 2 of the extracellular domain of a first VEGF receptor and the amino acid sequence of Ig domain 3 of the extracellular domain of a second VEGF receptor.

In a further embodiment of the fusion polypeptide, the first VEGF receptor is Flt1.

In yet a further embodiment of the fusion polypeptide, the second VEGF receptor is Flk1.

Still another embodiment of the fusion polypeptide is one in which the second VEGF receptor is Flt4.

Preferred embodiments include a fusion polypeptide wherein amino acid sequence of Ig domain 2 of the extracellular domain of the first VEGF receptor is upstream of the amino acid sequence of Ig domain 3 of the extracellular domain of the second VEGF receptor and a fusion polypeptide wherein the amino acid sequence of Ig domain 2 of the extracellular domain of the first VEGF receptor is downstream of the amino acid sequence of Ig domain 3 of the extracellular domain of the second VEGF receptor.

In yet another embodiment, the fusion polypeptide multimerizing component comprises an immunoglobulin domain including an embodiment wherein the immunoglobulin domain is selected from the group consisting of the Fc domain of IgG, the heavy chain of IgG, and the light chain of IgG.

Preferred embodiments include a fusion polypeptide comprising an amino acid sequence of a modified Flt1 receptor, wherein the amino acid sequence selected from the group consisting of (a) the amino acid sequence set forth in FIG. 13A-13D (SEQ ID NO:4); (b) the amino acid sequence set forth in FIG. 14A-14C (SEQ ID NO:6); (c) the amino acid sequence set forth in FIG. 15A-15C (SEQ ID NO:8); (d) the amino acid sequence set forth in FIG. 16A-16D (SEQ ID NO:10); (e) the amino acid sequence set forth in FIG. 21A-21C (SEQ ID NO:12); (f) the amino acid sequence set forth in FIG. 22A-22C (SEQ ID NO:14); and (g) the amino acid sequence set forth in FIG. 24A-24C (SEQ ID NO:16).

Another preferred embodiment is a method of decreasing or inhibiting plasma leakage in a mammal comprising administering to the mammal the fusion polypeptide described above.

An alternative preferred embodiment is a method of inhibiting VEGF receptor ligand activity in a mammal comprising administering to the mammal an effective amount of the fusion polypeptide described above.

BRIEF DESCRIPTION OF THE FIGURES.

FIG. 1. IEF gel analysis of unmodified and acetylated Flt1(1-3)-Fc proteins. Unmodified Flt1(1-3)-Fc protein is unable to enter the gel due to its >9.3 pI, whereas acetylated Flt1(1-3)-Fc is able to enter the gel and equilibrate at pI 5.2.

FIG. 2. Binding of unmodified Flt1(1-3)-Fc and acetylated Flt1(1-3)-Fc proteins to MATRIGEL® coated plates. Unmodified Flt1(1-3)-Fc proteins binds extensive to extracellular matrix components in Matrigel.RTM., whereas acetylated Flt1(1-3)-Fc does not bind.

FIG. 3. Binding of unmodified Flt1(1-3)-Fc, acetylated Flt1(i-3)-Fc, and pegylated Flt1(1-3)-Fc in a BIACORE™-based assay. Acetylated (columns 13-16), pegylated (columns 17-20), and heparin-treated Flt1(1-3)-Fc (columns 21-24) are each able to completely compete 25 with the

BIACORE™ chip-bound Flt1(1-3)-Fc for VEGF binding as compared to control (columns 1-4) and irrelevant protein (columns 5-8). Unmodified Flt1(1-3)-Fc (columns 5-6) appears to only partially compete with BIACORE™ chip-bound Flt1(1-3)-Fc for VEGF binding. However, washing the bound samples with 0.5M NaCl (columns 7-8) results in a binding profile similar to the modified forms of Flt1(1-3)-Fc, indicating that the unmodified protein is exhibiting non-specific binding to the chip that can be eliminated by the salt wash. However, washing the bound samples with 0.5M NaCl (columns 7-8) results in a binding profile similar to the modified forms of Flt1(1-3)-Fc, indicating that the unmodified protein is exhibiting non-specific binding to the chip that can be eliminated by the salt wash.

FIG. 4. Binding of unmodified Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc, and pegylated Flt1(1-3)-Fc to VEGF in an ELISA-based assay. Both pegylated and acetylated Flt1(1-3)-Fc proteins bind to VEGF with affinities approaching that of unmodified Flt1(1-3)-Fc.

FIG. 5. Pharmacokinetic profiles of unmodified Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc, and pegylated Flt1(1-3)-Fc. Balb/c mice (23-28 g) were injected subcutaneously with 4 mg/kg of unmodified, acetylated, or pegylated Flt1(1-3)-Fc. The mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days, and 3 days after injection of protein and the sera were assayed in a standard ELISA-based assay designed to detect Flt1(1-3)-Fc protein. The T_{max} for all of the Flt1(1-3)-Fc proteins was between the 6 hour and 24 hour time points. The C_{max} for the different proteins was as follows: Unmodified: 0.06 µg/ml-0.15 µg/ml; acetylated: 1.5 µg/ml-4.0 µg/ml; and pegylated: approximately 5 µg/ml.

FIG. 6A-6B. IEF gel analysis of unmodified and step-acetylated Flt1(1-3)-Fc proteins. Unmodified Flt1(1-3)-Fc protein is unable to enter the gel due to its >9.3 pI, whereas most of the step-acetylated Flt1(1-3)-Fc samples (30-100 fold excess samples) were able to migrate into the gel and equilibrate at pIs ranging between 4.55-8.43, depending on the degree of acetylation.

FIG. 7. Binding of unmodified Flt1(1-3)-Fc and step-acetylated Flt1 (1-3)-Fc proteins to MATRIGEL® coated plates. As with the irrelevant control protein, rTie2-Fc, step-acetylated Flt1(1-3)-Fc (20 and 30 fold excess samples) does not exhibit any binding to the Matrigel coated plate, whereas the non-acetylated Flt1(1-3)-Fc protein exhibits significant binding. The 10 fold excess sample shows reduced binding, but the degree of acetylation is not enough to completely block binding to extracellular matrix components.

FIG. 8. Binding of unmodified Flt1(1-3)-Fc and step-acetylated Flt1 (1-3)-Fc in a BIACORE™-based assay. At a sub-stoichiometric ratio (0.5 µg/ml of either unmodified Flt1(1-3) or step-acetylated Flt1(1-3)-Fc vs. 0.2 µg/ml VEGF), there is not enough Flt1(1-3)-Fc (either unmodified or step-acetylated) in the solution to completely bind the VEGF. At 1.0 µg/ml, which approximates a 1:1 stoichiometric ratio, the both unmodified and step-acetylated Flt1 (1-3)-Fc are better able to compete for VEGF binding, but there is still insufficient Flt1(1-3)-Fc protein (either unmodified or step-acetylated) to completely saturate the available VEGF. However, at 5.0 µg/ml, which is several times greater than a 1:1 stoichiometric ratio, both the Flt1(1-3)-Fc and the step-acetylated Flt1(1-3)-Fc proteins are able to saturate the VEGF, regardless of the degree of acetylation.

FIG. 9. Pharmacokinetic profiles of unmodified Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc. Balb/c mice (23-28 g) were injected subcutaneously with 4 mg/kg of unmodified or 10, 20, 40, 60 and 100 fold excess samples of step-

acetylated Flt1(1-3)-Fc (3 mice for unmodified, 10, 20 and 40 fold excess samples and 2 mice for 60 and 100 fold excess samples). The mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days and 3 days after injection. The sera were assayed in an ELISA-based assay designed to detect Flt1 (1-3)-Fc. The T_{max} for all of the Flt1(1-3)-Fc proteins tested was at the 6 hour time point but the C_{max} was as follows: Unmodified Flt1(1-3)-Fc: 0.06 $\mu\text{g/ml}$; 10 fold excess sample—0.7 $\mu\text{g/ml}$, 20 fold excess sample—2 $\mu\text{g/ml}$, 40 fold excess sample—4 $\mu\text{g/ml}$, 60 fold excess sample—2 $\mu\text{g/ml}$, 100 fold excess sample—1 $\mu\text{g/ml}$.

FIG. 10A-10D. Nucleic acid (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of Flt1(1-3)-Fc.

FIG. 11. Schematic diagram of the structure of Flt1.

FIG. 12A and 12B. Hydrophilicity analysis of the amino acid sequences of Ig domain 2 and Ig domain 3 of Flt1.

FIG. 13A-13D. Nucleic acid (SEQ ID NO:3) and deduced amino acid sequence (SEQ ID NO:4) of Mut1: Flt1(1-3 Δ_B)-Fc.

FIG. 14A-14C. Nucleic acid (SEQ ID NO:5) and deduced amino acid sequence (SEQ ID NO:6) of Mut2: Flt1(2-3 Δ_B)-Fc.

FIG. 15A-15C. Nucleic acid (SEQ ID NO:7) and deduced amino acid sequence (SEQ ID NO:8) of Mut3: Flt1(2-3)-Fc.

FIG. 16A-16D. Nucleic acid (SEQ ID NO:9) and deduced amino acid sequence (SEQ ID NO:10) of Mut4: Flt1(1-3 $R \rightarrow N$)-Fc.

FIG. 17. Binding of unmodified Flt1(1-3)-Fc, basic region deletion mutant Flt1(1-3)-Fc, and Flt1(1-3) $R \rightarrow N$ mutant proteins in a BIACORE™-based assay. At the sub-stoichiometric ratio (0.25 $\mu\text{g/ml}$ Flt1(1-3)-Fc of unmodified, acetylated or genetically modified samples vs. 01. $\mu\text{g/ml}$ VEGF), there is insufficient Flt1(1-3)-Fc protein to block binding of VEGF to the Flt1(1-3)-Fc immobilized on the BIACORE™ chip. At 0.5 $\mu\text{g/ml}$ of unmodified, acetylated or genetically modified Flt1(1-3)-Fc proteins, the stoichiometric ratio approximates 1:1 and there is an increased ability to block VEGF binding to the BIACORE™ chip. At 1.0 $\mu\text{g/ml}$ of unmodified, acetylated or genetically modified Flt1(1-3)-Fc proteins, which is approximately a 10:1 stoichiometric ratio, the Flt1(1-3)-Fc proteins are able to block binding of VEGF to the BIACORE™ chip, but they are not equivalent. Unmodified, acetylated, and Mut1: Flt1(1-3 Δ_B)-Fc are essentially equal in their ability to block VEGF binding, whereas Mut4: Flt1(1-3 $R \rightarrow N$)-Fc is somewhat less efficient at blocking binding.

FIG. 18. Binding of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3 Δ_B)-Fc, Mut2: Flt1(2-3 Δ_B)-Fc, and Flt1(2-3) mutant proteins to Matrigel® coated plates. Unmodified Flt1(1-3)-Fc protein binds avidly to these wells, the Mut3: Flt1(2-3)-Fc protein binds somewhat more weakly, the Mut1: Flt1(1-3 Δ_B)-Fc protein binds -more weakly still, and the Mut2: Flt1(2-3 Δ_B)-Fc protein shows the best profile, binding more weakly than any of the other mutant proteins. The Mut4: Flt1(1-3 $R \rightarrow N$)-Fc glycosylation mutant protein shows only marginal benefit on the Matrigel assay.

FIG. 19. Binding of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3 Δ_B)-Fc, Mut2: Flt1(2-3 Δ_B)-Fc, and Flt1(2-3) mutant proteins in an ELISA-based assay. At the concentrations tested, unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3 Δ_B)-Fc, Mut2: Flt1(2-3 Δ_B)-Fc, and Flt1(2-3) mutant proteins bind VEGF similarly.

FIG. 20. Pharmacokinetic profiles of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3 Δ_B)-Fc, Mut2: Flt1(2-3 Δ_B)-Fc, and Flt1(2-3) mutant proteins. the C_{max} for these reagents was

as follows: Unmodified Flt1(1-3)-Fc—0.15 $\mu\text{g/ml}$; 40 fold molar excess acetylated Flt1(1-3)-Fc—1.5 $\mu\text{g/ml}$; and Mut1: Flt1(1-3 Δ_B)-Fc—0.7 $\mu\text{g/ml}$.

FIG. 21A-21C. Nucleotide (SEQ ID NO:11) and deduced amino acid sequence (SEQ ID NO:12) of the modified Flt1 receptor termed Flt1D2.Flk1D3.Fc $\Delta C1$ (a).

FIG. 22A-22C. Nucleotide (SEQ ID NO:13) and deduced amino acid sequence (SEQ ID NO:14) of the modified Flt1 receptor termed Flt1D2.VEGFR3D3.Fc $\Delta C1$ (a).

FIG. 23. Extracellular Matrix (ECM) Assay. The results of this assay demonstrate that the Flt1D2.Flk1D3.Fc $\Delta C1$ (a) and Flt1D2.VEGFR3D3.Fc $\Delta C1$ (a) proteins are considerably less sticky to the ECM as compared to the Flt1(1-3)-Fc protein.

FIG. 24A-24C. Nucleotide (SEQ ID NO:15) and deduced amino acid sequence (SEQ ID NO:16) of the modified Flt1 receptor termed VEGFR1R2-Fc $\Delta C1$ (a).

FIG. 25A-25C. Phosphorylation assay. At a 1.5 molar excess of either Flt1(1-3)-Fc, Flt1(1-3)-Fc (A40) or transient Flt1D2Flk1D3.Fc $\Delta C1$ (a) there is complete blockage of receptor stimulation by these these is modified Flt1 receptors as compared to control media challenge. In contrast, transient Flt1D2VEGFR3D3.Fc $\Delta C1$ (a) does not show significant blockage at this molar excess, as compared with VEGF positive control challenge. Similar results are seen in FIG. 25B, where the modified Flt receptors are in a 3-fold molar excess to VEGF165 ligand. In FIG. 25C, where the modified Flt1 receptors are in a 6-fold molar excess to VEGF165 ligand, transient Flt1D2VEGFR3D3.Fc $\Delta C1$ (a) can now be shown to be partially blocking VEGF165-induced stimulation of cell-surface receptors.

FIG. 26A-26B. Phosphorylation assay. Detection by Western blot of tyrosine phosphorylated VEGFR2(Flk1) by VEGF165 ligand stimulation shows that cell-surface receptors are not phosphorylated by challenge samples which have VEGF165 preincubated with 1 and 2 fold molar excess (FIG. 26A) or 3 and 4 fold molar excess (FIG. 26B) of either transient Flt1D2Flk1D3.Fc $\Delta C1$ (a), stable Flt1D2Flk1D3.Fc $\Delta C1$ (a), or transient VEGFR1R2-Fc $\Delta C1$ (a). At all modified Flt1 receptor concentrations tested there is complete binding of VEGF165 ligand during the preincubation, resulting in no detectable stimulation of cell-surface receptors by unbound VEGF165 as compared to control media challenge.

FIG. 27. MG/R2 Cell proliferation assay. The following modified Flt receptors Flt1(1-3)-Fc, Flt1D2.Flk1D3.Fc $\Delta C1$ (a) and Flt1D2.VEGFR3D3.Fc $\Delta C1$ (a), plus an irrelevant receptor termed Tie2-Fc as a negative control, were titrated from 40 nM to 20 pM and incubated on the cells for 1 hr at 37° C. Human recombinant VEGF165 in defined media was then added to all the wells at a concentration of 1.56 nM. The negative control receptor Tie2-Fc does not block VEGF165-induced cell proliferation at any concentration whereas Flt1D2.Flk1D3.Fc $\Delta C1$ (a) blocks 1.56 nM VEGF165 with a half maximal dose of 0.8 nM. Flt1(1-3)-Fc and Flt1D2.VEGFR3D3.Fc $\Delta C1$ (a) are less effective in blocking VEGF165 in this assay with a half maximal dose of ~2 nM. VEGF165 alone gives a reading of 1.2 absorbance units and the background is 0.38 absorbance units.

FIG. 28. BIACORE™ analysis of Binding Stoichiometry. Binding 20 stoichiometry was calculated as a molar ratio of bound VEGF165 to the immobilized Flt1D2Flk1D3.Fc $\Delta C1$ (a) or VEGFR1R2-Fc $\Delta C1$ (a), using the conversion factor of 1000 RU equivalent to 1 ng/ml. The results indicated binding stoichiometry of one VEGF165 dimeric molecule per one Flt1D2Flk1D3.Fc $\Delta C1$ (a) or VEGFR1R2-Fc $\Delta C1$ (a) molecule.

11

FIG. 29 and FIG. 30. Size Exclusion Chromatography Stoichiometry. Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a) at a concentration of 1 nM (estimated to be 1000 times higher than the KD of the Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a)/VEGF165 interaction) were mixed with varied concentrations of VEGF165. After incubation, concentrations of the free Flt1D2Flk1D3.FcΔC1(a) in solution were measured. The data shows that the addition of 1 nM VEGF165 into the Flt1D2Flk1D3.FcΔC1(a) solution completely blocks Flt1D2Flk1D3.FcΔC1(a) binding to the VEGF165 surface. This result suggested the binding stoichiometry of one VEGF165 molecule per one Flt1D2Flk1D3.FcΔC1(a) molecule.

FIG. 31. Size Exclusion Chromatography (SEC) under native conditions. Peak #1 represents the Flt1D2Flk1D3.FcΔC1(a)/VEGF165 complex and peak #2 represents unbound VEGF165. Fractions eluted between 1.1 and 1.2 ml were combined and guanidinium hydrochloride (GuHCl) was added to a final concentration 4.5M to dissociate the complex.

FIG. 32. Size Exclusion Chromatography (SEC) under dissociative conditions. To separate the components of the receptor-ligand complex and to determine their molar ratio, 50 .mu.l of dissociated complex was loaded onto a SUPER-POSE™ 12 PC 3.2/30 equilibrated in 6M GuHCl and eluted. Peak #1 represents Flt1D2Flk1D3.FcΔC1(a) and peak #2 represents VEGF165.

FIG. 33, FIG. 34 and FIG. 35. Size Exclusion Chromatography (SEC) with On-Line Light Scattering. Size exclusion chromatography column with a MiniDawn on-line light scattering detector (Wyatt Technology, Santa Barbara, Calif.) and refractive index (RI) detectors (Shimadzu, Kyoto, Japan) was used to determine the molecular weight (MW) of the receptor-ligand complex. As shown in FIG. 33, the elution profile shows two peaks. Peak #1 represents the receptor-ligand complex and peak #2 represents the unbound VEGF165. MW was calculated from LS and RI signals. The same procedure was used to determine MW of the individual components of the receptor-ligand complex. The results of these determinations are as follows: MW of the Flt1D2Flk1D3.FcΔC1(a)/VEGF165 complex at the peak position is 157 300 (FIG. 33), the MW of VEGF165 at the peak position is 44 390 (FIG. 34) and the MW of R1R2 at the peak is 113 300 (FIG. 35).

FIG. 36. Peptide mapping and glycosylation analysis. The disulfide structures and glycosylation sites in Flt1D2.Flk1D3.FcΔC1(a) (SEQ ID NO:12) were determined by a peptide mapping method. There are a total of ten cysteines in Flt1D2.Flk1D3.FcΔC1(a); six of them belong to the Fc region. Cys27 is disulfide bonded to Cys76. Cys121 is disulfide bonded to Cys 182. The first two cysteines in the Fc region (Cys211 and Cys214) form an intermolecular disulfide bond with the same two cysteines in another Fc chain. However, it can not be determined whether disulfide bonding is occurring between same cysteines (Cys211 to Cys211, for example) or between Cys211 and Cys211. Cys216 is disulfide bonded to Cys306. Cys 352 is disulfide bonded to Cys410.

There are five possible N-linked glycosylation sites in Flt1D2.Flk1D3.FcΔC1(a) (SEQ ID NO:12) and are found to be glycosylated to varying degrees. Complete glycosylation is observed at Asn33, Asn193, and Asn282. Partial glycosylation is observed on Asn65 and Asn120. Sites of glycosylation are highlighted by underline in the Figure.

FIG. 37. Pharmacokinetics of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a). Balb/c mice were injected subcutaneously with 4 mg/kg of

12

Flt1(1-3)-Fc (A40), CHO transiently expressed Flt1D2.Flk1D3.FcΔC1(a), CHO stably expressed Flt1D2.Flk1D3.FcΔC1(a), and CHO transiently expressed VEGFR1R2-FcΔC1(a). The mice were tail bled at 1, 2, 4, 6, 24 hrs, 2 days, 3 days and 6 days after injection. The sera were assayed in an ELISA designed to detect Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a). The Tmax for Flt1(1-3)-Fc (A40) was at 6 hrs while the Tmax for the transient and stable Flt1D2.Flk1D3.FcΔC1(a) and the transient VEGFR1R2-FcΔC1(a) was 24 hrs. The Cmax for Flt1(1-3)-Fc (A40) was 8 μg/ml, For both transients (Flt1D2.Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a)) the Cmax was 18 μg/ml and the Cmax for the stable VEGFR1R2-FcΔC1(a) was 30 μg/ml.

FIG. 38. Pharmacokinetics of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a). Balb/c mice were injected subcutaneously with 4 mg/kg of Flt1(1-3)-Fc (A40), CHO transiently expressed Flt1D2.Flk1D3.FcΔC1(a) and CHO transiently expressed Flt1D2.VEGFR3D3.FcΔC1(a). The mice were tail bled at 1, 2, 5, 6, 7, 8, 12, 15 and 20 days after injection. The sera were assayed in an ELISA designed to detect Flt1(1-3)-Fc, Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a). Flt1(1-3)-Fc (A40) could no longer be detected in the serum after day 5 whereas Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a) were detectable for 15 days or more.

FIG. 39. The Ability of Flt1D2.Flk1D3.FcΔC1(a) to Inhibit HT-1080 Fibrosarcoma Tumor Growth In Vivo. Every other day or 2 times per week treatment of SCID mice with Flt1D2.Flk1D3.FcΔC1(a) at 25 mg/Kg significantly decreases the growth of subcutaneous HT-1080 fibrosarcoma tumors.

FIG. 40. The Ability of Flt1D2.Flk1D3.FcΔC1(a) to Inhibit C6 Glioma Tumor Growth In Vivo. Every other day or 2 times a week treatment of SCID mice with Flt1D2.Flk1D3.FcΔC1(a) significantly decreases the growth of subcutaneous C6 glioma tumors at doses as low as 2.5 mg/Kg.

FIG. 41. VEGF-Induced Uterine Hyperpermeability. PMSG injected subcutaneously (5 IU) to induce ovulation in prepubertal female rats results in a surge of estradiol after 2 days which in turn causes an induction of VEGF in the uterus. This induction results in hyperpermeability of the uterus and an increase in uterine wet. Subcutaneous injection of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a) at 25 mg/kg at 1 hr after PMSG injection results in about a 50% inhibition of the increase in uterine wet weight.

FIG. 42A-42B. Assessment of Corpus Luteum Angiogenesis Using Progesterone as a Readout. PMSG was injected subcutaneously (5 IU) to induce ovulation in prepubertal female rats, resulting in a fully functioning corpus luteum containing a dense network of blood vessels that secretes progesterone into the blood stream to prepare the uterus for implantation. The induction of angiogenesis in the corpus luteum requires VEGF. Resting levels of progesterone are about 5 ng/ml and can be induced to 25-40 ng/ml after PMSG. Subcutaneous injection of Flt1(1-3)-Fc (A40) or Flt1D2.Flk1D3.FcΔC1(a) at 25 mg/kg or 5 mg/kg at 1 hr. after PMSG injection resulted in a complete inhibition of the progesterone induction on day 4.

DETAILED DESCRIPTION OF THE
INVENTION

It has been a long standing problem in the art to produce a receptor based VEGF antagonist that has a pharmacokinetic profile that is appropriate for consideration of the antagonist as a therapeutic candidate. Applicants describe herein, for the first time, a chimeric polypeptide molecule, capable of antagonizing VEGF activity, that exhibits improved pharmacokinetic properties as compared to other known receptor-based VEGF antagonists. The chimeric polypeptide molecules described herein thus provide for the first time appropriate molecules for use in therapies in which antagonism of VEGF is a desired result.

The present invention provides for novel chimeric polypeptide molecules formed by fusing a modified extracellular ligand binding domain of the Flt1 receptor to the Fc region of IgG.

The extracellular ligand binding domain is defined as the portion of a receptor that, in its native conformation in the cell membrane, is oriented extracellularly where it can contact with its cognate ligand. The extracellular ligand binding domain does not include the hydrophobic amino acids associated with the receptor's transmembrane domain or any amino acids associated with the receptor's intracellular domain. Generally, the intracellular or cytoplasmic domain of a receptor is usually composed of positively charged or polar amino acids (i.e. lysine, arginine, histidine, glutamic acid, aspartic acid). The preceding 15-30, predominantly hydrophobic or apolar amino acids (i.e. leucine, valine, isoleucine, and phenylalanine) comprise the transmembrane domain. The extracellular domain comprises the amino acids that precede the hydrophobic transmembrane stretch of amino acids. Usually the transmembrane domain is flanked by positively charged or polar amino acids such as lysine or arginine. von Heijne has published detailed rules that are commonly referred to by skilled artisans when determining which amino acids of a given receptor belong to the extracellular, transmembrane, or intracellular domains (See von Heijne, 1995, *BioEssays* 17:25-30). Alternatively, websites on the Internet have become available to provide protein chemists with information about making predictions about protein domains.

The present invention provides for the construction of nucleic acid molecules encoding chimeric polypeptide molecules that are inserted into a vector that is able to express the chimeric polypeptide molecules when introduced into an appropriate host cell. Appropriate host cells include, but are not limited to, bacterial cells, yeast cells, insect cells, and mammalian cells. Any of the methods known to one skilled in the art for the insertion of DNA fragments into a vector may be used to construct expression vectors encoding the chimeric polypeptide molecules under control of transcriptional/translational control signals. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinations (genetic recombination) (See Sambrook, et al., *Molecular Cloning*, A Laboratory Manual, Cold Spring Harbor Laboratory; *Current Protocols in Molecular Biology*, Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY).

Expression of nucleic acid molecules encoding the chimeric polypeptide molecules may be regulated by a second nucleic acid sequence so that the chimeric polypeptide molecule is expressed in a host transformed with the recombinant DNA molecule. For example, expression of the chimeric polypeptide molecules described herein may be controlled by any promoter/enhancer element known in the

art. Promoters which may be used to control expression of the chimeric polypeptide molecules include, but are not limited to, the long terminal repeat as described in Squinto et al., (1991, *Cell* 65:1-20); the SV40 early promoter region (Bernoist and Chambon, 1981, *Nature* 290:304-310), the CMV promoter, the M-MuLV 5' terminal repeat the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, *Cell* 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, *Proc. Natl. Acad. Sci. U.S.A.* 78:144-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, *Nature* 296:39-42); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Kamaroff, et al., 1978, *Proc. Natl. Acad. Sci. U.S.A.* 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:21-25, see also "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242:74-94); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADH (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, *Cell* 38:639-646; Ornitz et al., 1986, *Cold Spring Harbor Symp. Quant. Biol.* 50:399-409; MacDonald, 1987, *Hepatology* 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, *Nature* 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, *Cell* 38:647-658; Adames et al., 1985, *Nature* 318:533-538; Alexander et al., 1987, *Mol. Cell. Biol.* 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, *Cell* 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, *Genes and Devel.* 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, *Mol. Cell. Biol.* 5:1639-1648; Hammer et al., 1987, *Science* 235:53-58); alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, *Genes and Devel.* 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogam et al., 1985, *Nature* 315:338-340; Kollias et al., 1986, *Cell* 46:89-94); myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, *Cell* 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Shani, 1985, *Nature* 314:283-286), and gonadotropin releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, *Science* 234:1372-1378).

Thus, according to the invention, expression vectors capable of being replicated in a bacterial or eukaryotic host comprising chimeric polypeptide molecule-encoding nucleic acid as described herein, are used to transfect the host and thereby direct expression of such nucleic acids to produce the chimeric polypeptide molecules, which may then be recovered in a biologically active form. As used herein, a biologically active form includes a form capable of binding to VEGF.

Expression vectors containing the chimeric nucleic acid molecules described herein can be identified by three general approaches: (a) DNA-DNA hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising

sequences that are homologous to the inserted chimeric polypeptide molecule sequences. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the chimeric polypeptide molecule DNA sequence is inserted within the marker gene sequence of the vector, recombinants containing the insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the chimeric polypeptide molecules.

Cells of the present invention may transiently or, preferably, constitutively and permanently express the chimeric polypeptide molecules.

The chimeric polypeptide molecules may be purified by any technique which allows for the subsequent formation of a stable, biologically active chimeric polypeptide molecule. For example, and not by way of limitation, the factors may be recovered from cells either as soluble proteins or as inclusion bodies, from which they may be extracted quantitatively by 8M guanidinium hydrochloride and dialysis (see, for example, Builder, et al., U.S. Pat. No. 5,663,304). In order to further purify the factors, conventional ion exchange chromatography, hydrophobic interaction chromatography, reverse phase chromatography or gel filtration may be used.

In one embodiment of the invention, the nucleotide sequence encoding the first component is upstream of the nucleotide sequence encoding the second component. In another embodiment of the invention, the nucleotide sequence encoding the first component is downstream of the nucleotide sequence encoding the second component. Further embodiments of the invention may be prepared in which the order of the first, second and third fusion polypeptide components are rearranged. For example, if the nucleotide sequence encoding the first component is designated 1, the nucleotide sequence encoding the second component is designated 2, and the nucleotide sequence of the third component is designated 3, then the order of the components in the isolated nucleic acid of the invention as read from 5' to 3' may be any of the following six combinations: 1,2,3; 1,3,2; 2,1,3; 2,3,1; 3,1,2; or 3,2,1.

The present invention also has diagnostic and therapeutic utilities. In particular embodiments of the invention, methods of detecting aberrancies in the function or expression of the chimeric polypeptide molecules described herein may be used in the diagnosis of disorders. In other embodiments, manipulation of the chimeric polypeptide molecules or agonists or antagonists which bind the chimeric polypeptide molecules may be used in the treatment of diseases. In further embodiments, the chimeric polypeptide molecule is utilized as an agent to block the binding of a binding agent to its target.

By way of example, but not limitation, the method of the invention may be useful in treating clinical conditions that are characterized by vascular permeability, edema or inflammation such as brain edema associated with injury, stroke or tumor; edema associated with inflammatory disorders such as psoriasis or arthritis, including rheumatoid arthritis; asthma; generalized edema associated with burns; ascites

and pleural effusion associated with tumors, inflammation or trauma; chronic airway inflammation; capillary leak syndrome; sepsis;

kidney disease associated with increased leakage of protein; and eye disorders such as age related macular degeneration and diabetic retinopathy.

An amino acid sequence analysis of Flt1(1-3)-Fc revealed the presence of an unusually high number (46) of the basic amino acid residue lysine. An IEF analysis of Flt1(1-3)-Fc showed that this protein has pI greater than 9.3, confirming the prediction that the protein is very basic. It was hypothesized that the basic nature of Flt1(1-3)-Fc protein was causing it to bind to extracellular matrix components and that this interaction might be the cause of the extremely short detectable circulating serum half-life exhibited by Flt1(1-3)-Fc when injected into mice. In order to test this hypothesis, Flt1(1-3)-Fc protein was acetylated at the lysine residues to reduce the basic charge. Acetylated Flt1(1-3)-Fc was then tested in the assays described *infra*.

The following examples are offered by way of illustration and not by way of limitation.

EXAMPLES

Example 1

Expression of Flt1(1-3)-Fc Protein in CHO K1 Cells

Using standard molecular biology techniques (see e.g., Molecular Cloning, A Laboratory Manual (Sambrook, et al., Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY), the gene encoding Flt1(1-3)-Fc was inserted into the expression vector pEE14.1 (Lonza Biologics, plc) at a multiple cloning site downstream of the CMV promoter. CHO K1 cells were transfected with the pEE14.1/Flt1(1-3)-Fc DNA construct using lipofectamine (Gaithersburg, Md.). The transfected CHO K1 cells were grown in glutamine-free DMEM (JRH, Kansas City, Mo.) containing 25 μ M methionine sulfoximine (MSX) from Sigma Inc., St. Louis, Mo., and high recombinant protein expressors were obtained by screening the CHO K1 cell supernatants from over 100 hand-picked colony isolates using a standard immunoassay which captures and detects human Fc. The selected hand-picked clone was amplified in the presence of 100 μ M MSX followed by a second round of screening of the amplified clones. The highest producing clone had a specific productivity of recombinant Flt1(1-3)-Fc protein of 55 pg/cell/day.

The selected clone was expanded in 225 cm² T-flasks (Corning, Acton, Mass.) and then into 8.5 L roller bottles (Corning, Acton, Mass.) using the cell culture media described *supra*. Cells were removed from the roller bottles by standard trypsinization and put into 3.5 L of suspension medium. The suspension medium is comprised of glutamine-free ISCHO medium (Irvine Scientific, Santa Ana, Calif.) containing 5% fetal bovine serum (FBS from Hyclone Labs, Logan, Utah), 100 μ M MSX and GS supplement (JRH Scientific, Kansas City, Mo.) in a 5 L Celligen bioreactor (New Brunswick Scientific, New Brunswick, N.J.) at a density of 0.3×10^6 cells/mL. After the cells reached a density of 3.6×10^6 cells/mL and were adapted to suspension they were transferred to a 60 L bioreactor (ABEC, Allentown, Pa.) at a density of 0.5×10^6 cells/mL in 20 L of ISCHO medium with 5% fetal bovine serum. After two days an additional 20 L of ISCHO+5% fetal bovine serum was added

17

to the bioreactor. The cells were allowed to grow for an additional two days reaching a final density of 3.1×10^6 cells/mL, and a final Flt1(1-3)-Fc concentration at harvest was 95 mg/L. At harvest the cells were removed by tangential flow filtration using 0.45 μ m ProstaK Filters (Millipore, Inc., Bedford, Mass.).

Example 2

Purification of Flt1(1-3)-Fc Protein Obtained from CHO K1 Cells

Flt1(1-3)-Fc protein was initially purified by affinity chromatography. A Protein A column was used to bind, with high specificity, the Fc portion of the molecule. This affinity-purified protein was then concentrated and passed over a SEC column. The protein was then eluted into the formulation buffer. The following describes these procedures in detail.

Materials and Methods

All chemicals were obtained from J. T. Baker, Phillipsburg, N.J. with the exception of PBS, which was obtained as a 10.times. concentrate from Life Technologies, Gaithersburg, Md. Protein A Fast Flow and SUPERDEX™ 200 preparation grade resins were obtained from Pharmacia, Piscataway, N.J. Equipment and membranes for protein concentration were obtained from Millipore, Bedford, Mass.

Approximately 40 L of 0.45 μ m-filtered CHO conditioned media containing Flt1(1-3)-Fc protein was applied to a 290 mL Protein A Fast Flow column (10 cm diameter) that had been equilibrated with PBS. The column was washed with PBS containing 350 mM NaCl and 0.02% CHAPS and the bound protein was eluted with 20 mM Citric Acid containing 10 mM Na_2HPO_4 . The single peak in the elution was collected and its pH was raised to neutrality with 1M NaOH. The eluate fractions was concentrated to approximately 9 mg/mL using 10K regenerated cellulose membranes by both tangential flow filtration and by stirred cell concentration. To remove aggregates and other contaminants, the concentrated protein was applied to a column packed with Superdex 200 preparation grade resin (10 cm $\times$ 55 cm) and run in PBS containing 5% glycerol. The main peak fractions were pooled, sterile filtered, aliquoted and stored at -80°C .

Example 3

Acetylation of Flt1(1-3)-Fc Protein

Two milligrams of Flt1(1-3)-Fc protein were acetylated as described in the instruction manual provided with the sulfo-NHS-acetate modification kit (Pierce Chemical Co., Rockford, Ill., Cat.#26777).

Example 4

Characterization of Acetylated Flt1(1-3)-Fc Protein

(a.) IEF analysis: Flt1(1-3)-Fc and acetylated Flt1(1-3)-Fc were analyzed by standard IEF analysis. As shown in FIG. 1, Flt1(1-3)-Fc protein is not able to migrate into the gel and therefore must have a pI greater than 9.3, the highest pI in the standard. However, acetylated Flt1(1-3)-Fc is able to migrate into the gel and equilibrate at a pI of approximately 5.2. This result demonstrates that acetylation reduces the net positive charge of the protein and therefore its pI considerably.

18

(b.) Binding to Extracellular Matrix Components

To test for binding to extracellular matrix components, Flt1(1-3)-Fc and acetylated Flt1(1-3)-Fc were tested in an assay designed to mimic the interaction with extracellular matrix components. In this assay, 96-well tissue culture plates are coated with Matrigel (Biocoat MATRIGEL® matrix thin layer 96 well plate, Catalog #40607, Becton Dickinson Labware, Bedford, Mass.). The plates are incubated with varying concentrations of either Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc, or rTie2-Fc (an irrelevant control) protein are added to the wells. The plates are incubated for 1-2 hours at either room temperature or 37°C . degrees and then detection of bound proteins is accomplished by adding a secondary alkaline phosphatase-conjugated anti-human Fc antibody to the wells. Finally, alkaline phosphatase substrate is added to the wells and optical density is measured. FIG. 2 shows the results of this assay. Like the irrelevant control protein rTie2-Fc, acetylated Flt1(1-3)-Fc does not exhibit any binding to the Matrigel coated plate, whereas the non-acetylated Flt1(1-3)-Fc protein exhibits significant binding. This result indicates that acetylation of basic amino acid residues is an effective way to interfere with the charge interactions that exist between positively charged proteins and the negatively charged extracellular matrix components they are exposed to in vivo.

Example 5

Pegylation of Flt1(1-3)-Fc Protein

Although pegylation (polyethylene glycol—PEG) of proteins has been shown to increase their in vivo potency by enhancing stability and bioavailability while minimizing immunogenicity (see references cited supra), it is counter-intuitive that pegylating molecules that are too large to be filtered by the kidney glomeruli would improve their pharmacokinetic properties. Without being bound by theory, Applicants postulated that pegylation of the Flt1(1-3)-Fc molecules could improve the pharmacokinetic properties, possibly not by altering the positive charge or by decreasing the pI of Flt1(1-3)-Fc, but rather by physically shielding the positive charges from interacting with the extracellular matrix. Applicants decided to attempt to improve the pharmacokinetic properties of Flt1(1-3)-Fc molecules by attaching strands of 20K PEGs as described infra.

Materials and Methods

Purified Flt1(1-3)-Fc derived from CHO cells (see supra) was used in the following pegylation experiments. Functionalized PEGs were obtained from Shearwater Polymers, Huntsville, Ala.; Bicine from Sigma, St Louis, Mo.; Superose 6 column from Pharmacia, Piscataway, N.J.; PBS as a 10 $\times$ concentrate from Life Technologies, Gaithersburg, Md.; Glycerol from J. T. Baker, Phillipsburg, N.J.; and Bis-Tris precast gels from Novex, Calif.

20K PEG strands functionalized with amine-specific terminal moieties were used in small-scale reaction studies that were set-up to evaluate different reaction conditions in which the PEG:protein stoichiometry was varied. Based on these reactions and the analyses of samples on standard SDS-PAGE, Flt1(1-3)-Fc at a concentration of 1.5 mg/mL was reacted at pH 8.1 with 20K SPA-PEG (PEG succinimidyl propionate) molecules at a PEG-to-Flt1(1-3)-Fc monomer molar ratio of 1:6. The reaction was allowed to proceed at 8°C . overnight. For initial purification, the reaction products were applied to a 10 mm $\times$ 30 cm Superose 6 column equilibrated with PBS containing 5% Glycerol. The column appeared to separate pegylated Flt1(1-3)-Fc molecules based on the extent of pegylation. Fractions corresponding to what appeared to be primarily mono-pegylated

19

and di-pegylated dimeric Flt1(1-3)-Fc, as judged by banding patterns on reducing and non-reducing SDS-PAGE gels were pooled. The protein concentration was determined by measuring absorbance at 280 nm. The pegylated Flt1(1-3)-Fc protein was sterile filtered, aliquoted and stored at -40° C.

Example 6

Binding of Unmodified, Acetylated, and Pegylated Flt1(1-3)-Fc in a BIACORE™-Based Assay

Unmodified, acetylated, and pegylated Flt1(1-3)-Fc proteins were tested in a BIACORE™-based assay to evaluate their ability to bind to the Flt1 ligand, VEGF. In this assay, unmodified Flt1(1-3)-Fc protein was immobilized on the surface of a BIACORE™ chip (see BIACORE™ Instruction Manual, Pharmacia, Inc., Piscataway, N.J., for standard procedures) and a sample containing 0.2 µg/ml VEGF and either unmodified Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc or pegylated Flt1(1-3)-Fc (each at 25 µg/ml) was passed over the Flt1(1-3)-Fc-coated chip. To minimize the effects of non-specific binding, the bound samples were washed with a 0.5M NaCl wash. In one sample, unmodified Flt1(1-3)-Fc was mixed with heparin. Heparin is a negatively charged molecule and the Flt1(1-3)-Fc protein is a positively charged molecule, so when the two molecules are mixed together, they should interact through their respective charges. This essentially neutralizes Flt1(1-3)-Fc's inherent positive charge making the molecule behave as if it has been chemically or genetically modified so as to reduce its charge and its tendency to bind via charge interactions. As shown in FIG. 3, acetylated (columns 13-16), pegylated (columns 17-20), and heparin-treated Flt1(1-3)-Fc (columns 21-24) are each able to completely compete with the BIACORE™ chip-bound Flt1(1-3)-Fc for VEGF binding as compared to control (columns 1-4) and irrelevant protein (columns 5-8). Unmodified Flt1(1-3)-Fc (columns 5-6) appeared to only partially compete with BIACORE™ chip-bound Flt1(1-3)-Fc for VEGF binding. However, washing the bound samples with 0.5M NaCl (columns 7-8) resulted in a binding profile similar to the modified forms of Flt1(1-3)-Fc, indicating that the unmodified protein was exhibiting non-specific binding to the chip that could be eliminated by the salt wash.

Example 7

Binding of Unmodified, Acetylated, and Pegylated Flt1(1-3)-Fc in an ELISA-Based Assay

Unmodified, acetylated, and pegylated Flt1(1-3)-Fc proteins were tested in a standard ELISA-based assay to evaluate their ability to bind the Flt1 receptor ligand VEGF. As shown in FIG. 4, both pegylated and acetylated Flt1(1-3)-Fc proteins are capable of binding to VEGF, demonstrating that modifying the protein either by pegylation or acetylation does not destroy its ability to bind its ligand.

Example 8

Pharmacokinetic Analysis of Unmodified Flt1(1-3)-Fc, Acetylated Flt1(1-3)-Fc, and Pegylated Flt1(1-3)-Fc

In vivo experiments were designed to assess the pharmacokinetic profiles of unmodified Flt1(1-3)-Fc, acetylated Flt1(1-3)-Fc, and pegylated Flt1(1-3)-Fc protein. Balb/c

20

mice (23-28 g; 3 mice/group) were injected subcutaneously with 4 mg/kg of unmodified, acetylated, or pegylated Flt1(1-3)-Fc. The mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days, and 3 days after injection of protein. The sera were assayed in a standard ELISA-based assay designed to detect Flt1(1-3)-Fc protein. Briefly, the assay involves coating an ELISA plate with VEGF, binding the unmodified, acetylated, or pegylated Flt1(1-3)-Fc-containing sera, and reporting with an anti-Fc antibody linked to alkaline phosphatase. As shown in FIG. 5, the T_{max} for all of the Flt1(1-3)-Fc proteins was between the 6 hour and 24 hour time points. The C_{max} for the different proteins was as follows: Unmodified: 0.06 µg/ml-0.15 µg/ml; acetylated: 1.5 µg/ml-4.0 µg/ml; and pegylated: approximately 5 µg/ml.

Example 9

Step-Acetylation of Flt1(1-3)-Fc

To determine what minimal amount of acetylation is necessary to eliminate binding to extracellular matrix components, an experiment was designed that acetylated the Flt1(1-3)-Fc protein in a step-wise fashion by using increasing amounts of molar excess of acetylation reagent in the acetylation reaction mixture. The range of molar excess was as follows: 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 moles of acetylation reagent per 1 mole of Flt1(1-3)-Fc monomer. The reactions were performed as detailed in the instruction manual provided with the sulfo-NHS-Acetate modification kit (Pierce Chemical Co., Rockford, Ill., Cat.# 26777).

Example 10

Characterization of Step-Acetylated Flt1(1-3)-Fc

(a.) IEF analysis Unmodified Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc proteins were analyzed by standard IEF analysis. As shown in FIG. 6A-6B, unmodified Flt1(1-3)-Fc protein was not able to migrate into the gel due to its extremely high pI (greater than 9.3). However, most of the step-acetylated Flt1(1-3)-Fc samples (30-100 fold molar excess samples) were able to migrate into the gel and equilibrate at pIs ranging between 4.55-8.43, depending on the degree of acetylation of the protein. This result demonstrates that acetylation can change the positive charge of the protein in a dose-dependent manner and that reduction of the pI can be controlled by controlling the degree of acetylation.

(b.) Binding of Step-Acetylated Flt1(1-3)-Fc to Extracellular Matrix Components

To test for binding to extracellular matrix components, Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc were tested in the above-described assay designed to mimic the interaction with extracellular matrix components. Varying concentrations of either unmodified Flt1(1-3)-Fc, step-acetylated Flt1(1-3)-Fc (10, 20, and 30 fold molar excess samples), or rTie2-Fc (an irrelevant control) protein were added to the wells. The plates were incubated for 1-2 hours at room temperature or 37° C. and then detection of bound proteins was accomplished by adding a secondary alkaline phosphatase-conjugated anti-human Fc antibody to the wells. Alkaline phosphatase substrate was subsequently added to the wells and optical density measured. FIG. 7 shows the results of this assay. Like the irrelevant control protein rTie2-Fc, step-acetylated Flt1(1-3)-Fc (20 and 30 fold molar excess samples) did not exhibit any significant

binding to the Matrigel coated plate, whereas the non-acetylated Flt1(1-3)-Fc protein exhibited significant binding. The binding is saturable, indicating that the Flt1(1-3)-Fc protein may be binding to specific sites, rather than a more general charge-mediated interaction that might not be saturable. The 10 fold molar excess sample showed reduced binding, but the degree of acetylation was not enough to completely block binding to extracellular matrix components. The 20 fold molar excess and higher samples displayed no detectable binding, despite the fact that by IEF analysis (FIG. 6A and 6B) the lower molar excess samples still had a large net positive charge. This result demonstrates that it is not necessary to completely acetylate all available basic amino acids in order to eliminate binding to extracellular matrix components.

(c.) Binding of Step-Acetylated Flt1(1-3)-Fc in a Biacore-Based Assay.

(c.) Binding of Step-Acetylated Flt1(1-3)-Fc in a BIACORE™-Based Assay

Unmodified and step-acetylated Flt1(1-3)-Fc proteins where tested in a BIACORE™-based assay to evaluate their ability to bind to the Flt1 ligand, VEGF. In this assay, unmodified Flt1(1-3)-Fc protein (0.5, 1.0, or 5.0 µg/ml) was immobilized on the surface of a BIACORE™ chip (see BIACORE™ Instruction Manual, Pharmacia, Inc., Piscataway, N.J., for standard procedures) and a solution containing 0.2 µg/ml VEGF and either unmodified Flt1(1-3)-Fc (at either 0.5, 1.0, or 5.0 µg/ml) or 10 different step-acetylated Flt1(1-3)-Fc samples (at 0.5, 1.0, or 5.0 µg/ml each) were passed over the Flt1 (1-3)-Fc-coated chip. As shown in FIG. 8, at a sub-stoichiometric ratio (0.5 µg/ml of either unmodified Flt1(1-3) or step-acetylated Flt1(1-3)-Fc vs. 0.2 µg/ml VEGF), there is not enough Flt1(1-3)-Fc (either unmodified or step-acetylated) in the solution to completely bind the VEGF. At 1.0 µg/ml, which approximates a 1:1 stoichiometric ratio, both unmodified and step-acetylated Flt1(1-3)-Fc are better able to compete for VEGF binding, but there is still insufficient Flt1(1-3)-Fc protein (either unmodified or step-acetylated) to completely bind the available VEGF. However, at 5.0 µg/ml, which is several times greater than a 1:1 stoichiometric ratio, both the Flt1(1-3)-Fc and the step-acetylated Flt1(1-3)-Fc proteins are able to bind the VEGF, regardless of the degree of acetylation. This clearly demonstrates that acetylation does not alter Flt1(1-3)-Fc's ability to bind VEGF.

(d.) Pharmacokinetic Analysis of Step-Acetylated Flt1(1-3)-Fc

In vivo experiments were designed to assess the pharmacokinetic profiles of unmodified Flt1(1-3)-Fc and step-acetylated Flt1(1-3)-Fc protein. Balb/c mice (23-28 g) were injected subcutaneously with 4 mg/kg of unmodified or 10, 20, 40, 60 and 100 fold molar excess samples of step-acetylated Flt1(1-3)-Fc (3 mice for unmodified, 10, 20 and 40 fold molar excess samples and 2 mice for 60 and 100 fold molar excess samples). The mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days and 3 days after injection. The sera were assayed in an ELISA-based assay designed to detect Flt1 (1-3)-Fc (described supra). FIG. 9 details the results of this study. The T_{max} for all of the Flt1(1-3)-Fc proteins tested was at the 6 hour time point but the C_{max} was as follows: Unmodified Flt1(1-3)-Fc: 0.06 µg/ml; 10 fold molar excess sample—0.7 µg/ml, 20 fold molar excess sample—2 µg/ml, 40 fold molar excess sample—4 µg/ml, 60 fold molar excess sample—2 µg/ml, 100 fold molar excess sample—1 µg/ml.

This results demonstrates that acetylation or pegylation of Flt1(1-3)-Fc significantly improves its pharmacokinetic profile.

Example 11

Construction of Flt1(1-3)-Fc Basic Region Deletion Mutant Designated Mut1: Flt1(1-3)_{ΔB}-Fc

Based on the observation that acetylated Flt1(1-3)-Fc, which has a pI below 6, has much better pharmacokinetics than the highly positive unmodified Flt1(1-3)-Fc (pI>9.3), it was asked whether the difference in pharmacokinetics could be attributed to the net charge of the protein. Which made it stick to negatively charged extracellular matrix components, or whether there were perhaps specific locations on the surface of the Flt1(1-3)-Fc protein that constituted specific binding sites for extracellular matrix components. For example, many proteins are known to have heparin binding sites, often consisting of a cluster of basic residues. Sometimes these residues are found in a cluster on the primary sequence of the protein; some of the literature has identified "consensus sequences" for such heparin binding sites (see for example Hileman, et al., 1998, Bioessays 20(2):156-67). In other cases, the known crystal structure of a protein reveals a cluster of positively charged residues on the surface of a protein, but the residues come from different regions of the primary sequence and are only brought together when the protein folds into its tertiary structure. Thus it is difficult to deduce whether an isolated amino acid residue forms part of a cluster of basic residues on the surface of the protein. However, if there is a cluster of positively charged amino acid residues in the primary sequence, it is not unreasonable to surmise that the residues are spatially close to one another and might therefore be part of an extracellular matrix component binding site. Flt1 receptor. has been studied extensively and various domains have been described (see for example Tanaka et al., 1997, Jpn. J. Cancer Res 88:867-876). Referring to the nucleic acid and amino acid sequence set forth in FIG. 10A-10D of this application, one can identify the signal sequence for secretion which is located at the beginning of the sequence and extends to the glycine coded for by nucleotides 76-78. The mature protein begins with Ser-Lys-Leu-Lys, starting at nucleotide 79 of the nucleic acid sequence. Flt1 Ig domain 1 extends from nucleotide 79 to 393, ending with the amino acids Ser-Asp-Thr. Flt1 Ig domain 2 extends from nucleotide 394 to 687 (encoding Gly-Arg-Pro to Asn-Thr-Ile), and Flt1 Ig domain 3 extends from nucleotides 688 to 996 (encoding Ile-Asp-Val to Asp-Lys-Ala). There is a bridging amino acid sequence, Gly-Pro-Gly, encoded by nucleotides 997-1005, followed by the nucleotide sequence encoding human Fc (nucleotides 1006-1701 or amino acids Glu-Pro-Lys to Pro-Gly-Lys-stop).

A more detailed analysis of the Flt1 amino acid sequence reveals that there is a cluster, namely, amino acid residues 272-281 (KNKRASVRR) of FIG. 10A-10D, in which 6 out of 10 amino acid residues are basic. This sequence is located in Flt1 Ig domain 3 of the receptor (see FIG. 11), which is not itself essential for binding of VEGF ligand, but which confers a higher affinity binding to ligand. An alignment of the sequence of Ig domain 3 with that of Ig domain 2 reveals that in this region, there is very poor alignment between the two Ig domains, and that there are about 10 additional amino acids in Ig domain 3. An analysis of the hydrophilicity profiles MACVECTOR™ computer software) of these two domains clearly indicates the presence of a hydrophilic

23

region in the protein (FIG. 12A-12B). These observations raised the possibility that the actual three dimensional conformation of Flt1 Ig domain 3 allowed for some type of protrusion that is not in Flt1 Ig domain 2. To test this hypothesis, the 10 additional amino acids were deleted and the resulting protein was tested to see whether the deletion would affect the pharmacokinetics favorably without seriously compromising the affinity of the receptor for VEGF. This DNA construct, which was constructed using standard molecular biology techniques (see e.g., Molecular Cloning, A Laboratory Manual (Sambrook, F et al., Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, N.Y.) in the mammalian expression vector pMT21, (Genetics Institute, Inc., Cambridge, Mass.), is referred to as Mut1: Flt1(1-3ΔB)-Fc. The Mut1: Flt1(1-3ΔB)-Fc construct was derived from Flt1(1-3)-Fc by deletion of nucleotides 814-843 (set forth in FIG. 10A-10D), which deletes the highly basic 10-amino acid residue sequence Lys-Asn-Lys-Arg-Ala-Ser-Val-Arg-Arg-Arg from Flt1 Ig domain 3.

The final DNA construct was sequence-verified using an ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, Calif.). The sequence of Mut1: Flt1(1-3_{ΔB})-Fc is set forth in FIG. 13A-13D.

Example 12

Construction of Flt1(1-3)-Fc Basic Region Deletion Mutant Designated Mut2: Flt1(2-3_{ΔB})-Fc

A second deletion mutant construct, designated Mut2: Flt1(2-3_{ΔB})-Fc, was derived from the Mut1: Flt1(1-3_{ΔB})-Fc construct by deletion of Flt1 Ig domain 1 encoded by nucleotides 79-393 (see FIG. 10A-10D); for convenience, nucleotides 73-78 (TCA GGT) were changed to TCC GGA. This introduced a restriction site (BspE1) without altering the associated amino acid sequence, Ser-Gly. This DNA construct, which was constructed using standard molecular biology techniques (see e.g., Molecular Cloning, A Laboratory Manual (Sambrook, et al., Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al., Greene Publ. Assoc., Wiley-Interscience, NY) in the mammalian expression vector pMT21 (Genetics Institute, Inc., Cambridge, Mass.), was also sequence-verified using an ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, Calif.). The sequence of Mut2: Flt1(2-3_{ΔB})-Fc is set forth in FIG. 14A-14C.

Example 13

Construction of Flt1(1-3)-Fc Deletion Mutant Designated Mut3: Flt1(2-3)-Fc

A third deletion mutant construct, designated Mut3: Flt1(2-3)-Fc, was constructed the same way as the Mut2: Flt1(2-3_{ΔB})-Fc construct, except that Flt1 Ig domain 3 was left intact (the basic region amino acids were not deleted). The construct was constructed using standard molecular biology techniques and the final construct was sequence-verified as described supra. The sequence of Mut3: Flt1(2-3)-Fc is set forth in FIG. 15A-15C.

24

Example 14

Construction of Flt1(1-3)-Fc Basic Region N-glycosylation Mutant Designated Mut4: Flt1(1-3_{R->N})-Fc

A final construct was made in which a N-glycosylation site was introduced into the middle of the basic region of Flt1 Ig domain 3. This construct was designated Mut4: Flt1(1-3_{R->N})-Fc and was made by changing nucleotides 824-825 from GA to AC, consequently changing the coded Arg residue (AGA) into an Asn residue (AAC) (see FIG. 10A-10D). The resulting amino acid sequence is therefore changed from Arg-Ala-Ser to Asn-Ala-Ser, which matches the canonical signal (Asn-Xxx-Ser/Thr) for the addition of a N-glycosylation site at the Asn residue. The sequence of Mut4: Flt1(1-3_{R->N})-Fc is set forth in FIG. 16A-16D.

Example 15

Characterization of Acetylated Flt1(1-3)-Fc Mut1: Flt1(1-3_{ΔB})-Fc, and Mut4: Flt1(1-3_{R->N})-Fc mutants

(a.) Binding to Extracellular Matrix Components

To determine whether the three modified proteins were more or less likely to have improved pharmacokinetic properties, Matrigel coated 96-well dishes (as described supra) were incubated with varying concentrations of the mutant proteins and detected with anti-human Fc/alkaline-phosphatase conjugated antibodies. As shown in FIG. 18, this experiment showed that while the unmodified Flt1(1-3)-Fc protein could bind avidly to these wells, the Mut3: Flt1(2-3)-Fc protein bound somewhat more weakly, the Mut1: Flt1(1-3_{ΔB})-Fc protein bound more weakly still, and the Mut2: Flt1(2-3_{ΔB})-Fc protein showed the best profile, binding more weakly than any of the other mutant proteins. The Mut4: Flt1(1-3_{R->N})-Fc glycosylation mutant protein showed only marginal benefit on the Matrigel assay. These results confirm the hypothesis that a linear sequence of positive amino acids can be deleted from the primary sequence resulting in a decrease in charge interaction with extracellular matrix components.

(b.) Binding of Mut1: Flt1(1-3ΔB)-Fc and Mut4: Flt1(1-3_{R->N})-Fc in a BIACORE™-Based Assay.

Unmodified and acetylated Flt1(1-3)-Fc and genetically modified Mut1: Flt1(1-3ΔB)-Fc and Mut4: Flt1(1-3_{R->N})-Fc proteins were tested in a BIACORE™-based assay to evaluate their ability to bind to the Flt1 ligand, VEGF. In this assay, unmodified Flt1(1-3)-Fc protein (0.25, 0.5, or 1.0 μg/ml) was immobilized on the surface of a BIACORE™ chip (see BIACORE™ Instruction Manual, Pharmacia, Inc., Piscataway, N.J., for standard procedures) and a solution containing 0.1 μg/ml VEGF and either purified or COS cell supernatant containing unmodified Flt1(1-3)-Fc (at approximately (0.25, 0.5, or 1.0 μg/ml), purified acetylated Flt1(1-3)-Fc (at (0.25, 0.5, or 1.0 μg/ml), COS cell supernatant containing Mut1: Flt1(1-3ΔB)-Fc. (at approximately (0.25, 0.5, or 1.0 μg/ml), or COS cell supernatant containing Mut4: Flt1(1-3_{R->N})-Fc (at approximately (0.25, 0.5, or 1.0 μg/ml) were passed over the Flt1(1-3)-Fc-coated chip. As shown in FIG. 17, at the sub-stoichiometric ratio (0.25 μg/ml Flt1(1-3)-Fc of unmodified, acetylated or genetically modified samples vs. 0.1 μg/ml VEGF), there is insufficient Flt1(1-3)-Fc protein to block binding of VEGF to the Flt1(1-3)-Fc immobilized on the BIACORE™ chip. At 0.5 μg/ml of unmodified, acetylated or genetically modified Flt1(1-3)-Fc proteins, the stoichiometric ratio approximates 1:1 and there

is an increased ability to block VEGF binding to the BIA-CORE™ chip. At 1.0 µg/ml of unmodified, acetylated or genetically modified Flt1(1-3)-Fc proteins, which is approximately a 10:1 stoichiometric ratio, the Flt1(1-3)-Fc proteins are able to block binding of VEGF to the BIA-CORE™ chip, but they are not equivalent. Unmodified, acetylated, and Mut1: Flt1(1-3ΔB)-Fc are essentially equal in their ability to block VEGF binding, whereas Mut4: Flt1(1-3_{R→N})-Fc is somewhat less efficient at blocking binding. These results confirm the hypothesis that it is possible to reduce the non-specific binding of a positively charged molecule by genetically removing a linear sequence of predominantly negatively charged amino acids.

(c.) Binding of Mut1: Flt1(1-3_{ΔB})-Fc, Mut2: Flt1(2-3_{ΔB})-Fc, Mut3: Flt1(2-3)-Fc, and in an ELISA-Based Assay.

To determine whether the three mutant proteins could bind the Flt1 ligand VEGF, binding experiments were done in which 96-well plates coated with VEGF were incubated with varying concentrations of the respective mutant protein, and after washing, the amount bound was detected by incubating with an alkaline phosphatase conjugated anti-human Fc antibody and quantitated colorimetrically by the addition of an appropriate alkaline phosphatase substrate. As shown in FIG. 19, this experiment showed that all the mutant proteins could bind VEGF similarly, at the concentrations tested.

Example 16

Pharmacokinetic Analysis of Acetylated Flt1(1-3)-Fc, Mut1: Flt1(1-3_{ΔB})-Fc, and Unmodified Flt1(1-3)-Fc

In vivo experiments were designed to assess the pharmacokinetic profiles of unmodified Flt1(1-3)-Fc, Mut1: Flt1(1-3_{ΔB})-Fc, and 40 fold molar excess acetylated Flt1(1-3)-Fc protein. Balb/c mice (25-30 g) were injected subcutaneously with 4 mg/kg of unmodified Flt1(1-3)-Fc, 40 fold molar excess acetylated Flt1(1-3)-Fc, and Mut1: Flt1(1-3_{ΔB})-Fc proteins (4 mice each). These mice were tail bled at 1, 2, 4, 6, 24 hours, 2 days, 3 days, and 5 days after injection. The sera were assayed in an ELISA designed to detect Flt1(1-3)-Fc protein which involves coating an ELISA plate with VEGF, binding the Flt1(1-3)-Fc and reporting with an anti-Fc antibody linked to alkaline phosphatase. As shown in FIG. 20, the C_{max} for these reagents was as follows: Unmodified Flt1(1-3)-Fc—0.15 µg/ml; 40 fold molar excess acetylated Flt1(1-3)-Fc—1.5 µg/ml; and Mut1: Flt1(1-3_{ΔB})-Fc—0.7 µg/ml.

Example 17

Modified Flt1 Receptor Vector Construction

The rationale for constructing modified versions of the Flt1 receptor (also known as VEGFR1) was based on the observation that the protein sequence of Flt1 was highly basic, and was therefore likely to stick to extracellular matrix (ECM). The highly basic nature of Flt1 probably explains why unmodified Flt1(1-3)-Fc (described supra) has poor pharmacokinetics that make it difficult to use as a therapeutic agent. As described supra, the chemically modified form of 40 fold molar excess acetylated Flt1(1-3)-Fc, hereinafter termed A40 exhibited a greatly improved pharmacokinetic (PK) profile over the non-acetylated Flt1(1-3)-Fc. Therefore, attempts were made to engineer DNA mol-

ecules that could be used to recombinantly express modified forms of a Flt1 receptor molecule that would possess the improved PK profile exhibited by A40 and still maintain the ability to bind tightly to VEGF.

It is known in the literature that the first Ig domain of Flt1 (which has a net charge of +5 at neutral pH) is not essential for tight binding to VEGF, so this domain was deleted. The third Ig domain (having a net charge of +11) is not essential for binding, but confers higher affinity for VEGF than the second Ig domain, so instead of deleting it entirely, it was replaced with the equivalent domains of the Flt1 receptor relatives Flk1 (also known as VEGFR2) and Flt4 (also known as VEGFR3). These chimeric molecules (denoted R1R2 (Flt1.D2.FlklD3.FcΔC1(a) and VEGFR1R2-FcΔC1(a) and R1R3 (Flt1D2.VEGFR3D3-FcΔC1(a) and VEGFR1R3-FcΔC1(a) respectively, wherein R1 and FlklD2=Ig domain 2 of Flt1 (VEGFR1); R2 and FlklD3=Ig domain 3 of Flk1 (VEGFR2); and R3 and VEGFR3D3=Ig domain 3 of Flt4 (VEGFR3)) were much less sticky to ECM, as judged by an in vitro ECM binding assay as described infra, had greatly improved PK as described infra. In addition, these molecules were able to bind VEGF tightly as described infra and block phosphorylation of the native Flk1 receptor expressed in endothelial cells as described infra.

(a) Construction of the Expression Plasmid pFlt1D2.FlklD3.FcΔC1(a)

Expression plasmids pMT21 .Flt1(1-3).Fc (6519bp) and pMT21.Flkl(1-3).Fc (5230bp) are plasmids that encode ampicillin resistance and Fc-tagged versions of Ig domains 1-3 of human Flt1 and human Flk1, respectively. These plasmids were used to construct a DNA fragment consisting of a fusion of Ig domain 2 of Flt1 with Ig domain 3 of Flk1, using PCR amplification of the respective Ig domains followed by further rounds of PCR to achieve fusion of the two domains into a single fragment. For Ig domain 2 of Flt1, the 5' and 3' amplification primers were as follows:

```
5': bsp/flt1D2
(5'-GACTAGCAGTCCGGAGGTAGACCTTCGTAGAGATG-3')

3': Flt1D2-FlklD3.as
(5'-CGGACTCAGAACACATCTATGATTGTATTGGT-3')
```

The 5' amplification primer encodes a BspE1 restriction enzyme site upstream of Ig domain 2 of Flt1, defined by the amino acid sequence GRPFVEM (corresponding to amino acids 27-33 of FIG. 21A-21C). The 3' primer encodes the reverse complement of the 3' end of Flt1 Ig domain 2 fused directly to the 5' beginning of Flk1 Ig domain 3, with the fusion point defined as TIID of Flt1 (corresponding to amino acids 123-126 of FIG. 21A-21C) and continuing into VVLS (corresponding to amino acids 127-130 of FIG. 21A-21C) of Flk1.

For Ig domain 3 of Flk1, the 5' and 3' amplification primers were as follows:

```
5': Flt1D2-FlklD3.s
(5'-ACAATCATAGATGTGGTTCTGAGTCCGTCTCATGG-3')

3': FlklD3/apa/srf.as
(5'-GATAATGCCCGGGCCCTTTTCATGGACCCGTGACAAATG-3')
```

The 5' amplification primer encodes the end of Flt1 Ig domain 2 fused directly to the beginning of Flk1 Ig domain 3, as described above. The 3' amplification primer encodes the end of Flk1 Ig domain 3, defined by the amino acids

27

VRVHEK (corresponding to amino acids 223-228 of FIG. 21A-21C), followed by a bridging sequence that includes a recognition sequence for the restriction enzyme SrfI, and encodes the amino acids GPG. The bridging sequence corresponds to amino acids 229-231 of FIG. 21A-21C.

After a round of PCR amplification to produce the individual domains, the products were combined in a tube and subjected to a further round of PCR with the primers bsp/flt1D2 and Flk1D3/apa/srf.as (described supra) to produce the fusion product. This PCR product was subsequently digested with the restriction enzymes BspEI and SmaI and the resulting 614bp fragment was subcloned into the BspEI to SrfI restriction sites of the vector pMT21/ΔB2.Fc, to create the plasmid pMT21/Flt1D2.Flk1D3.Fc. The nucleotide sequence of the Flt1D2-Flk1D3 gene fusion insert was verified by standard sequence analysis. This plasmid was then digested with the restriction enzymes EcoRI and SrfI and the resulting 702bp fragment was transferred into the EcoRI to SrfI restriction sites of the plasmid pFlt1(1-3)B2-FcΔC1(a) to produce the plasmid pFlt1D2.Flk1D3.FcΔC1(a). The complete DNA and deduced amino acid sequences of the Flt1D2.Flk1D3.FcΔC1(a) chimeric molecule is set forth in FIG. 21A-21C.

(b) Construction of the Expression Plasmid pFlt1D2VEGFR3D3FcΔC1(a)

The expression plasmid pMT21.Flt1(1-3).Fc (6519bp) encodes ampicillin resistance and an Fc-tagged version of Ig domains 1-3 of human Flt1 receptor. This plasmid was used to produce a DNA fragment containing Ig domain 2 of Flt1 by PCR. RNA from the cell line HEL921.7 was used to produce Ig domain 3 of Flk1, using standard RT-PCR methodology. A further round of PCR amplification was used to achieve fusion of the two Ig domains into a single fused fragment. For Ig domain 2 of Flt1, the 5' and 3' amplification primers were as follows:

```
5': bsp/flt1D2
(5'-GACTAGCAGTCCGGAGGTAGACCTTTCGTAGAGATG-3')

3': Flt1D2.VEGFR3D3.as
(TTCCTGGGCAACAGCTGGATATCATGATTGTATTGGT)
```

The 5' amplification primer encodes a BspEI restriction site upstream of Ig domain 2 of Flt1, defined by the amino acid sequence GRPFVEM (corresponding to amino acids 27-33 of FIG. 22A-22C). The 3' amplification primer encodes the reverse complement of the end of Flt1 Ig domain 2 fused directly to the beginning of VEGFR3 Ig domain 3, with the fusion point defined as TIIID of Flt1 (corresponding to amino acids 123-126 of FIG. 22A-22C) and continuing into IQLL of VEGFR3 (corresponding to amino acids 127-130 of FIG. 22A-22C).

For Ig domain 3 of VEGFR3, the 5' and 3' primers used for RT-PCR were as follows:

```
5': R3D3.s
(ATCCAGCTGTTGCCAGGAAGTCGCTGGAGCTGCTGGTA)

3': R3D3.as
(ATTTCATGCACAATGACCTCGGTGCTCTCCGAAATCG)
```

Both the 5' and 3' amplification primers match the sequence of VEGFR3. The 296bp amplification product of this RT-PCR reaction was isolated by standard techniques and subjected to a second round of PCR to add suitable sequences to allow for fusion of the Flt1D2 with the Flk1D3

28

domains and fusion of the Flk1D3 and Fc domains via a GPG bridge (see below). The amplification primers were as follows:

```
5': Flt1D2.VEGFR3D3.s
(TCATAGATATCCAGCTGTTGCCAGGAAGTCGCTGGAG)

3': VEGFR3D3/srf.as
(GATAATGCCCGGCCATTTTCATGCACAATGACCTCGGT)
```

The 5' amplification primer encodes the 3' end of Flt1 Ig domain 2 fused directly to the beginning (5' end) of VEGFR3 Ig domain 3, as described above. The 3' amplification primer encodes the 3' end of VEGFR3 Ig domain 3, defined by the amino acids VIVHEN (corresponding to amino acids 221-226 of FIG. 22A-22C), followed by a bridging sequence that includes a recognition sequence for SrfI, and encodes the amino acids GPG. The bridging sequence corresponds to amino acids 227-229 of FIG. 22A-22C.

After one round (for Flt1 Ig domain 2) or two rounds (for Flt4 Ig domain 3) of PCR to produce the individual Ig domains, the PCR products were combined in a tube and subjected to a further round of PCR amplification with the amplification primers bsp/flt1D2 and VEGFR3D3/srf.as described supra, to produce the fusion product. This PCR product was subsequently digested with the restriction enzymes BspEI and SmaI and the resulting 625bp fragment was subcloned into the BspEI to SrfI restriction sites of the vector pMT21/Flt1ΔB2.Fc (described supra), to create the plasmid pMT21/Flt1D2.VEGFR3D3.Fc. The sequence of the Flt1D2-VEGFR3D3 gene fusion insert was verified by standard sequence analysis. This plasmid was then digested with the restriction enzymes EcoRI and SrfI and the resulting 693bp fragment was subcloned into the EcoRI to SrfI restriction sites of the plasmid pFlt1(1-3)ΔB2-FcΔC1(a) to produce the plasmid designated pFlt1D2.VEGFR3D3.FcΔC1(a). The complete DNA deduced amino acid sequence of the Flt1D2.VEGFR3D3.FcΔC1(a) chimeric molecule is set forth in FIG. 22A-22C.

Example 18

Extracellular Matrix Binding (ECM) Binding Assay

ECM-coated plates (Becton Dickinson catalog #35-4607) were rehydrated with warm DME supplemented with glutamine (2 mM), 100 U penicillin, 100 U streptomycin, and 10% BCS for at least 1 hr. before adding samples. The plates were then incubated for 1 hr. at room temperature with varying concentrations of Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a) starting at 10 nM with subsequent 2-fold dilutions in PBS plus 10% BCS. The plates were then washed 3 times with PBS plus 0.1% Triton-X and incubated with alkaline phosphatase-conjugated anti-human Fc antibody (Promega, 1:4000 in PBS plus 10% BCS) for 1 hr. at room temperature. The plates were then washed 4 times with PBS 0.1% Triton-X and alkaline phosphatase buffer/pNPP solution (Sigma) was added for color development. Plates were read at λ=405-570 nm. The results of this experiment are shown in FIG. 23 and demonstrate that the Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a) proteins are considerably less sticky to the ECM as compared to the Flt1(1-3)-Fc protein.

Example 19

Transient Expression of pFlt1D2.Flk1D3.FcΔC1(a)
in CHO-K1 (E1A) cells

A large scale (2 L) culture of *E. coli* DH10B cells carrying the pFlt1D2.Flk1D3.FcΔC1(a) plasmid described supra in Example 17(a) was grown overnight in Terrific Broth (TB) plus 100 μg/ml ampicillin. The next day, the plasmid DNA was extracted using a QIAGEN ENDOFREE™ Megaprep kit following the manufacturer's protocol. The concentration of the purified plasmid DNA was determined by standard techniques using a UV spectrophotometer and fluorometer. The plasmid DNA was verified by standard restriction enzyme digestion of aliquots using the restriction enzymes EcoRI plus NotI and AseI. All restriction enzyme digest fragments corresponded to the predicted sizes when analyzed on a 1% agarose gel.

Forty 15 cm petri plates were seeded with CHO-K1/E1A cells at a density of 4×10^6 cells/plate. Plating media was Gibco Ham's F-12 supplemented with 10% HYCLONE™ Fetal Bovine Serum (FBS), 100 U penicillin/100 U streptomycin and glutamine (2 mM). The following day each plate of cells was transfected with 6 μg of the pFlt1D2.Flk1D3.FcΔC1(a) plasmid DNA using Gibco Opti-mem and Gibco Lipofectamine in 12 ml volume, following the manufacturer's protocol. Four hours after adding the transfection mix to the cells, 12 ml/plate of Opti-mem supplemented with 10% FBS was added. Plates were incubated at 37° C. in a 5% CO₂ incubator overnight. The following day the media was removed from each plate and 25 ml expression media (Gibco CHO-S-SFM II supplemented with glutamine (2 mM) and 1 mM sodium butyrate) was added. The plates were incubated at 37° C. for 3 days. After 3 days of incubation, the media was aspirated from each plate and centrifuged at 400 rpm in a swinging bucket rotor to pellet cells. The supernatant was decanted into sterile 1 L bottles and purification of the expressed protein was performed as described infra.

Example 20

Construction pVEGFR1R2-FcΔC1C(a) Expression
Vector

The pVEGFR1R2.FcΔC1(a) expression plasmid was constructed by insertion of DNA encoding amino acids SDT (corresponding to amino acids 27-29 of FIG. 24A-24C) between Flt1d2-Flk1d3-FcΔC1(a) amino acids 26 and 27 of FIG. 21A-21C (GG) and removal of DNA encoding amino acids GPG corresponding to amino acids 229-231 of Figure. The SDT amino acid sequence is native to the Flt1 receptor and was added back in to decrease the likelihood of heterogeneous N-terminal processing. The GPG (bridging sequence) was removed so that the Flt1 and Flk1 Ig domains were fused directly to one another. The complete DNA and deduced amino acid sequences of the pVEGFR1R2.FcΔC1(a) chimeric molecule is set forth in FIG. 24A-24C.

Example 21

Cell Culture Process Used to Produce Modified
Flt1 Receptors(a) Cell Culture Process Used to Produce
Flt1D2.Flk1D3.FcΔC1(a)

The process for production of Flt1D2.Flk1D3.FcΔC1(a) protein using the expression plasmid pFlt1D2.Flk1D3.FcΔC1(a) described supra in Example 1

involves suspension culture of recombinant Chinese hamster ovary (CHO K1/E1A) cells which constitutively express the protein product. The cells are grown in bioreactors and the protein product is isolated and purified by affinity and size exclusion chromatography. The process is provided in greater detail below.

Cell Expansion

Two confluent T-225 cm² flasks containing the Flt1D2.Flk1D3.FcΔC1(a) expressing cell line were expanded by passaging cells into eight T-225 cm² flasks in medium (GMEM +10% serum, GIBCO) and incubated at 37° C. and 5% CO₂. When the flasks approached confluence (approximately 3 to 4 days) the cells were detached using trypsin. Fresh medium was added to protect the cells from further exposure to the trypsin. The cells were centrifuged and resuspended in fresh medium then transferred to eight 850 cm² roller bottles and incubated at 37° C. and 5% CO₂ until confluent.

Suspension Culture in Bioreactors

Cells grown in roller bottles were trypsinized to detach them from the surface and washed with suspension culture medium. The cells are aseptically transferred to a 5 L bioreactor (New Brunswick Celligen Plus) where the cells are grown in 3.5 L of suspension culture. The suspension culture medium was a glutamine-free low glucose modification of IS-CHO (Irvine Scientific) to which 5% fetal bovine serum (Hyclone), GS supplement (Life Technologies) and 25 μM methionine sulfoximine (Sigma) was added. The pH was controlled at 7.2 by addition of carbon dioxide to the inlet gas or by addition of a liquid solution of sodium carbonate to the bioreactor. Dissolved oxygen level was maintained at 30% of saturation by addition of oxygen or nitrogen to the inlet gas and temperature controlled at 37° C. When a density of 4×10^6 cells/mL was reached the cells were transferred to a 40 L bioreactor containing the same medium and setpoints for controlling the bioreactor. The temperature setpoint was reduced to 34° C. to slow cell growth and increase the relative rate of protein expression.

Cell Culture Process Used to Produce
Flt1D2.VEGFR3D3.FcΔC1(a)

The same methodologies as described supra for Flt1D2.Flk1D3.FcΔC1(a) were used to produce Flt1D2.VEGFR3D3.FcΔC1(a).

Example 22

Harvest and Purification of Modified Flt1 Receptors

(a) Harvest and Purification of Flt1D2.Flk1D3.FcΔC1(a)

The product protein was aseptically harvested from the bioreactor while retaining cells using Millipore Prostak tangential-flow filtration modules and a low-shear mechanical pump (Fristam). Fresh medium was added to the bioreactor to replace that removed during the harvest filtration. Approximately 40 L of harvest filtrate was then loaded onto a 400 mL column containing Protein A SEPHAROSE™ resin (Amersham Pharmacia). After loading the resin was washed with buffer containing 10 mM sodium phosphate, 500 mM sodium chloride, pH 7.2 to remove any unbound contaminating proteins. Flt1D2.Flk1D3.FcΔC1(a) protein was eluted with a pH 3.0 citrate buffer. The eluted protein was neutralized by addition of Tris base and frozen at -20° C.

31

Several frozen lots of Flt1D2.Flk1D3.FcΔC1(a) protein from the Protein A step above -were thawed, pooled and concentrated using a Millipore 30 kD nominal molecular weight cutoff (NMWCO) tangential flow filtration membrane. The protein was transferred to a stirred cell concentrator (Millipore) and further concentrated to 30 mg/mL using a 30 kD NMWCO membrane. The concentrated protein was loaded onto a size exclusion column packed with Superdex 200 resin (Amersham Pharmacia) that was equilibrated with phosphate buffered saline plus 5% glycerol. The same buffer was used to run the column. The fractions corresponding to Flt1D2.Flk1D3.FcΔC1(a) dimer were pooled, sterile filtered through a 0.22 micron filter, aliquoted and frozen.

(b) Harvest and Purification of Flt1D2.VEGFR3D3.FcΔC1(a)

The same methodologies as described supra for Flt1D2.Flk1D3.FcΔC1(a) were used to harvest and purify Flt1D2.VEGFR3D3.FcΔC1(a).

Example 23

Phosphorylation Assay for Transiently Expressed VEGFR2

Primary human umbilical vein endothelial cells (HU-VECs), passage 4-6, were starved for 2 hrs in serum-free DME high glucose media. Samples containing 40 ng/mL (1 nM) human VEGF165, which is a ligand for the VEGF receptors Flt1, Flk1 and Flt4(VEGFR3) were prepared and were preincubated for 1 hr. at room temperature with varying amounts of the modified Flt1 receptors Flt1(1-3)-Fc, Flt1(1-3)-Fc (A40), Flt1D2Flk1D3.FcΔC1(a) and Flt1D2VEGFR3D3.FcΔC1(a) in serum-free DME-high glucose media containing 0.1% BSA. Cells were challenged for minutes with the samples prepared above +/- VEGF165, followed by whole cell lysis using complete lysis buffer. Cell lysates were immunoprecipitated with an antibody directed against the C-terminus of VEGFR2 receptor. The immunoprecipitated lysates were loaded onto 4-12% SDS-PAGE Novex gel and then transferred to PVDF membrane using standard transfer methodologies. Detection of phosphorylated VEGFR2 was done by immunoblotting with the anti-phospho Tyrosine mAb called 4G10 (UBI) and developed using ECL-reagent (Amersham). FIGS. 25A-25C and 26A-26B show the results of this experiment. FIG. 25A-25C reveals that detection by Western blot of tyrosine phosphorylated VEGFR2(Flk1) by VEGF165 ligand stimulation shows that cell-surface receptors are phosphorylated to varying levels depending on which modified Flt1 receptor is used during the preincubations with VEGF. As is seen in FIG. 25A, at a 1.5 molar excess of either Flt1(1-3)-Fc, Flt1(1-3)-Fc (A40) or transient Flt1D2Flk1D3.FcΔC1(a) there is complete blockage of receptor stimulation by these three modified Flt1 receptors as compared to control media challenge. In contrast, transient Flt1D2VEGFR3D3.FcΔC1(a) does not show significant blockage at this molar excess, as compared with VEGF positive control challenge. Similar results are seen in FIG. 25B, where the modified Flt receptors are in a 3-fold molar excess to VEGF165 ligand. In FIG. 25C, where the modified Flt1 receptors are in a 6-fold molar excess to VEGF165 ligand, transient Flt1D2VEGFR3D3.FcΔC1(a) can now be shown to be partially blocking VEGF165-induced stimulation of cell-surface receptors.

In FIG. 26A-26B, detection by Western blot of tyrosine phosphorylated VEGFR2(Flk1) by VEGF165 ligand stimu-

32

lation shows that cell-surface receptors are not phosphorylated by challenge samples which have VEGF165 preincubated with 1 and 2 fold molar excess (FIG. 26A) or 3 and 4 fold molar excess (FIG. 26B) of either transient Flt1D2Flk1D3.FcΔC1(a), stable Flt1D2Flk1D3.FcΔC1(a), or transient VEGFR1R2-FcΔC1(a). At all modified Flt1 receptor concentrations tested there is complete binding of VEGF165 ligand during the preincubation, resulting in no detectable stimulation of cell-surface receptors by unbound VEGF165 as compared to control media challenge.

Example 24

Cell Proliferation Bioassay

The test cell population is MG87 cells that have been stably transfected with a expression plasmid that contains a DNA insert encoding the VEGFR2(Flk1) extracellular domain fused to the TrkB intracellular kinase domain, thus producing a chimeric molecule. The reason the TrkB intracellular kinase domain was used rather than the native VEGFR2(Flk1) intracellular kinase domain is that the intracellular kinase domain of VEGFR2(Flk1) does not cause a strong proliferative response when stimulated by VEGF165 in these cells. It is known that MG87 cells containing full length TrkB receptor give a robust proliferative response when stimulated with BDNF, so the TrkB intracellular kinase domain was engineered to replace the intracellular kinase domain of VEGFR2(Flk1) to take advantage of this proliferative response capability.

5×10^3 cells/well were plated in a 96 well plate and allowed to settle for 2 hrs at 37° C. The following modified Flt receptors Flt1(1-3)-Fc, Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a), plus an irrelevant receptor termed Tie2-Fc as a negative control, were titrated from 40 nM to 20 pM and incubated on the cells for 1 hr at 37° C. Human recombinant VEGF165 in defined media was then added to all the wells at a concentration of 1.56 nM. The plates were incubated for 72 hrs at 37° C. and then MTS (Owen's reagent, Promega) added and the plates were incubated for an additional for 4 hrs. Finally, the plates were read on a spectrophotometer at 450/570 nm. The results of this experiment are shown in FIG. 27. The control receptor Tie2-Fc does not block VEGF165-induced cell proliferation at any concentration whereas Flt1D2.Flk1D3.FcΔC1(a) blocks 1.56 nM VEGF165 with a half maximal dose of 0.8 nM. Flt1(1-3)-Fc and Flt1D2.VEGFR3D3.FcΔC1(a) are less effective in blocking VEGF165 in this assay with a half maximal dose of ~2 nM. VEGF165 alone gives a reading of 1.2 absorbance units and the background is 0.38 absorbance units.

Example 25

Binding Stoichiometry of Modified Flt Receptors to VEGF165

(a) BIACORE™ Analysis

The stoichiometry of Flt1D2Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a) interaction with human VEGF165 was determined by measuring either the level of VEGF saturation binding to the Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a) surfaces or measuring concentration of VEGF165 needed to completely prevent binding of Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a) to VEGF BIACORE™ chip surface.

Modified Flt receptors Flt1D2Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a), were captured with an anti-Fc specific antibody that was first immobilized on a BIACORE™ chip using amine-coupling chemistry. A blank antibody surface was used as a negative control. VEGF165 was injected at a concentration of 1 nM, 10 nM, and 50 nM over the Flt1D2Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a) surfaces at 10 μl/min for one hour. A real-time binding signal was recorded and saturation binding was achieved at the end of each injection. Binding stoichiometry was calculated as a molar ratio of bound VEGF165 to the immobilized Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a), using the conversion factor of 1000 RU equivalent to 1 ng/ml. The results indicated binding stoichiometry of one VEGF165 dimeric molecule per one Flt1 D2Flk1 D3.FcΔC1(a) or VEGFR1R2-Fc ΔC1(a) molecule (FIG. 28).

In solution, Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a) at a concentration of 1 nM (estimated to be 1000 times higher than the KD of the Flt1 D2Flk1 D3.FcΔC1(a) or VEGFR1 R2-FcΔC1(a)NEGF165 interaction) were mixed with varied concentrations of VEGF165. After one hour incubation, concentrations of the free Flt1D2Flk1D3.FcΔC1(a) in solution were measured as a binding signal to an amine-coupled VEGF165 surface. A calibration curve was used to convert the Flt1D2Flk1D3.FcΔC1(a) BIACORE™ binding signal to its molar concentration. The data showed that the addition of 1 nM VEGF165 into the Flt1D2Flk1D3.FcΔC1(a) solution completely blocked Flt1D2Flk1D3.FcΔC1(a) binding to the VEGF165 surface. This result suggested the binding stoichiometry of one VEGF165 molecule per one Flt1D2Flk1D3.FcΔC1(a) molecule (FIG. 29 and FIG. 30). When the concentration of Flt1D2Flk1D3.FcΔC1(a) was plotted as a function of added concentration of VEGF165, the slope of the linear portion was 1.06 for Flt1D2Flk1D3.FcΔC1(a) and -1.07 for VEGFR1R2-FcΔC1 (a). The magnitude of the slope, very close to negative one, was indicative that one molecule of VEGF165 bound to one molecule of either Flt1D2Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a).

(b) Size Exclusion Chromatography

Flt1D2Flk1D3.FcΔC1(a) was mixed with a 3-fold excess of VEGF165 and the receptor-ligand complex was purified using a Pharmacia SUPEROSE™ 6 size exclusion chromatography column. The receptor-ligand complex was then incubated in a buffer containing 6M guanidine hydrochloride in order to dissociate it into its component proteins. Flt1D2Flk1D3.FcΔC1(a) was separated from VEGF165 using SUPEROSE™ 6 size exclusion chromatography column run in 6M guanidium chloride. In order to determine complex stoichiometry, several injections of Flt1D2Flk1D3.FcΔC1(a) and VEGF165 were made and peak height or peak integrated intensity was plotted as a function of the concentration of injected protein. The calibration was done under condition identical to one used in separating components of Flt1D2Flk1D3.FcΔC1(a)VEGF complex. Quantification of the Flt1D2Flk1D3.FcΔC1(a)/VEGF complex composition was based on the calibration curves. The results of this experiment are set forth in FIG. 28, which shows the ratio of VEGF165 to Flt1D2Flk1D3.FcΔC1(a) in a complex to be 1:1.

Example 26

Determination of the Binding Stoichiometry of Flt1D2Flk1D3.FcΔC1(a)/VEGF165 Complex by Size Exclusion Chromatography

Flt1D2Flk1D3.FcΔC1(a)/VEGF165 Complex Preparation

VEGF165 (concentration=3.61 mg/ml) was mixed with CHO cell transiently expressed Flt1D2.Flk1D3.FcΔC1(a) (concentration=0.9 mg/ml) in molar ratio of 3:1 (VEGF165: Flt1D2.Flk1D3.FcΔC1(a)) and incubated overnight at 4° C.

(a) Size Exclusion Chromatography (SEC) Under Native Conditions

To separate the complex from excess of unbound VEGF165, 50 μl of the complex was loaded on a Pharmacia SUPEROSE™ 12 PC 3.2/30 which was equilibrated in PBS buffer. The sample was eluted with the same buffer at flow rate 40 μl/min. at room temperature. The results of this SEC are shown in FIG. 31. Peak #1 represents the complex and peak #2 represents unbound VEGF165. Fractions eluted between 1.1 and 1.2 ml were combined and guanidinium hydrochloride (GuHCl)was added to a final concentration 4.5M to dissociate the complex.

(b) Size Exclusion Chromatography (SEC) Under Dissociative Conditions

To separate the components of the receptor-ligand complex and to determine their molar ratio, 50 μl of dissociated complex as described supra was loaded onto a SUPER- OSE™ 12 PC 3.2/30 equilibrated in 6M GuHCl and eluted with the same solution at a flow rate 40 μl/min. at room temperature. The results of this SEC are shown in FIG. 32.

(c) Calculation of Flt1D2Flk1D3.FcΔC1(a):VEGF165 Complex Stoichiometry

The stoichiometry of the receptor-ligand complex was determined from the peak area or the peak height of the components. Concentrations of VEGF165 and Flt1D2Flk1D3.FcΔC1(a) corresponding to the peak height or peak area, respectively, were obtained from the standard curves for VEGF165 and Flt1D2Flk1D3.FcΔC1(a). To obtain a standard curve, four different concentrations (0.04 mg/ml -0.3 mg/ml) of either component were injected onto a Pharmacia SEPHAROSE™ 12 PC 3.2/30 column equilibrated in 6M guanidinium chloride and eluted with the same solution at flow rate 40 μl/min. at room temperature. The standard curve was obtained by plotting peak area or peak height vs protein concentration. The molar ratio of VEGF165:Flt1D2Flk1D3.FcΔC1(a) determined from the peak area of the components was 1.16. The molar ratio of VEGF165:Flt1D2Flk1D3.FcΔC1(a) determined from the peak height of the components was 1.10.

Example 27

Determination of the Stoichiometry of the Flt1D2Flk1D3.FcΔC1(a)/VEGF165 Complex by Size Exclusion Chromatography with On-Line Light Scattering

Complex Preparation

VEGF165 was mixed with CHO transiently expressed Flt1D2.Flk1D3.FcΔC1(a) protein in molar ratio of 3:1 (VEGF165:Flt1D2Flk1D3.FcΔC1(a)) and incubated overnight at 4° C.

(a) Size Exclusion Chromatography (SEC) with On-Line Light Scattering

Size exclusion chromatography column with a MiniDawn on-line light scattering detector (Wyatt Technology, Santa Barbara, Calif.) and refractive index (RI) detectors (Shimadzu, Kyoto, Japan) was used to determine the molecular weight (MW) of the receptor-ligand complex. Samples were injected onto a SUPEROSE™ 12 HR 10/30 column (Pharmacia) equilibrated in PBS buffer and eluted with the same buffer at flow rate 0.5 ml/min. at room temperature. As shown in FIG. 33, the elution profile shows two peaks. Peak #1 represents the receptor-ligand complex and peak #2 represents the unbound VEGF165. MW was calculated from LS and RI signals. The same procedure was used to determine MW of the individual components of the receptor-ligand complex. The results of these determinations are as follows: MW of the Flt1D2Flk1D3.FcΔC1(a)/VEGF-165 complex at the peak position is 157 300 (FIG. 33), the MW of VEGF165 at the peak position is 44 390 (FIG. 34) and the MW of R1R2 at the peak is 113 300 (FIG. 35).

These data indicated that the stoichiometry of the Flt1D2Flk1D3.FcΔC1(a)/VEGF complex is 1:1 as its corresponds to the sum of molecular weights for Flt1D2Flk1D3.FcΔC1(a) and VEGF165. Importantly, this method conclusively proved that the Flt1D2Flk1D3.FcΔC1(a)/VEGF165 complex was indeed composed of only one molecule of VEGF165 ligand and only one molecule of the Flt1D2Flk1D3.FcΔC1(a).

Example 28

Peptide Mapping of Flt1D2.Flk1D3.FcΔC1(a)

The disulfide structures and glycosylation sites in Flt1D2.Flk1D3.FcΔC1(a) were determined by a peptide mapping method. In this method, the protein was first cleaved with trypsin. Tryptic fragments were analyzed and identified by HPLC coupled with mass spectrometry, in addition to an N-terminal sequencing technique.

Reduction of the tryptic digest was employed to help identify disulfide-bond-containing fragments. Treatment of the tryptic digest with PNGase F (Glyko, Novato, Calif.) was employed to help identify fragments with N-linked glycosylation sites. The results are summarized in the accompanying FIG. 36.

There are a total of ten cysteines in Flt1D2.Flk1D3.FcΔC1(a); six of them belong to the Fc region. Cys27 has been confirmed to be disulfide bonded to Cys76. Cys121 is confirmed to be disulfide bonded to Cys182. The first two cysteines in the Fc region (Cys211 and Cys214) form an intermolecular disulfide bond with the same two cysteines in another Fc chain. However, because these two cysteines can not be separated enzymatically from each other, it can not be determined whether disulfide bonding is occurring between same cysteines (Cys211 to Cys211, for example) or between Cys211 and Cys214. Cys216 is confirmed to be disulfide bonded to Cys306. Cys352 is confirmed to be disulfide bonded to Cys410.

There are five possible N-linked glycosylation sites in Flt1D2.Flk1D3.FcΔC1(a). All five of them are found to be glycosylated to varying degrees. Complete glycosylation was observed at Asn33 (amino acid sequence NIT), Asn193 (amino acid sequence NST), and Asn282 (amino acid sequence NST). In addition, partial glycosylation is observed on Asn65 and Asn120. Sites of glycosylation are highlighted by underline in the FIG. 36.

Example 29

Pharmacokinetic Analysis of Modified Flt Receptors

(a) Pharmacokinetic Analysis of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a)

Balb/c mice (25-30 g) were injected subcutaneously with 4 mg/kg of Flt1(1-3)-Fc (A40), CHO transiently expressed Flt1D2.Flk1D3.FcΔC1(a), CHO stably expressed Flt1D2.Flk1D3.FcΔC1(a), and CHO transiently expressed VEGFR1R2-FcΔC1(a). The mice were tail bled at 1, 2, 4, 6, 24 hrs, 2 days, 3 days and 6 days after injection. The sera were assayed in an ELISA designed to detect Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a). The ELISA involves coating an ELISA plate with VEGF165, binding the detect Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) or VEGFR1R2-FcΔC1(a) and reporting with an anti-Fc antibody linked to horse radish peroxidase. The results of this experiments are shown in FIG. 37. The T_{max} for Flt1(1-3)-Fc (A40) was at 6 hrs while the T_{max} for the transient and stable Flt1D2.Flk1D3.FcΔC1(a) and the transient VEGFR1R2-FcΔC1(a) was 24 hrs. The C_{max} for Flt1(1-3)-Fc (A40) was 8 μg/ml. For both transients (Flt1D2.Flk1D3.FcΔC1(a) and VEGFR1R2-FcΔC1(a)) the C_{max} was 18 μg/ml and the C_{max} for the stable VEGFR1R2-FcΔC1(a) was 30 μg/ml.

(b) Pharmacokinetic Analysis of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a)

Balb/c mice (25-30 g) were injected subcutaneously with 4 mg/kg of Flt1(1-3)-Fc (A40), CHO transiently expressed Flt1D2.Flk1D3.FcΔC1(a) and CHO transiently expressed Flt1D2.VEGFR3D3.FcΔC1(a). The mice were tail bled at 1, 2, 5, 6, 7, 8, 12, 15 and 20 days after injection. The sera were assayed in an ELISA designed to detect Flt1(1-3)-Fc, Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a). The ELISA involves coating an ELISA plate with 165, binding the Flt1(1-3)-Fc, Flt1D2.Flk1D3.FcΔC1(a) or Flt1D2.VEGFR3D3.FcΔC1(a) and reporting with an anti-Fc antibody linked to horse radish peroxidase. Flt1(1-3)-Fc (A40) could no longer be detected in the serum after day 5 whereas, Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a) were detectable for 15 days or more. The results of this experiment are shown in FIG. 38.

Example 30

Evaluation of the Ability of Flt1D2.Flk1D3.FcΔC1(a) to Inhibit Tumor Growth in Vivo

To evaluate the ability of Flt1D2.Flk1D3.FcΔC1(a) to inhibit tumor growth in vivo a model in which tumor cell suspensions are implanted subcutaneously on the right flank of male severe combined immunodeficiency (SCID) mice was employed. Two cell lines, the human HT-1080 fibrosarcoma cell line (ATCC accession no. CCL-121) and the rat C6 glioma cell line (ATCC accession no. CCL-107), each of which exhibit distinctly different morphologies and growth characteristics, were used in the assay. The first dose of Flt1D2.Flk1D3.FcΔC1(a) (at 25 mg/Kg or as indicated in FIGS. 39 and 40) was given on the day of tumor implantation. Animals subsequently received subcutaneous injections of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) or vehicle either every other day (EOD) or two times per week

(2x/wk) for a period of 2 weeks. After 2 weeks, animals were perfused with fixative, tumors were removed and samples were blinded. Tumor volume was determined by measuring the length and width of visible subcutaneous tumors. Both of Flt1(1-3)-Fc (A40) and Flt1D2.Flk1D3.FcΔC1(a) significantly reduced the growth of tumors formed by HT-1080 and C6 cells. The results of these experiments are shown in FIG. 39 and FIG. 40.

Example 31

The Effect of VEGF165 and Modified Flt Receptors in Female Reproductive System

The stereotypic pattern of vascular remodeling which occur in the uterus and ovary over the course of the reproductive cycle has been well characterized, making these tissues particularly well suited to the study of mechanisms which regulate angiogenesis, vascular remodeling and vascular regression. Indeed, in situ hybridization studies in the reproductive tissues provided the first clear evidence that VEGF acts as a mediator of physiological angiogenesis in mature rodents, as well as humans and non-human primates (Phillips et al, 1990; Ravindranath et al, 1992; Shweiki et al, 1993; Kamat et al, 1995). As cyclic angiogenesis and vascular remodeling are prominent features of the normal ovary and uterus, it is not surprising that abnormal blood vessel growth and/or vascular dysfunction have been found to characterize many pathological conditions which affect these organs. Furthermore, these pathogenic vascular abnormalities are thought to be caused or perpetuated by the dysregulated expression of one or more angiogenic or anti-angiogenic factors, most prominently VEGF.

For example, abnormal angiogenesis is characteristic of polycystic ovary disease, endometriosis and endometrial carcinoma, and in each case VEGF is over expressed in the affected tissue (Kamat et al, 1995; Shifren et al, 1996; Guidi et al, 1996; Donnez et al, 1998). Overexpression of VEGF is also thought to play a pathogenic role in the establishment of systemic vascular hyperpermeability in ovarian hyperstimulation syndrome (McClure et al, 1994; Levin et al, 1998) and preeclampsia (Baker et al, 1995; Sharkey et al, 1996). In addition, VEGF has been implicated as the permeability factor responsible for the production of ascites associated with ovarian carcinoma and other tumors (Senger et al, 1983; Boockock et al, 1995). Agents which effectively neutralize the biological actions of VEGF can reasonably be anticipated to be of therapeutic benefit in the above and related conditions.

Angiogenesis and vascular remodeling are also hallmarks of blastocyst implantation and placental development (Findlay, 1986). VEGF is strongly expressed both in the maternal decidua and in embryonic trophoblasts, where it is thought to first stimulate expansion and hyperpermeability of the uterine vasculature during the peri-implantation period and subsequently mediate formation of both the maternal and embryonic components of the placental vasculature (Shweiki et al, 1993; Cullinan-Bove and Koos, 1993; Chakraborty et al, 1995; Das et al, 1997). VEGF is also required for luteal angiogenesis and associated progesterone secretion necessary to prepare the uterus for implantation (Ferrara et al, 1998). Thus, agents which inhibit the biological actions of VEGF may prove to be useful as contraceptive agents (by preventing implantation), or as abortifacients in the early stages of gestation. The latter application might find particular use as a non-surgical intervention for the termination of ectopic pregnancies.

While the expression of VEGF receptors is largely confined to the vascular endothelium in normal reproductive tissues, Flt1 is also expressed by trophoblasts in the placenta in both humans and animals (Clark et al, 1996; He et al, 1999) where it has been proposed to play a role in trophoblast invasion. Interestingly, both Flt1 and KDR (Flk1) are expressed by choriocarcinoma cell line BeWo (Charnock-Jones et al, 1994), and VEGF has been shown to promote DNA synthesis and tyrosine phosphorylation of MAP kinase in these cells. Furthermore, primary and metastatic ovarian carcinomas not only to express high levels of VEGF, but—in addition to the vascular endothelium—the tumor cells themselves express KDR and/or Flt1 (Boockock et al, 1995). These findings suggest that VEGF may not only be critically involved in the generation and maintenance of tumor vasculature, but that at least in some tumors of reproductive origin VEGF may subserve an autocrine role, directly supporting the survival and proliferation of the tumor cells. Thus agents which block the actions of VEGF may have particularly beneficial applications to the treatment of tumors of reproductive origin.

Methods and Results

(a) Assessment of VEGF-Induced Uterine Hyperpermeability

Pregnant mare's serum gonadotrophin (PMSG) was injected subcutaneously (5 IU) to induce ovulation in prepubertal female rats. This results in a surge of estradiol after 2 days which in turn causes an induction of VEGF in the uterus. It is reported that this induction results in hyperpermeability of the uterus and an increase in uterine wet weight 6 hrs. later and, therefore, could potentially be blocked by the modified Flt receptors Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a). In this in vivo model, the normal weight of the rat uterus is about 50 mg and this can be induced to 300-350 mg by PMSG. Desiccation of the tissue reveals that this is all water weight. Subcutaneous injection of Flt1(1-3)-Fc (A40), Flt1D2.Flk1D3.FcΔC1(a) and Flt1D2.VEGFR3D3.FcΔC1(a) at 25 mg/kg at 1 hr. after PMSG injection results in about a 50% inhibition of the increase in uterine wet weight. Increasing the dose of modified Flt receptor does not further reduce the increase in wet weight suggesting that there is a VEGF-independent component to this model. The results of this experiment are shown in FIG. 41.

(a) Assessment of Corpus Luteum Angiogenesis Using Progesterone as a Readout

Pregnant mare's serum gonadotrophin (PMSG) is injected subcutaneously (5 IU) to induce ovulation in prepubertal female rats. This results in a fully functioning corpus luteum containing a dense network of blood vessels after 4 days that allows for the secretion of progesterone into the blood stream in order to prepare the uterus for implantation. The induction of angiogenesis in the corpus luteum requires VEGF; therefore, blocking VEGF would result in a lack of new blood vessels and thus a lack of progesterone secreted into the blood stream. In this in vivo model, resting levels of progesterone are about 5 ng/ml and this can be induced to a level of 25-40 ng/ml after PMSG. Subcutaneous injection of Flt1(1-3)-Fc (A40) or Flt1D2.Flk1D3.FcΔC1(a) at 25 mg/kg or 5 mg/kg at 1 hr. after PMSG injection results in a complete inhibition of the progesterone induction on day 4. The results of this experiment are shown in FIG. 42A-42B.

39

Example 33

Pharmacokinetic Analysis of Flt1(1-3)-Fc (A40)
and Pegylated Flt1(1-3)-Fc

Flt1(1-3)-Fc was PEGylated with either 10 kD PEG or 20 kD PEG and tested in balb/c mice for their pharmacokinetic profile. Both PEGylated forms of Flt1(1-3)-Fc were found to have much better PK profiles than Flt1(1-3)-Fc (A40), with the Tmax occurring at 24 hrs. for the PEGylated molecules as opposed to 6 hrs. for Flt1(1-3)-Fc (A40).

Example 34

VEGF165 ELISA to Test Affinity of Modified Flt1
Receptor Variants

10 pM of VEGF165 was incubated overnight at room temperature with modified Flt1 receptor variants ranging from 160 pM to 0.1 pM. The modified Flt1 receptor variants used in this experiment were Flt1(1-3)-Fc, Flt1(1-3)-Fc (A40), transiently expressed Flt1D2Flk1D3.FcΔC1(a), transiently expressed Flt1D2VEFGFR3D3-FcΔC1(a), Flt1(1-

40

3_{NAS})-Fc, Flt1(1-3_{R->C})-Fc and Tie2-Fc. Flt1(1-3_{NAS})-Fc is a modified version of Flt1(1-3)-Fc in which the highly basic amino acid sequence KNKRASVRRR is replaced by NAS-VNGSR, resulting in the incorporation of two new glycosylation sites and a net reduction of five positive charges, both with the purpose of reducing the unfavorable effects of this sequence on PK. Flt1(1-3_{R->C})-Fc is a modification in which a single arginine (R) residue within the same basic amino acid sequence is changed to a cysteine (C) (KNKRASVRRR->KNKCASVRRR) to allow for pegylation at that residue, which could then shield the basic region from exerting its unfavorable effects on PK. After incubation the solution was transferred to a plate containing a capture antibody for VEGF165 (R&D). The amount of free VEGF165 was then determined using an antibody to report free VEGF165. This showed that the modified Flt1 receptor variant with the highest affinity. for VEGF165 (determined as the lowest amount of free VEGF165) was Flt1D2Flk1D3.FcΔC1(a), followed by Flt1(1-3)-Fc and Flt1(1-3)-Fc (A40) and then by Flt1(1-3_{R->C})-Fc, Flt1(1-3_{NAS})-Fc and Flt1D2VEFGFR3D3-FcΔC1(a). Tie2Fc has no affinity for VEGF165.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 38

<210> SEQ ID NO 1

<211> LENGTH: 1704

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1) ... (1701)

<400> SEQUENCE: 1

atg gtc agc tac tgg gac acc ggg gtc ctg ctg tgc gcg ctg ctc agc	48
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser	
1 5 10 15	
tgt ctg ctt ctc aca gga tct agt tca ggt tca aaa tta aaa gat cct	96
Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro	
20 25 30	
gaa ctg agt tta aaa ggc acc cag cac atc atg caa gca ggc cag aca	144
Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr	
35 40 45	
ctg cat ctc caa tgc agg ggg gaa gca gcc cat aaa tgg tct ttg cct	192
Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro	
50 55 60	
gaa atg gtg agt aag gaa agc gaa agg ctg agc ata act aaa tct gcc	240
Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala	
65 70 75 80	
tgt gga aga aat ggc aaa caa ttc tgc agt act tta acc ttg aac aca	288
Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr	
85 90 95	
gct caa gca aac cac act ggc ttc tac agc tgc aaa tat cta gct gta	336
Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val	
100 105 110	
cct act tca aag aag aag gaa aca gaa tct gca atc tat ata ttt att	384
Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile	
115 120 125	
agt gat aca ggt aga cct ttc gta gag atg tac agt gaa atc ccc gaa	432
Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu	

-continued

130	135	140	
att ata cac atg act gaa gga agg gag ctc gtc att ccc tgc cgg gtt Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val 145 150 155 160			480
acg tca cct aac atc act gtt act tta aaa aag ttt cca ctt gac act Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 165 170 175			528
ttg atc cct gat gga aaa cgc ata atc tgg gac agt aga aag ggc ttc Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe 180 185 190			576
atc ata tca aat gca acg tac aaa gaa ata ggg ctt ctg acc tgt gaa Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu 195 200 205			624
gca aca gtc aat ggg cat ttg tat aag aca aac tat ctc aca cat cga Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 210 215 220			672
caa acc aat aca atc ata gat gtc caa ata agc aca cca cgc cca gtc Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val 225 230 235 240			720
aaa tta ctt aga ggc cat act ctt gtc ctc aat tgt act gct acc act Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr 245 250 255			768
ccc ttg aac acg aga gtt caa atg acc tgg agt tac cct gat gaa aaa Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys 260 265 270			816
aat aag aga gct tcc gta agg cga cga att gac caa agc aat tcc cat Asn Lys Arg Ala Ser Val Arg Arg Ile Asp Gln Ser Asn Ser His 275 280 285			864
gcc aac ata ttc tac agt gtt ctt act att gac aaa atg cag aac aaa Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys Met Gln Asn Lys 290 295 300			912
gac aaa gga ctt tat act tgt cgt gta agg agt gga cca tca ttc aaa Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys 305 310 315 320			960
tct gtt aac acc tca gtg cat ata tat gat aaa gca ggc ccg ggc gag Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Gly Pro Gly Glu 325 330 335			1008
ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 340 345 350			1056
gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 355 360 365			1104
gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 370 375 380			1152
gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 385 390 395 400			1200
ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 405 410 415			1248
aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 420 425 430			1296
tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 435 440 445			1344
cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga			1392

[illegible]

```
<210> SEQ ID NO 2
<211> LENGTH: 567
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2
```

Met 1	Val	Ser	Tyr	Trp 5	Asp	Thr	Gly	Val	Leu 10	Leu	Cys	Ala	Leu	Leu 15	Ser
Cys	Leu	Leu	Leu 20	Thr	Gly	Ser	Ser	Ser 25	Gly	Ser	Lys	Leu	Lys 30	Asp	Pro
Glu	Leu	Ser 35	Leu	Lys	Gly	Thr	Gln 40	His	Ile	Met	Gln	Ala 45	Gly	Gln	Thr
Leu	His 50	Leu	Gln	Cys	Arg	Gly 55	Glu	Ala	Ala	His	Lys 60	Trp	Ser	Leu	Pro
Glu 65	Met	Val	Ser	Lys	Glu 70	Ser	Glu	Arg	Leu	Ser 75	Ile	Thr	Lys	Ser	Ala 80
Cys	Gly	Arg	Asn 85	Gly	Lys	Gln	Phe	Cys	Ser 90	Thr	Leu	Thr	Leu	Asn 95	Thr
Ala	Gln	Ala	Asn 100	His	Thr	Gly	Phe	Tyr 105	Ser	Cys	Lys	Tyr	Leu 110	Ala	Val
Pro	Thr	Ser 115	Lys	Lys	Lys	Glu	Thr 120	Glu	Ser	Ala	Ile	Tyr 125	Ile	Phe	Ile
Ser 130	Asp	Thr	Gly	Arg	Pro	Phe 135	Val	Glu	Met	Tyr 140	Ser	Glu	Ile	Pro	Glu
Ile 145	Ile	His	Met	Thr	Glu 150	Gly	Arg	Glu	Leu	Val 155	Ile	Pro	Cys	Arg	Val 160
Thr	Ser	Pro	Asn 165	Ile	Thr	Val	Thr	Leu	Lys 170	Lys	Phe	Pro	Leu	Asp 175	Thr
Leu	Ile	Pro	Asp 180	Gly	Lys	Arg	Ile	Ile 185	Trp	Asp	Ser	Arg	Lys 190	Gly	Phe
Ile	Ile	Ser 195	Asn	Ala	Thr	Tyr	Lys 200	Glu	Ile	Gly	Leu	Leu 205	Thr	Cys	Glu
Ala	Thr	Val	Asn	Gly	His	Leu	Tyr	Lys	Thr	Asn	Tyr	Leu	Thr	His	Arg

-continued

210	215	220
Gln Thr Asn Thr Ile	Ile Asp Val Gln Ile	Ser Thr Pro Arg Pro Val
225	230	235 240
Lys Leu Leu Arg Gly	His Thr Leu Val Leu	Asn Cys Thr Ala Thr Thr
	245	250 255
Pro Leu Asn Thr Arg	Val Gln Met Thr Trp	Ser Tyr Pro Asp Glu Lys
	260	265 270
Asn Lys Arg Ala Ser	Val Arg Arg Arg Ile	Asp Gln Ser Asn Ser His
	275	280 285
Ala Asn Ile Phe Tyr	Ser Val Leu Thr Ile	Asp Lys Met Gln Asn Lys
	290	295 300
Asp Lys Gly Leu Tyr	Thr Cys Arg Val Arg	Ser Gly Pro Ser Phe Lys
305	310	315 320
Ser Val Asn Thr Ser	Val His Ile Tyr Asp	Lys Ala Gly Pro Gly Glu
	325	330 335
Pro Lys Ser Cys Asp	Lys Thr His Thr Cys	Pro Pro Cys Pro Ala Pro
	340	345 350
Glu Leu Leu Gly Gly	Pro Ser Val Phe Leu	Phe Pro Pro Lys Pro Lys
	355	360 365
Asp Thr Leu Met Ile	Ser Arg Thr Pro Glu	Val Thr Cys Val Val Val
	370	375 380
Asp Val Ser His Glu	Asp Pro Glu Val Lys	Phe Asn Trp Tyr Val Asp
385	390	395 400
Gly Val Glu Val His	Asn Ala Lys Thr Lys	Pro Arg Glu Glu Gln Tyr
	405	410 415
Asn Ser Thr Tyr Arg	Val Val Ser Val Leu	Thr Val Leu His Gln Asp
	420	425 430
Trp Leu Asn Gly Lys	Glu Tyr Lys Cys Lys	Val Ser Asn Lys Ala Leu
	435	440 445
Pro Ala Pro Ile Glu	Lys Thr Ile Ser Lys	Ala Lys Gly Gln Pro Arg
	450	455 460
Glu Pro Gln Val Tyr	Thr Leu Pro Pro Ser	Arg Asp Glu Leu Thr Lys
465	470	475 480
Asn Gln Val Ser Leu	Thr Cys Leu Val Lys	Gly Phe Tyr Pro Ser Asp
	485	490 495
Ile Ala Val Glu Trp	Glu Ser Asn Gly Gln	Pro Glu Asn Asn Tyr Lys
	500	505 510
Thr Thr Pro Pro Val	Leu Asp Ser Asp Gly	Ser Phe Phe Leu Tyr Ser
	515	520 525
Lys Leu Thr Val Asp	Lys Ser Arg Trp Gln	Gln Gly Asn Val Phe Ser
	530	535 540
Cys Ser Val Met His	Glu Ala Leu His Asn	His Tyr Thr Gln Lys Ser
545	550	555 560
Leu Ser Leu Ser Pro	Gly Lys	
	565	

<210> SEQ ID NO 3
 <211> LENGTH: 1674
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1671)
 <400> SEQUENCE: 3

-continued

atg gtc agc tac tgg gac acc ggg gtc ctg ctg tgc gcg ctg ctc agc	48
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser	
1 5 10 15	
tgt ctg ctt ctc aca gga tct agt tca ggt tca aaa tta aaa gat cct	96
Cys Leu Leu Thr Gly Ser Ser Gly Ser Lys Leu Lys Asp Pro	
20 25 30	
gaa ctg agt tta aaa ggc acc cag cac atc atg caa gca ggc cag aca	144
Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr	
35 40 45	
ctg cat ctc caa tgc agg ggg gaa gca gcc cat aaa tgg tct ttg cct	192
Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro	
50 55 60	
gaa atg gtg agt aag gaa agc gaa agg ctg agc ata act aaa tct gcc	240
Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala	
65 70 75 80	
tgt gga aga aat ggc aaa caa ttc tgc agt act tta acc ttg aac aca	288
Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr	
85 90 95	
gct caa gca aac cac act ggc ttc tac agc tgc aaa tat cta gct gta	336
Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val	
100 105 110	
cct act tca aag aag aag gaa aca gaa tct gca atc tat ata ttt att	384
Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile	
115 120 125	
agt gat aca ggt aga cct ttc gta gag atg tac agt gaa atc ccc gaa	432
Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu	
130 135 140	
att ata cac atg act gaa gga agg gag ctc gtc att ccc tgc cgg gtt	480
Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val	
145 150 155 160	
acg tca cct aac atc act gtt act tta aaa aag ttt cca ctt gac act	528
Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr	
165 170 175	
ttg atc cct gat gga aaa cgc ata atc tgg gac agt aga aag ggc ttc	576
Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe	
180 185 190	
atc ata tca aat gca acg tac aaa gaa ata ggg ctt ctg acc tgt gaa	624
Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu	
195 200 205	
gca aca gtc aat ggg cat ttg tat aag aca aac tat ctc aca cat cga	672
Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg	
210 215 220	
caa acc aat aca atc ata gat gtc caa ata agc aca cca cgc cca gtc	720
Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val	
225 230 235 240	
aaa tta ctt aga ggc cat act ctt gtc ctc aat tgt act gct acc act	768
Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr	
245 250 255	
ccc ttg aac acg aga gtt caa atg acc tgg agt tac cct gat gaa att	816
Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Ile	
260 265 270	
gac caa agc aat tcc cat gcc aac ata ttc tac agt gtt ctt act att	864
Asp Gln Ser Asn Ser His Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile	
275 280 285	
gac aaa atg cag aac aaa gac aaa gga ctt tat act tgt cgt gta agg	912
Asp Lys Met Gln Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg	
290 295 300	
agt gga cca tca ttc aaa tct gtt aac acc tca gtg cat ata tat gat	960
Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His Ile Tyr Asp	
305 310 315 320	

-continued

aaa gca ggc ccg ggc gag ccc aaa tct tgt gac aaa act cac aca tgc Lys Ala Gly Pro Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 325 330 335	1008
cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 340 345 350	1056
ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 355 360 365	1104
gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 370 375 380	1152
ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 385 390 395 400	1200
ccg ccg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 405 410 415	1248
acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 420 425 430	1296
gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 435 440 445	1344
gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 450 455 460	1392
cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 465 470 475 480	1440
ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 485 490 495	1488
ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 500 505 510	1536
tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 515 520 525	1584
cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 530 535 540	1632
cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tga His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 545 550 555	1674

<210> SEQ ID NO 4

<211> LENGTH: 557

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
1 5 10 15

Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro
20 25 30

Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr
35 40 45

Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro

-continued

50					55					60					
Glu 65	Met	Val	Ser	Lys	Glu 70	Ser	Glu	Arg	Leu	Ser 75	Ile	Thr	Lys	Ser	Ala 80
Cys	Gly	Arg	Asn	Gly 85	Lys	Gln	Phe	Cys	Ser 90	Thr	Leu	Thr	Leu	Asn 95	Thr
Ala	Gln	Ala	Asn	His 100	Thr	Gly	Phe	Tyr 105	Ser	Cys	Lys	Tyr	Leu 110	Ala	Val
Pro	Thr	Ser	Lys	Lys 115	Lys	Glu	Thr 120	Glu	Ser	Ala	Ile	Tyr 125	Ile	Phe	Ile
Ser	Asp 130	Thr	Gly	Arg	Pro 135	Phe	Val	Glu	Met	Tyr 140	Ser	Glu	Ile	Pro	Glu
Ile 145	Ile	His	Met	Thr 150	Glu	Gly	Arg	Glu	Leu	Val 155	Ile	Pro	Cys	Arg	Val 160
Thr	Ser	Pro	Asn	Ile 165	Thr	Val	Thr	Leu	Lys 170	Lys	Phe	Pro	Leu	Asp 175	Thr
Leu	Ile	Pro	Asp 180	Gly	Lys	Arg	Ile	Ile 185	Trp	Asp	Ser	Arg	Lys 190	Gly	Phe
Ile	Ile	Ser 195	Asn	Ala	Thr	Tyr	Lys 200	Glu	Ile	Gly	Leu	Leu 205	Thr	Cys	Glu
Ala	Thr 210	Val	Asn	Gly	His 215	Leu	Tyr	Lys	Thr	Asn	Tyr 220	Leu	Thr	His	Arg
Gln 225	Thr	Asn	Thr	Ile	Ile 230	Asp	Val	Gln	Ile	Ser 235	Thr	Pro	Arg	Pro	Val 240
Lys	Leu	Leu	Arg	Gly 245	His	Thr	Leu	Val	Leu 250	Asn	Cys	Thr	Ala	Thr 255	Thr
Pro	Leu	Asn	Thr 260	Arg	Val	Gln	Met	Thr 265	Trp	Ser	Tyr	Pro	Asp 270	Glu	Ile
Asp	Gln	Ser 275	Asn	Ser	His	Ala	Asn 280	Ile	Phe	Tyr	Ser	Val 285	Leu	Thr	Ile
Asp	Lys 290	Met	Gln	Asn	Lys 295	Asp	Lys	Gly	Leu	Tyr 300	Thr	Cys	Arg	Val	Arg
Ser 305	Gly	Pro	Ser	Phe	Lys 310	Ser	Val	Asn	Thr	Ser 315	Val	His	Ile	Tyr	Asp 320
Lys	Ala	Gly	Pro	Gly 325	Glu	Pro	Lys	Ser	Cys 330	Asp	Lys	Thr	His	Thr 335	Cys
Pro	Pro	Cys	Pro	Ala 340	Pro	Glu	Leu	Leu 345	Gly	Gly	Pro	Ser	Val 350	Phe	Leu
Phe	Pro 355	Pro	Lys	Pro	Lys	Asp 360	Thr	Leu	Met	Ile	Ser	Arg 365	Thr	Pro	Glu
Val	Thr 370	Cys	Val	Val	Val	Asp 375	Val	Ser	His	Glu 380	Asp	Pro	Glu	Val	Lys
Phe 385	Asn	Trp	Tyr	Val	Asp 390	Gly	Val	Glu	Val	His 395	Asn	Ala	Lys	Thr	Lys 400
Pro	Arg	Glu	Glu	Gln 405	Tyr	Asn	Ser	Thr	Tyr 410	Arg	Val	Val	Ser	Val 415	Leu
Thr	Val	Leu	His 420	Gln	Asp	Trp	Leu	Asn 425	Gly	Lys	Glu	Tyr	Lys 430	Cys	Lys
Val	Ser	Asn	Lys 435	Ala	Leu	Pro	Ala 440	Pro	Ile	Glu	Lys	Thr 445	Ile	Ser	Lys
Ala	Lys 450	Gly	Gln	Pro	Arg	Glu 455	Pro	Gln	Val	Tyr 460	Thr	Leu	Pro	Pro	Ser
Arg 465	Asp	Glu	Leu	Thr	Lys 470	Asn	Gln	Val	Ser	Leu 475	Thr	Cys	Leu	Val	Lys 480

Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	
				485												
Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	
				500												
Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	
				515												
Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	
				530												
His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys				
				545												
				550												
				555												
 <210> SEQ ID NO 5 <211> LENGTH: 1359 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)...(1356) <400> SEQUENCE: 5																
atg	gtc	agc	tac	tgg	gac	acc	ggg	gtc	ctg	ctg	tgc	gcg	ctg	ctc	agc	48
Met	Val	Ser	Tyr	Trp	Asp	Thr	Gly	Val	Leu	Leu	Cys	Ala	Leu	Leu	Ser	
				5												
				10												
				15												
tgt	ctg	ctt	ctc	aca	gga	tct	agt	tcc	gga	ggt	aga	cct	ttc	gta	gag	96
Cys	Leu	Leu	Leu	Thr	Gly	Ser	Ser	Ser	Gly	Gly	Arg	Pro	Phe	Val	Glu	
				20												
				25												
				30												
atg	tac	agt	gaa	atc	ccc	gaa	att	ata	cac	atg	act	gaa	gga	agg	gag	144
Met	Tyr	Ser	Glu	Ile	Pro	Glu	Ile	Ile	His	Met	Thr	Glu	Gly	Arg	Glu	
				35												
				40												
				45												
ctc	gtc	att	ccc	tgc	cgg	gtt	acg	tca	cct	aac	atc	act	gtt	act	tta	192
Leu	Val	Ile	Pro	Cys	Arg	Val	Thr	Ser	Pro	Asn	Ile	Thr	Val	Thr	Leu	
				50												
				55												
				60												
aaa	aag	ttt	cca	ctt	gac	act	ttg	atc	cct	gat	gga	aaa	cgc	ata	atc	240
Lys	Lys	Phe	Pro	Leu	Asp	Thr	Leu	Ile	Pro	Asp	Gly	Lys	Arg	Ile	Ile	
				65												
				70												
				75												
tgg	gac	agt	aga	aag	ggc	ttc	atc	ata	tca	aat	gca	acg	tac	aaa	gaa	288
Trp	Asp	Ser	Arg	Lys	Gly	Phe	Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys	Glu	
				85												
				90												
				95												
ata	ggg	ctt	ctg	acc	tgt	gaa	gca	aca	gtc	aat	ggg	cat	ttg	tat	aag	336
Ile	Gly	Leu	Leu	Thr	Cys	Glu	Ala	Thr	Val	Asn	Gly	His	Leu	Tyr	Lys	
				100												
				105												
				110												
aca	aac	tat	ctc	aca	cat	cga	caa	acc	aat	aca	atc	ata	gat	gtc	caa	384
Thr	Asn	Tyr	Leu	Thr	His	Arg	Gln	Thr	Asn	Thr	Ile	Ile	Asp	Val	Gln	
				115												
				120												
				125												
ata	agc	aca	cca	cgc	cca	gtc	aaa	tta	ctt	aga	ggc	cat	act	ctt	gtc	432
Ile	Ser	Thr	Pro	Arg	Pro	Val	Lys	Leu	Leu	Arg	Gly	His	Thr	Leu	Val	
				130												
				135												
				140												
ctc	aat	tgt	act	gct	acc	act	ccc	ttg	aac	acg	aga	gtt	caa	atg	acc	480
Leu	Asn	Cys	Thr	Ala	Thr	Thr	Pro	Leu	Asn	Thr	Arg	Val	Gln	Met	Thr	
				145												
				150												
				155												
tgg	agt	tac	cct	gat	gaa	att	gac	caa	agc	aat	tcc	cat	gcc	aac	ata	528
Trp	Ser	Tyr	Pro	Asp	Glu	Ile	Asp	Gln	Ser	Asn	Ser	His	Ala	Asn	Ile	

-continued

acc tca gtg cat ata tat gat aaa gca ggc ccg ggc gag ccc aaa tct	672
Thr Ser Val His Ile Tyr Asp Lys Ala Gly Pro Gly Glu Pro Lys Ser	
210 215 220	
tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg	720
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu	
225 230 235 240	
ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc	768
Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu	
245 250 255	
atg atc tcc ccg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc	816
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser	
260 265 270	
cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag	864
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu	
275 280 285	
gtg cat aat gcc aag aca aag ccg ccg gag gag cag tac aac agc acg	912
Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr	
290 295 300	
tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat	960
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn	
305 310 315 320	
ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc	1008
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro	
325 330 335	
atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag	1056
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln	
340 345 350	
gtg tac acc ctg ccc cca tcc ccg gat gag ctg acc aag aac cag gtc	1104
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val	
355 360 365	
agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg	1152
Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val	
370 375 380	
gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct	1200
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro	
385 390 395 400	
ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc	1248
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr	
405 410 415	
gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg	1296
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val	
420 425 430	
atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg	1344
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu	
435 440 445	
tct ccg ggt aaa tga	1359
Ser Pro Gly Lys	
450	

<210> SEQ ID NO 6

<211> LENGTH: 452

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
1 5 10 15

Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Gly Arg Pro Phe Val Glu
20 25 30

Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu

	35					40					45				
Leu	Val	Ile	Pro	Cys	Arg	Val	Thr	Ser	Pro	Asn	Ile	Thr	Val	Thr	Leu
50						55					60				
Lys	Lys	Phe	Pro	Leu	Asp	Thr	Leu	Ile	Pro	Asp	Gly	Lys	Arg	Ile	Ile
65					70					75				80	
Trp	Asp	Ser	Arg	Lys	Gly	Phe	Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys	Glu
				85					90					95	
Ile	Gly	Leu	Leu	Thr	Cys	Glu	Ala	Thr	Val	Asn	Gly	His	Leu	Tyr	Lys
			100					105					110		
Thr	Asn	Tyr	Leu	Thr	His	Arg	Gln	Thr	Asn	Thr	Ile	Ile	Asp	Val	Gln
			115				120					125			
Ile	Ser	Thr	Pro	Arg	Pro	Val	Lys	Leu	Leu	Arg	Gly	His	Thr	Leu	Val
			130			135					140				
Leu	Asn	Cys	Thr	Ala	Thr	Thr	Pro	Leu	Asn	Thr	Arg	Val	Gln	Met	Thr
145					150					155					160
Trp	Ser	Tyr	Pro	Asp	Glu	Ile	Asp	Gln	Ser	Asn	Ser	His	Ala	Asn	Ile
				165				170						175	
Phe	Tyr	Ser	Val	Leu	Thr	Ile	Asp	Lys	Met	Gln	Asn	Lys	Asp	Lys	Gly
			180					185					190		
Leu	Tyr	Thr	Cys	Arg	Val	Arg	Ser	Gly	Pro	Ser	Phe	Lys	Ser	Val	Asn
			195				200					205			
Thr	Ser	Val	His	Ile	Tyr	Asp	Lys	Ala	Gly	Pro	Gly	Glu	Pro	Lys	Ser
			210			215					220				
Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu
225					230					235					240
Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu
				245				250						255	
Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser
			260					265					270		
His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu
			275				280					285			
Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr
			290			295					300				
Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn
305					310					315					320
Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro
				325				330					335		
Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln
			340					345					350		
Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val
			355				360					365			
Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val
			370			375					380				
Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro
385				390						395					400
Pro</															

-continued

<210> SEQ ID NO 7
 <211> LENGTH: 1389
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)...(1386)

<400> SEQUENCE: 7

atg gtc agc tac tgg gac acc ggg gtc ctg ctg tgc gcg ctg ctc agc	48
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser	
1 5 10 15	
tgt ctg ctt ctc aca gga tct agt tcc gga ggt aga cct ttc gta gag	96
Cys Leu Leu Thr Gly Ser Ser Ser Gly Gly Arg Pro Phe Val Glu	
20 25 30	
atg tac agt gaa atc ccc gaa att ata cac atg act gaa gga agg gag	144
Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu	
35 40 45	
ctc gtc att ccc tgc cgg gtt acg tca cct aac atc act gtt act tta	192
Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu	
50 55 60	
aaa aag ttt cca ctt gac act ttg atc cct gat gga aaa cgc ata atc	240
Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile	
65 70 75 80	
tgg gac agt aga aag ggc ttc atc ata tca aat gca acg tac aaa gaa	288
Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu	
85 90 95	
ata ggg ctt ctg acc tgt gaa gca aca gtc aat ggg cat ttg tat aag	336
Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys	
100 105 110	
aca aac tat ctc aca cat cga caa acc aat aca atc ata gat gtc caa	384
Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Val Gln	
115 120 125	
ata agc aca cca cgc cca gtc aaa tta ctt aga ggc cat act ctt gtc	432
Ile Ser Thr Pro Arg Pro Val Lys Leu Leu Arg Gly His Thr Leu Val	
130 135 140	
ctc aat tgt act gct acc act ccc ttg aac acg aga gtt caa atg acc	480
Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr Arg Val Gln Met Thr	
145 150 155 160	
tgg agt tac cct gat gaa aaa aat aag aga gct tcc gta agg cga cga	528
Trp Ser Tyr Pro Asp Glu Lys Asn Lys Arg Ala Ser Val Arg Arg Arg	
165 170 175	
att gac caa agc aat tcc cat gcc aac ata ttc tac agt gtt ctt act	576
Ile Asp Gln Ser Asn Ser His Ala Asn Ile Phe Tyr Ser Val Leu Thr	
180 185 190	
att gac aaa atg cag aac aaa gac aaa gga ctt tat act tgt cgt gta	624
Ile Asp Lys Met Gln Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val	
195 200 205	
agg agt gga cca tca ttc aaa tct gtt aac acc tca gtg cat ata tat	672
Arg Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His Ile Tyr	
210 215 220	
gat aaa gca ggc cgg ggc gag ccc aaa tct tgt gac aaa act cac aca	720
Asp Lys Ala Gly Pro Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr	
225 230 235 240	
tgc cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc	768
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe	
245 250 255	
ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct	816
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro	
260 265 270	

-continued

gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc	864
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val	
275 280 285	
aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca	912
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr	
290 295 300	
aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc	960
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val	
305 310 315 320	
ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc	1008
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys	
325 330 335	
aag gtc tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc	1056
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser	
340 345 350	
aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca	1104
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro	
355 360 365	
tcc cgg gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc	1152
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val	
370 375 380	
aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg	1200
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly	
385 390 395 400	
cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac	1248
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp	
405 410 415	
ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg	1296
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp	
420 425 430	
cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac	1344
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His	
435 440 445	
aac cac tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa	1386
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys	
450 455 460	
tga	1389

<210> SEQ ID NO 8

<211> LENGTH: 462

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser	
1 5 10 15	
Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Gly Arg Pro Phe Val Glu	
20 25 30	
Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu	
35 40 45	
Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu	
50 55 60	
Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile	
65 70 75 80	
Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu	
85 90 95	
Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys	
100 105 110	

-continued

Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Val Gln
 115 120 125
 Ile Ser Thr Pro Arg Pro Val Lys Leu Leu Arg Gly His Thr Leu Val
 130 135 140
 Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr Arg Val Gln Met Thr
 145 150 155 160
 Trp Ser Tyr Pro Asp Glu Lys Asn Lys Arg Ala Ser Val Arg Arg Arg
 165 170 175
 Ile Asp Gln Ser Asn Ser His Ala Asn Ile Phe Tyr Ser Val Leu Thr
 180 185 190
 Ile Asp Lys Met Gln Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val
 195 200 205
 Arg Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His Ile Tyr
 210 215 220
 Asp Lys Ala Gly Pro Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr
 225 230 235 240
 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
 245 250 255
 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
 260 265 270
 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
 275 280 285
 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
 290 295 300
 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
 305 310 315 320
 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
 325 330 335
 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
 340 345 350
 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
 355 360 365
 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
 370 375 380
 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
 385 390 395 400
 Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
 405 410 415
 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
 420 425 430
 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
 435 440 445
 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 450 455 460

<210> SEQ ID NO 9
 <211> LENGTH: 1704
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1) ... (1701)

<400> SEQUENCE: 9

atg gtc agc tac tgg gac acc ggg gtc ctg ctg tgc gcg ctg ctc agc

-continued

Met	Val	Ser	Tyr	Trp	Asp	Thr	Gly	Val	Leu	Leu	Cys	Ala	Leu	Leu	Ser	
1				5					10					15		
tgt	ctg	ctt	ctc	aca	gga	tct	agt	tca	ggt	tca	aaa	tta	aaa	gat	cct	96
Cys	Leu	Leu	Leu	Thr	Gly	Ser	Ser	Ser	Gly	Ser	Lys	Leu	Lys	Asp	Pro	
			20					25					30			
gaa	ctg	agt	tta	aaa	ggc	acc	cag	cac	atc	atg	caa	gca	ggc	cag	aca	144
Glu	Leu	Ser	Leu	Lys	Gly	Thr	Gln	His	Ile	Met	Gln	Ala	Gly	Gln	Thr	
		35					40				45					
ctg	cat	ctc	caa	tgc	agg	ggg	gaa	gca	gcc	cat	aaa	tgg	tct	ttg	cct	192
Leu	His	Leu	Gln	Cys	Arg	Gly	Glu	Ala	Ala	His	Lys	Trp	Ser	Leu	Pro	
	50					55				60						
gaa	atg	gtg	agt	aag	gaa	agc	gaa	agg	ctg	agc	ata	act	aaa	tct	gcc	240
Glu	Met	Val	Ser	Lys	Glu	Ser	Glu	Arg	Leu	Ser	Ile	Thr	Lys	Ser	Ala	
	65			70					75					80		
tgt	gga	aga	aat	ggc	aaa	caa	ttc	tgc	agt	act	tta	acc	ttg	aac	aca	288
Cys	Gly	Arg	Asn	Gly	Lys	Gln	Phe	Cys	Ser	Thr	Leu	Thr	Leu	Asn	Thr	
			85					90					95			
gct	caa	gca	aac	cac	act	ggc	ttc	tac	agc	tgc	aaa	tat	cta	gct	gta	336
Ala	Gln	Ala	Asn	His	Thr	Gly	Phe	Tyr	Ser	Cys	Lys	Tyr	Leu	Ala	Val	
			100					105					110			
cct	act	tca	aag	aag	aag	gaa	aca	gaa	tct	gca	atc	tat	ata	ttt	att	384
Pro	Thr	Ser	Lys	Lys	Lys	Glu	Thr	Glu	Ser	Ala	Ile	Tyr	Ile	Phe	Ile	
		115				120						125				
agt	gat	aca	ggt	aga	cct	ttc	gta	gag	atg	tac	agt	gaa	atc	ccc	gaa	432
Ser	Asp	Thr	Gly	Arg	Pro	Phe	Val	Glu	Met	Tyr	Ser	Glu	Ile	Pro	Glu	
	130					135					140					
att	ata	cac	atg	act	gaa	gga	agg	gag	ctc	gtc	att	ccc	tgc	cgg	gtt	480
Ile	Ile	His	Met	Thr	Glu	Gly	Arg	Glu	Leu	Val	Ile	Pro	Cys	Arg	Val	
	145				150					155				160		
acg	tca	cct	aac	atc	act	gtt	act	tta	aaa	aag	ttt	cca	ctt	gac	act	528
Thr	Ser	Pro	Asn	Ile	Thr	Val	Thr	Leu	Lys	Lys	Phe	Pro	Leu	Asp	Thr	
			165					170					175			
ttg	atc	cct	gat	gga	aaa	cgc	ata	atc	tgg	gac	agt	aga	aag	ggc	ttc	576
Leu	Ile	Pro	Asp	Gly	Lys	Arg	Ile	Ile	Trp	Asp	Ser	Arg	Lys	Gly	Phe	
		180					185						190			
atc	ata	tca	aat	gca	acg	tac	aaa	gaa	ata	ggg	ctt	ctg	acc	tgt	gaa	624
Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys	Glu	Ile	Gly	Leu	Leu	Thr	Cys	Glu	
		195				200						205				
gca	aca	gtc	aat	ggg	cat	ttg	tat	aag	aca	aac	tat	ctc	aca	cat	cga	672
Ala	Thr	Val	Asn	Gly	His	Leu	Tyr	Lys	Thr	Asn	Tyr	Leu	Thr	His	Arg	
	210					215					220					
caa	acc	aat	aca	atc	ata	gat	gtc	caa	ata	agc	aca	cca	cgc	cca	gtc	720
Gln	Thr	Asn	Thr	Ile	Ile	Asp	Val	Gln	Ile	Ser	Thr	Pro	Arg	Pro	Val	
	225					230				235				240		
aaa	tta	ctt	aga	ggc	cat	act	ctt	gtc	ctc	aat	tgt	act	gct	acc	act	768
Lys	Leu	Leu	Arg	Gly	His	Thr	Leu	Val	Leu	Asn	Cys	Thr	Ala	Thr	Thr	
			245					250					255			
ccc	ttg	aac	acg	aga	gtt	caa	atg	acc	tgg	agt	tac	cct	gat	gaa	aaa	816
Pro	Leu	Asn	Thr	Arg	Val	Gln	Met	Thr	Trp	Ser	Tyr	Pro	Asp	Glu	Lys	
		260					265						270			
aat	aag	aac	gct	tcc	gta	agg	cga	cga	att	gac	caa	agc	aat	tcc	cat	864
Asn	Lys	Asn	Ala	Ser	Val	Arg	Arg	Arg	Ile	Asp	Gln	Ser	Asn	Ser	His	
		275				280						285				
gcc	aac	ata	ttc	tac	agt	gtt	ctt	act	att	gac	aaa	atg	cag	aac	aaa	912
Ala	Asn	Ile	Phe	Tyr	Ser	Val	Leu	Thr	Ile	Asp	Lys	Met	Gln	Asn	Lys	
		290				295					300					
gac	aaa	gga	ctt	tat	act	tgt	cgt	gta	agg	agt	gga	cca	tca	ttc	aaa	960
Asp	Lys	Gly	Leu	Tyr	Thr	Cys	Arg	Val	Arg	Ser	Gly	Pro	Ser	Phe	Lys	
	305				310					315				320		

-continued

tct gtt aac acc tca gtg cat ata tat gat aaa gca ggc ccg ggc gag Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Gly Pro Gly Glu 325 330 335	1008
ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 340 345 350	1056
gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 355 360 365	1104
gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 370 375 380	1152
gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 385 390 395 400	1200
ggc gtg gag gtg cat aat gcc aag aca aag ccg ccg gag gag cag tac Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 405 410 415	1248
aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 420 425 430	1296
tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 435 440 445	1344
cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 450 455 460	1392
gaa cca cag gtg tac acc ctg ccc cca tcc ccg gat gag ctg acc aag Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 465 470 475 480	1440
aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 485 490 495	1488
atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 500 505 510	1536
acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 515 520 525	1584
aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 530 535 540	1632
tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 545 550 555 560	1680
ctc tcc ctg tct ccg ggt aaa tga Leu Ser Leu Ser Pro Gly Lys 565	1704

<210> SEQ ID NO 10

<211> LENGTH: 567

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser 1 5 10 15
--

Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro 20 25 30

Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr

-continued

35					40					45					
Leu	His	Leu	Gln	Cys	Arg	Gly	Glu	Ala	Ala	His	Lys	Trp	Ser	Leu	Pro
50						55					60				
Glu	Met	Val	Ser	Lys	Glu	Ser	Glu	Arg	Leu	Ser	Ile	Thr	Lys	Ser	Ala
65					70					75					80
Cys	Gly	Arg	Asn	Gly	Lys	Gln	Phe	Cys	Ser	Thr	Leu	Thr	Leu	Asn	Thr
				85					90					95	
Ala	Gln	Ala	Asn	His	Thr	Gly	Phe	Tyr	Ser	Cys	Lys	Tyr	Leu	Ala	Val
			100					105					110		
Pro	Thr	Ser	Lys	Lys	Lys	Glu	Thr	Glu	Ser	Ala	Ile	Tyr	Ile	Phe	Ile
			115				120					125			
Ser	Asp	Thr	Gly	Arg	Pro	Phe	Val	Glu	Met	Tyr	Ser	Glu	Ile	Pro	Glu
	130					135					140				
Ile	Ile	His	Met	Thr	Glu	Gly	Arg	Glu	Leu	Val	Ile	Pro	Cys	Arg	Val
145					150					155					160
Thr	Ser	Pro	Asn	Ile	Thr	Val	Thr	Leu	Lys	Lys	Phe	Pro	Leu	Asp	Thr
			165						170					175	
Leu	Ile	Pro	Asp	Gly	Lys	Arg	Ile	Ile	Trp	Asp	Ser	Arg	Lys	Gly	Phe
			180					185					190		
Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys	Glu	Ile	Gly	Leu	Leu	Thr	Cys	Glu
		195					200					205			
Ala	Thr	Val	Asn	Gly	His	Leu	Tyr	Lys	Thr	Asn	Tyr	Leu	Thr	His	Arg
	210					215					220				
Gln	Thr	Asn	Thr	Ile	Ile	Asp	Val	Gln	Ile	Ser	Thr	Pro	Arg	Pro	Val
225					230					235					240
Lys	Leu	Leu	Arg	Gly	His	Thr	Leu	Val	Leu	Asn	Cys	Thr	Ala	Thr	Thr
			245						250					255	
Pro	Leu	Asn	Thr	Arg	Val	Gln	Met	Thr	Trp	Ser	Tyr	Pro	Asp	Glu	Lys
			260					265					270		
Asn	Lys	Asn	Ala	Ser	Val	Arg	Arg	Arg	Ile	Asp	Gln	Ser	Asn	Ser	His
		275					280					285			
Ala	Asn	Ile	Phe	Tyr	Ser	Val	Leu	Thr	Ile	Asp	Lys	Met	Gln	Asn	Lys
	290					295					300				
Asp	Lys	Gly	Leu	Tyr	Thr	Cys	Arg	Val	Arg	Ser	Gly	Pro	Ser	Phe	Lys
305					310					315					320
Ser	Val	Asn	Thr	Ser	Val	His	Ile	Tyr	Asp	Lys	Ala	Gly	Pro	Gly	Glu
			325						330					335	
Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro
			340					345					350		
Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys
		355					360					365			
Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val
	370					375						380			
Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp
385					390					395					400
Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr
			405						410					415	
Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp
			420					425					430		
Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu
		435					440					445			
Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg
	450					455					460				

-continued

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
 465 470 475 480

Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 485 490 495

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
 500 505 510

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 515 520 525

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
 530 535 540

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
 545 550 555 560

Leu Ser Leu Ser Pro Gly Lys
 565

<210> SEQ ID NO 11
 <211> LENGTH: 1453
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (69)...(1442)

<400> SEQUENCE: 11

aagcttgggc tgcaggtcga tcgactctag aggatcgatc cccgggcgag ctcgatttcg 60

caaccacc atg gtc agc tac tgg gac acc ggg gtc ctg ctg tgc gcg ctg 110
 Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu
 1 5 10

ctc agc tgt ctg ctt ctc aca gga tct agt tcc gga ggt aga cct ttc 158
 Leu Ser Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Gly Arg Pro Phe
 15 20 25 30

gta gag atg tac agt gaa atc ccc gaa att ata cac atg act gaa gga 206
 Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly
 35 40 45

agg gag ctg gtc att ccc tgc cgg gtt acg tca cct aac atc act gtt 254
 Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val
 50 55 60

act tta aaa aag ttt cca ctt gac act ttg atc cct gat gga aaa cgc 302
 Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg
 65 70 75

ata atc tgg gac agt aga aag ggc ttc atc ata tca aat gca acg tac 350
 Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr
 80 85 90

aaa gaa ata ggg ctt ctg acc tgt gaa gca aca gtc aat ggg cat ttg 398
 Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu
 95 100 105 110

tat aag aca aac tat ctc aca cat cga caa acc aat aca atc ata gat 446
 Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp
 115 120 125

gtg gtt ctg agt ccg tct cat gga att gaa cta tct gtt gga gaa aag 494
 Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu Lys
 130 135 140

ctt gtc tta aat tgt aca gca aga act gaa cta aat gtg ggg att gac 542
 Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile Asp
 145 150 155

ttc aac tgg gaa tac cct tct tcg aag cat cag cat aag aaa ctt gta 590
 Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu Val
 160 165 170

-continued

aac cga gac cta aaa acc cag tct ggg agt gag atg aag aaa ttt ttg Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe Leu 175 180 185 190	638
agc acc tta act ata gat ggt gta acc cgg agt gac caa gga ttg tac Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu Tyr 195 200 205	686
acc tgt gca gca tcc agt ggg ctg atg acc aag aag aac agc aca ttt Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr Phe 210 215 220	734
gtc agg gtc cat gaa aag ggc ccg ggc gac aaa act cac aca tgc cca Val Arg Val His Glu Lys Gly Pro Gly Asp Lys Thr His Thr Cys Pro 225 230 235	782
ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc Pro Cys Pro Ala Pro Glu Leu Gly Gly Pro Ser Val Phe Leu Phe 240 245 250	830
ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 255 260 265 270	878
aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 275 280 285	926
aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 290 295 300	974
cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 305 310 315	1022
gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 320 325 330	1070
tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 335 340 345 350	1118
aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 355 360 365	1166
gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 370 375 380	1214
ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 385 390 395	1262
gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 400 405 410	1310
ttc ttc ctc tat agc aag ctc acc gtg gac aag agc agg tgg cag cag Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 415 420 425 430	1358
ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 435 440 445	1406
tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tgagcggccg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455	1452
c	1453

<210> SEQ ID NO 12

<211> LENGTH: 458

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 12

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
 1 5 10 15
 Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Gly Arg Pro Phe Val Glu
 20 25 30
 Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu
 35 40 45
 Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu
 50 55 60
 Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile
 65 70 75 80
 Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu
 85 90 95
 Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys
 100 105 110
 Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Val Val
 115 120 125
 Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu Lys Leu Val
 130 135 140
 Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile Asp Phe Asn
 145 150 155 160
 Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu Val Asn Arg
 165 170 175
 Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe Leu Ser Thr
 180 185 190
 Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu Tyr Thr Cys
 195 200 205
 Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr Phe Val Arg
 210 215 220
 Val His Glu Lys Gly Pro Gly Asp Lys Thr His Thr Cys Pro Pro Cys
 225 230 235 240
 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 245 250 255
 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 260 265 270
 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 275 280 285
 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 290 295 300
 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 305 310 315 320
 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 325 330 335
 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 340 345 350
 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 355 360 365
 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 370 375 380
 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 385 390 395 400
 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe

-continued

405	410	415	
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn			
420	425	430	
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr			
435	440	445	
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys			
450	455		
<210> SEQ ID NO 13			
<211> LENGTH: 1444			
<212> TYPE: DNA			
<213> ORGANISM: Homo sapiens			
<220> FEATURE:			
<221> NAME/KEY: CDS			
<222> LOCATION: (69)...(1433)			
<400> SEQUENCE: 13			
aagcttgggc tgcaggtcga tcgactctag aggatcgatc cccgggagag ctggaattcg			60
caaccacc atg gtc agc tac tgg gac acc ggg gtc ctg ctg tgc gcg ctg			110
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu			
1 5 10			
ctc agc tgt ctg ctt ctc aca gga tct agt tcc gga ggt aga cct ttc			158
Leu Ser Cys Leu Leu Thr Gly Ser Ser Ser Gly Gly Arg Pro Phe			
15 20 25 30			
gta gag atg tac agt gaa atc ccc gaa att ata cac atg act gaa gga			206
Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly			
35 40 45			
agg gag ctc gtc att ccc tgc cgg gtt acg tca cct aac atc act gtt			254
Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val			
50 55 60			
act tta aaa aag ttt cca ctt gac act ttg atc cct gat gga aaa cgc			302
Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg			
65 70 75			
ata atc tgg gac agt aga aag ggc ttc atc ata tca aat gca acg tac			350
Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr			
80 85 90			
aaa gaa ata ggg ctt ctg acc tgt gaa gca aca gtc aat ggg cat ttg			398
Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu			
95 100 105 110			
tat aag aca aac tat ctc aca cat cga caa acc aat aca atc ata gat			446
Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp			
115 120 125			
atc cag ctg ttg ccc agg aag tgc ctg gag ctg ctg gta ggg gag aag			494
Ile Gln Leu Leu Pro Arg Lys Ser Leu Glu Leu Leu Val Gly Glu Lys			
130 135 140			
ctg gtc ctc aac tgc acc gtg tgg gct gag ttt aac tca ggt gtc acc			542
Leu Val Leu Asn Cys Thr Val Trp Ala Glu Phe Asn Ser Gly Val Thr			
145 150 155			
ttt gac tgg gac tac cca ggg aag cag gca gag cgg ggt aag tgg gtg			590
Phe Asp Trp Asp Tyr Pro Gly Lys Gln Ala Glu Arg Gly Lys Trp Val			
160 165 170			
ccc gag cga cgc tcc caa cag acc cac aca gaa ctc tcc agc atc ctg			638
Pro Glu Arg Arg Ser Gln Gln Thr His Thr Glu Leu Ser Ser Ile Leu			
175 180 185 190			
acc atc cac aac gtc agc cag cac gac ctg ggc tgc tat gtg tgc aag			686
Thr Ile His Asn Val Ser Gln His Asp Leu Gly Ser Tyr Val Cys Lys			
195 200 205			
gcc aac aac ggc atc cag cga ttt cgg gag agc acc gag gtc att gtg			734
Ala Asn Asn Gly Ile Gln Arg Phe Arg Glu Ser Thr Glu Val Ile Val			
210 215 220			

-continued

cat gaa aat ggc ccg ggc gac aaa act cac aca tgc cca ccg tgc cca His Glu Asn Gly Pro Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro 225 230 235	782
gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 240 245 250	830
ccc aag gac acc ctc atg atc tcc ccg acc cct gag gtc aca tgc gtg Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 255 260 265 270	878
gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 275 280 285	926
gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg ccg gag gag Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 290 295 300	974
cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 305 310 315	1022
cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 320 325 330	1070
gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 335 340 345 350	1118
ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc ccg gat gag ctg Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 355 360 365	1166
acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 370 375 380	1214
agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 385 390 395	1262
tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 400 405 410	1310
tat agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 415 420 425 430	1358
ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 435 440 445	1406
aag agc ctc tcc ctg tct ccg ggt aaa tgagcggccg c Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455	1444

<210> SEQ ID NO 14

<211> LENGTH: 455

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser	
1 5 10 15	

Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Gly Arg Pro Phe Val Glu	
20 25 30	

Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu	
35 40 45	

Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu	
---	--

-continued

50	55	60
Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile 65 70 75 80		
Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu 85 90 95		
Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys 100 105 110		
Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile Asp Ile Gln 115 120 125		
Leu Leu Pro Arg Lys Ser Leu Glu Leu Leu Val Gly Glu Lys Leu Val 130 135 140		
Leu Asn Cys Thr Val Trp Ala Glu Phe Asn Ser Gly Val Thr Phe Asp 145 150 155 160		
Trp Asp Tyr Pro Gly Lys Gln Ala Glu Arg Gly Lys Trp Val Pro Glu 165 170 175		
Arg Arg Ser Gln Gln Thr His Thr Glu Leu Ser Ser Ile Leu Thr Ile 180 185 190		
His Asn Val Ser Gln His Asp Leu Gly Ser Tyr Val Cys Lys Ala Asn 195 200 205		
Asn Gly Ile Gln Arg Phe Arg Glu Ser Thr Glu Val Ile Val His Glu 210 215 220		
Asn Gly Pro Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 225 230 235 240		
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 245 250 255		
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 260 265 270		
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 275 280 285		
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 290 295 300		
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 305 310 315 320		
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 325 330 335		
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 340 345 350		
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 355 360 365		
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 370 375 380		
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 385 390 395 400		
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 405 410 415		
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 420 425 430		
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 435 440 445		
Leu Ser Leu Ser Pro Gly Lys 450 455		

-continued

```

<211> LENGTH: 1377
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(1374)

<400> SEQUENCE: 15

atg gtc agc tac tgg gac acc ggg gtc ctg ctg tgc gcg ctg ctc agc      48
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
  1             5             10             15

tgt ctg ctt ctc aca gga tct agt tcc gga agt gat acc ggt aga cct      96
Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Asp Thr Gly Arg Pro
             20             25             30

ttc gta gag atg tac agt gaa atc ccc gaa att ata cac atg act gaa     144
Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu
             35             40             45

gga agg gag ctc gtc att ccc tgc cgg gtt acg tca cct aac atc act     192
Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr
             50             55             60

gtt act tta aaa aag ttt cca ctt gac act ttg atc cct gat gga aaa     240
Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys
             65             70             75             80

cgc ata atc tgg gac agt aga aag ggc ttc atc ata tca aat gca acg     288
Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr
             85             90             95

tac aaa gaa ata ggg ctt ctg acc tgt gaa gca aca gtc aat ggg cat     336
Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His
             100            105            110

ttg tat aag aca aac tat ctc aca cat cga caa acc aat aca atc ata     384
Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile
             115            120            125

gat gtg gtt ctg agt ccg tct cat gga att gaa cta tct gtt gga gaa     432
Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu
             130            135            140

aag ctt gtc tta aat tgt aca gca aga act gaa cta aat gtg ggg att     480
Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Ile
             145            150            155            160

gac ttc aac tgg gaa tac cct tct tcg aag cat cag cat aag aaa ctt     528
Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gln His Lys Lys Leu
             165            170            175

gta aac cga gac cta aaa acc cag tct ggg agt gag atg aag aaa ttt     576
Val Asn Arg Asp Leu Lys Thr Gln Ser Gly Ser Glu Met Lys Lys Phe
             180            185            190

ttg agc acc tta act ata gat ggt gta acc cgg agt gac caa gga ttg     624
Leu Ser Thr Leu Thr Ile Asp Gly Val Thr Arg Ser Asp Gln Gly Leu
             195            200            205

tac acc tgt gca gca tcc agt ggg ctg atg acc aag aag aac agc aca     672
Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr
             210            215            220

ttt gtc agg gtc cat gaa aag gac aaa act cac aca tgc cca ccg tgc     720
Phe Val Arg Val His Glu Lys Asp Lys Thr His Thr Cys Pro Pro Cys
             225            230            235            240

cca gca cct gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca     768
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
             245            250            255

aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc     816
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
             260            265            270

gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg     864
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp

```

-continued

275	280	285	
tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag			912
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu			
290	295	300	
gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg			960
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu			
305	310	315	320
cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac			1008
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn			
325	330	335	
aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg			1056
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly			
340	345	350	
cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag			1104
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu			
355	360	365	
ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat			1152
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr			
370	375	380	
ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac			1200
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn			
385	390	395	400
aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc			1248
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe			
405	410	415	
ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac			1296
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn			
420	425	430	
gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg			1344
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr			
435	440	445	
cag aag agc ctc tcc ctg tct ccg ggt aaa tga			1377
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys			
450	455		
<210> SEQ ID NO 16			
<211> LENGTH: 458			
<212> TYPE: PRT			
<213> ORGANISM: Homo sapiens			
<400> SEQUENCE: 16			
Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser			
1	5	10	15
Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Asp Thr Gly Arg Pro			
20	25	30	
Phe Val Glu Met Tyr Ser Glu Ile Pro Glu Ile Ile His Met Thr Glu			
35	40	45	
Gly Arg Glu Leu Val Ile Pro Cys Arg Val Thr Ser Pro Asn Ile Thr			
50	55	60	
Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys			
65	70	75	80
Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr			
85	90	95	
Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His			
100	105	110	
Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gln Thr Asn Thr Ile Ile			
115	120	125	
Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly Glu			

-continued

130					135					140					
Lys	Leu	Val	Leu	Asn	Cys	Thr	Ala	Arg	Thr	Glu	Leu	Asn	Val	Gly	Ile
145					150					155				160	
Asp	Phe	Asn	Trp	Glu	Tyr	Pro	Ser	Ser	Lys	His	Gln	His	Lys	Lys	Leu
				165					170					175	
Val	Asn	Arg	Asp	Leu	Lys	Thr	Gln	Ser	Gly	Ser	Glu	Met	Lys	Lys	Phe
			180					185					190		
Leu	Ser	Thr	Leu	Thr	Ile	Asp	Gly	Val	Thr	Arg	Ser	Asp	Gln	Gly	Leu
		195					200					205			
Tyr	Thr	Cys	Ala	Ala	Ser	Ser	Gly	Leu	Met	Thr	Lys	Lys	Asn	Ser	Thr
		210					215					220			
Phe	Val	Arg	Val	His	Glu	Lys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys
225					230					235					240
Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro
				245					250					255	
Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys
			260					265					270		
Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp
			275				280					285			
Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu
		290					295					300			
Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu
305					310					315					320
His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn
				325					330					335	
Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly
			340					345					350		
Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu
		355					360					365			
Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr
		370					375					380			
Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn
385					390					395					400
Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe
				405					410					415	
Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn
			420					425					430		
Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr
			435				440					445			
Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys						
450					455										

<210> SEQ ID NO 17

<211> LENGTH: 430

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

Gly	Arg	Pro	Phe	Val	Glu	Met	Tyr	Ser	Glu	Ile	Pro	Glu	Ile	Ile	His
1				5					10					15	
Met	Thr	Glu	Gly	Arg	Glu	Leu	Val	Ile	Pro	Cys	Arg	Val	Thr	Ser	Pro
			20					25					30		
Asn	Ile	Thr	Val	Thr	Leu	Lys	Lys	Phe	Pro	Leu	Asp	Thr	Leu	Ile	Pro
			35				40					45			

-continued

Asp	Gly	Lys	Arg	Ile	Ile	Trp	Asp	Ser	Arg	Lys	Gly	Phe	Ile	Ile	Ser
50						55					60				
Asn	Ala	Thr	Tyr	Lys	Glu	Ile	Gly	Leu	Leu	Thr	Cys	Glu	Ala	Thr	Val
65					70					75					80
Asn	Gly	His	Leu	Tyr	Lys	Thr	Asn	Tyr	Leu	Thr	His	Arg	Gln	Thr	Asn
			85						90					95	
Thr	Ile	Ile	Asp	Val	Val	Leu	Ser	Pro	Ser	His	Gly	Ile	Glu	Leu	Ser
			100					105					110		
Val	Gly	Glu	Lys	Leu	Val	Leu	Asn	Cys	Thr	Ala	Arg	Thr	Glu	Leu	Asn
		115					120					125			
Val	Gly	Ile	Asp	Phe	Asn	Trp	Glu	Tyr	Pro	Ser	Ser	Lys	His	Gln	His
		130				135					140				
Lys	Lys	Leu	Val	Asn	Arg	Asp	Leu	Lys	Thr	Gln	Ser	Gly	Ser	Glu	Met
145				150						155					160
Lys	Lys	Phe	Leu	Ser	Thr	Leu	Thr	Ile	Asp	Gly	Val	Thr	Arg	Ser	Asp
			165					170						175	
Gln	Gly	Leu	Tyr	Thr	Cys	Ala	Ala	Ser	Ser	Gly	Leu	Met	Thr	Lys	Lys
		180						185					190		
Asn	Ser	Thr	Phe	Val	Arg	Val	His	Glu	Lys	Gly	Pro	Gly	Asp	Lys	Thr
		195				200						205			
His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser
		210				215					220				
Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg
225				230						235					240
Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro
			245						250					255	
Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala
		260						265					270		
Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val
		275					280						285		
Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr
		290				295					300				
Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr
305					310					315					320
Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu
			325						330					335	
Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys
			340					345					350		
Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser
		355					360					365			
Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp
		370				375					380				
Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser
385					390					395					400
Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala
			405						410					415	
Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Pro	Gly	Lys		
			420					425					430		

<210> SEQ ID NO 18

<211> LENGTH: 36

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

-continued

<400> SEQUENCE: 18

gactagcagt ccggaggtag acctttcgta gagatg

36

<210> SEQ ID NO 19

<211> LENGTH: 33

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 19

cggactcaga accacatcta tgattgtatt ggt

33

<210> SEQ ID NO 20

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 20

Gly Arg Pro Phe Val Glu Met

1

5

<210> SEQ ID NO 21

<211> LENGTH: 35

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 21

acaatcatag atgtggttct ggtccgtct catgg

35

<210> SEQ ID NO 22

<211> LENGTH: 38

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 22

gataatgccc gggccctttt catggaccct gacaaatg

38

<210> SEQ ID NO 23

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 23

Val Arg Val His Glu Lys

1

5

<210> SEQ ID NO 24

<211> LENGTH: 36

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 24

gactagcagt ccggaggtag acctttcgta gagatg

36

<210> SEQ ID NO 25

<211> LENGTH: 38

<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 25

ttcctgggca acagctggat atctatgatt gtattggt 38

<210> SEQ ID NO 26
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 26

Ile Gln Leu Leu
1

<210> SEQ ID NO 27
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 27

atccagctgt tgcccaggaa gtcgctggag ctgctggta 39

<210> SEQ ID NO 28
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 28

attttcatgc acaatgacct cgggtgctctc ccgaaatcg 39

<210> SEQ ID NO 29
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 29

tcatagatat ccagctgttg cccaggaagt cgctggag 38

<210> SEQ ID NO 30
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 30

gataatgccg gggccatttt catgcacaat gacctcgg 39

<210> SEQ ID NO 31
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 31

Val Ile Val His Glu Asn
1 5

-continued

<210> SEQ ID NO 32
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: modified Flt1 receptor

<400> SEQUENCE: 32

Lys Asn Lys Arg Ala Ser Val Arg Arg Arg
1 5 10

<210> SEQ ID NO 33
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: modified Flt1 receptor

<400> SEQUENCE: 33

Asn Ala Ser Val Asn Gly Ser Arg
1 5

<210> SEQ ID NO 34
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: modified Flt1 receptor

<400> SEQUENCE: 34

Lys Asn Lys Cys Ala Ser Val Arg Arg Arg
1 5 10

<210> SEQ ID NO 35
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 35

Ser Lys Leu Lys
1

<210> SEQ ID NO 36
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 36

Lys Asn Lys Arg Ala Ser Val Arg Arg
1 5

<210> SEQ ID NO 37
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 37

Thr Ile Ile Asp
1

<210> SEQ ID NO 38
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 38

Val Val Leu Ser
1

We claim:

1. A method of inhibiting vascular endothelial growth factor (VEGF) activity in a mammal, comprising:

administering a pharmaceutical composition to the mammal, wherein the pharmaceutical composition comprises

(a) a VEGF antagonist, and

(b) a pharmaceutically acceptable carrier

wherein the VEGF antagonist comprises a dimeric fusion polypeptide comprising two fusion polypeptides, each fusion polypeptide comprising:

(i) a VEGF receptor component consisting of an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor human Flt1 and Ig domain 3 of a second VEGF receptor human Flk1 or human Flt4; and

(ii) a multimerizing component, wherein VEGF activity is inhibited.

2. The method of claim 1, wherein the mammal is a human.

10 3. A method of inhibiting tumor growth in a mammal, comprising:

administering a pharmaceutical composition to the mammal, wherein the pharmaceutical composition comprises

15 (a) a VEGF antagonist, and

(b) a pharmaceutically acceptable carrier

wherein the VEGF antagonist comprises a dimeric fusion polypeptide comprising two fusion polypeptides, each fusion polypeptide comprising:

20 (i) a VEGF receptor component consisting of an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor human Flt1 and Ig domain 3 of a second VEGF receptor human Flk1 or human Flt4; and

25 (ii) a multimerizing component, wherein tumor growth is inhibited.

* * * * *